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Targeting the Colchicine Binding Site on Tubulin to Overcome Multidrug
Resistance and Anticancer Efficacy of Selective Survivin Inhibitors
Abstract
Tubulin inhibitors are widely used as chemotherapeutic agents, and their successis attributed to their
ability to target microtubule dynamics and disrupt critical cellular functions including cell signaling,
motility, intracellular trafficking, and mitosis. Interference with microtubule dynamics consequently
disrupts mitotic progression and ultimately leads to apoptosis, validating microtubule dynamics as an
excellent target for anticancer agents. While this class of drug has proven to be effective against many
cancer types, the clinical efficacy of current tubulin inhibitors is often limited by the development of
multidrug resistance. The most common form of resistance to these agents arises from the
overexpression of drug efflux transporters. Extensive research efforts have attempted to develop
colchicine binding site inhibitors, which are reported to be significantly less susceptible to multidrug
resistance and have therapeutic advantages over agents that target the taxane and vinca alkaloid site.
Herein, we evaluated the anticancer activity of novel small-molecules that target the colchicine binding
site, focusing on the most promising compounds from several structural scaffolds including indolylimidazopyridines (DJ95 and DJ101), VERU-111 analogs with a modified indole moiety (10ab and 10bb) or
3,4,5-trimethoxyphenyl moiety (13f), and heterocyclic pyrimidines (4a, 6a, 5a, and 5b). We demonstrated
the cytotoxic potency of these compounds against a variety of cancer cell lines, including malignant
melanomas, taxaneresistant prostate cancer cells, and drug efflux pump-overexpressing cell lines. Their
mechanism of action was revealed through tubulin polymerization inhibition, disruption of microtubule
networks and mitotic spindle formation, and confirmed through X-ray crystallography, which detailed their
specific molecular interactions with tubulin in the colchicine binding pocket. Furthermore, these
compounds exhibited hallmark characteristics of colchicine binding site agents, such as arresting cells in
the G2/M phase of the cell cycle, inducing apoptosis in a concentration-dependent manner, and impeding
cancer cell proliferation and migration. Finally, the compounds were efficacious in vivo against melanoma
and taxane-resistant prostate cancer xenograft tumors. Several agents were evaluated for ability to
prevent melanoma metastases to the lungs in experimental mouse models, and they potently inhibited
the development metastatic foci. Safety assessment by pharmacological profiling demonstrated minimal
interactions to physiologically important targets and pathophysiological analysis of major organs from
the in vivo treatment groups did not expose apparent drug-related injury. Several of the investigated
compounds also demonstrated vascular disrupting properties by targeting tumor vasculature and
inhibiting capillary-like network formation of endothelial cells. Ultimately, these compounds exhibit strong
anticancer efficacy, specifically target the colchicine binding site, and have great potential as cancer
therapeutics, particularly for multidrug resistance phenotypes.
Another target we explored for anticancer intervention was survivin. Survivin is the smallest member the
inhibitor of apoptosis protein family and its overexpression in tumor cells is been positively correlated
with the development of multidrug resistance and radiation resistance. Because it is differentially
expressed in healthy tissues and tumors, it is an attractive therapeutic target. Using the scaffold of
UC-112, which was previously identified through virtual screening, we evaluated a series of analogs
designed to optimize potency and improve selectivity to survivin over other inhibitor of apoptosis
proteins. We identified compound 10f, which was highly cytotoxic to melanoma and Pglycoprotein
overexpressing cell lines, induced apoptotic cascades in a concentrationdependent manner, specifically
downregulated survivin protein levels, and significantly inhibited tumor growth in vivo. Ultimately, these
results validated our in-depth biological investigation of novel scaffolds of survivin inhibitors and verified
the anticancer efficacy of 10f.
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ABSTRACT
Tubulin inhibitors are widely used as chemotherapeutic agents, and their success
is attributed to their ability to target microtubule dynamics and disrupt critical cellular
functions including cell signaling, motility, intracellular trafficking, and mitosis.
Interference with microtubule dynamics consequently disrupts mitotic progression and
ultimately leads to apoptosis, validating microtubule dynamics as an excellent target for
anticancer agents. While this class of drug has proven to be effective against many cancer
types, the clinical efficacy of current tubulin inhibitors is often limited by the
development of multidrug resistance. The most common form of resistance to these
agents arises from the overexpression of drug efflux transporters. Extensive research
efforts have attempted to develop colchicine binding site inhibitors, which are reported to
be significantly less susceptible to multidrug resistance and have therapeutic advantages
over agents that target the taxane and vinca alkaloid site. Herein, we evaluated the
anticancer activity of novel small-molecules that target the colchicine binding site,
focusing on the most promising compounds from several structural scaffolds including
indolyl-imidazopyridines (DJ95 and DJ101), VERU-111 analogs with a modified indole
moiety (10ab and 10bb) or 3,4,5-trimethoxyphenyl moiety (13f), and heterocyclic
pyrimidines (4a, 6a, 5a, and 5b). We demonstrated the cytotoxic potency of these
compounds against a variety of cancer cell lines, including malignant melanomas, taxaneresistant prostate cancer cells, and drug efflux pump-overexpressing cell lines. Their
mechanism of action was revealed through tubulin polymerization inhibition, disruption
of microtubule networks and mitotic spindle formation, and confirmed through X-ray
crystallography, which detailed their specific molecular interactions with tubulin in the
colchicine binding pocket. Furthermore, these compounds exhibited hallmark
characteristics of colchicine binding site agents, such as arresting cells in the G2/M phase
of the cell cycle, inducing apoptosis in a concentration-dependent manner, and impeding
cancer cell proliferation and migration. Finally, the compounds were efficacious in vivo
against melanoma and taxane-resistant prostate cancer xenograft tumors. Several agents
were evaluated for ability to prevent melanoma metastases to the lungs in experimental
mouse models, and they potently inhibited the development metastatic foci. Safety
assessment by pharmacological profiling demonstrated minimal interactions to
physiologically important targets and pathophysiological analysis of major organs from
the in vivo treatment groups did not expose apparent drug-related injury. Several of the
investigated compounds also demonstrated vascular disrupting properties by targeting
tumor vasculature and inhibiting capillary-like network formation of endothelial cells.
Ultimately, these compounds exhibit strong anticancer efficacy, specifically target the
colchicine binding site, and have great potential as cancer therapeutics, particularly for
multidrug resistance phenotypes.
Another target we explored for anticancer intervention was survivin. Survivin is
the smallest member the inhibitor of apoptosis protein family and its overexpression in
tumor cells is been positively correlated with the development of multidrug resistance
and radiation resistance. Because it is differentially expressed in healthy tissues and
tumors, it is an attractive therapeutic target. Using the scaffold of UC-112, which was
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previously identified through virtual screening, we evaluated a series of analogs designed
to optimize potency and improve selectivity to survivin over other inhibitor of apoptosis
proteins. We identified compound 10f, which was highly cytotoxic to melanoma and Pglycoprotein overexpressing cell lines, induced apoptotic cascades in a concentrationdependent manner, specifically downregulated survivin protein levels, and significantly
inhibited tumor growth in vivo. Ultimately, these results validated our in-depth biological
investigation of novel scaffolds of survivin inhibitors and verified the anticancer efficacy
of 10f.
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CHAPTER 1.

INTRODUCTION TO TUBULIN INHIBITORS

Microtubule Dynamics as an Anticancer Drug Target
Microtubules are key components of the cellular cytoskeleton and have essential
roles in proliferation, intracellular trafficking, migration, and mitosis. Microtubules are
composed of α and β tubulin protein heterodimers that bind in a head-to-tail fashion and
form cylindrical polymeric tubes of 13 protofilaments that measure approximately 25 nm
in diameter (1, 2). Microtubules undergo stochastic phases of growth and shrinkage in a
phenomenon termed “dynamic instability.” Dynamic instability includes the rates of
polymerization and depolymerization and the frequencies of the transition between
polymerization to depolymerization (“catastrophe”), and vice versa (“rescue”) (1).
Another characteristic of microtubules involves “treadmilling,” or the net change in
growth on one end and shrinkage on the opposite end of the protofilament. Each α and β
tubulin subunit can accommodate one molecule of GTP; the α bound-GTP is not
hydrolyzed or exchanged, but the GTP bound to the β tubulin can be hydrolyzed after
being merged into the polymeric tubulin (3). Microtubules cycle through stages of adding
GTP-tubulin dimers to their growing end, hydrolyzing GTP to GDP in the microtubule
protofilament, and dissociating the GDP dimer from the microtubule, though the
conformations affiliated with each of these mechanical states are complex. Free GTPtubulin dimers naturally have a 12 degree kink at the intradimer surface but convert to a
straight, expanded conformation when they bind to the microtubule end, introducing
strain energy into the microtubule lattice (4, 5). Once the GTP is hydrolyzed to GDP,
there is a conformational change and an accompanying relaxation in strain energy (6).
Figure 1-1 shows the cycling between microtubule polymerization and depolymerization
states. In the polymerization state, microtubules adapt a straight structure, stabilized
through lateral interactions, but hydrolyzed GDP-tubulin in the depolymerization state
bow outward from the protofilament (7). It is generally accepted that a GTP rich “cap” on
the end of the microtubule will allow it to stabilize and grow, however, when the cap is
lost through hydrolysis to GDP, the core of the unstable protofilament rapidly shortens as
the GDP tubulin subunits are released from the microtubule ends (1, 8, 9).
Both polymerizing and depolymerizing microtubules are observed within a cell
population, supporting that dynamics are an intrinsic property of the polymer, and while
the exact biomechanics of the phenomenon are not completely understood, dynamic
instability is linked to the hydrolysis of GTP (2, 3, 10). Microtubule dynamics are also
governed by a variety of regulator proteins and mechanisms, and they function both
spatially and temporally (11). Furthermore, they are essential for successful mitotic
events governed by mitotic spindles and mitotic organizing centers. Mitotic spindle
microtubules are significantly more dynamic than the interphase cytoskeleton
microtubule networks. The mitotic spindles radiate outwards from centrioles and attach to
the centromeres of sister chromatids in dividing cells (12). This is followed by a
simultaneous addition of tubulin at the kinetochore and is accompanied by a comparable
rate of tubulin loss at the opposite poles (13, 14). If a chromosome is unable to achieve
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Figure 1-1. Microtubule structure and dynamics.
A) Conformational changes of microtubules during catastrophe and rescue phases.
During polymerization, GTP-tubulin is added to the growing end of the microtubule.
During depolymerization, GTP is hydrolyzed to GDP and the GDP-protofilaments peel
away from the microtubule and are released. A GTP rich cap stabilizes the microtubule
and acts as a primer for tubulin polymerization. B) Binding sites on the tubulin dimer.
The α and Ⱦ tubulin dimer each contain a site that can accommodate a GTP molecule.
The α tubulin has a non-exchange N site and the Ⱦ tubulin has an exchangeable E site.
The vinca alkaloids bind near the E site on the Ⱦ tubulin dimer. Taxanes act at a site on
the lumen of GDP- bound Ⱦ tubulin and promote the stable, straight conformation. The
colchicine site is at the interface of the α and Ⱦ tubulin dimer and ligand binding causes
interdimer bending that favors destabilization.
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bipolar attachment to the spindle, the cell is unable to continue through the cell cycle and
is blocked in the metaphase, eventually to succumb to apoptosis (15).
Interfering with microtubule dynamics is an attractive anticancer strategy, and
many drugs employing this tactic are therapeutically effective in a wide range of
malignancies. Mitotic arrest in the G2/M phase, a hallmark of microtubule targeting
agents, is thought to occur through the perturbation of mitotic spindle machinery and
failure to pass mitotic checkpoints. There are several sites on the tubulin heterodimer to
which microtubule targeting agents can bind, the most common being the vinca alkaloid,
taxane, and colchicine binding sites (Figure 1-1B). These drugs are generally divided
into one of two classes; stabilizing agents, which enhance polymerization, or
destabilizing agents, which inhibit tubulin polymerization.
Stabilizing Agents
Stabilizing agents are able to promote polymerization of tubulin even when the
unfavorable GDP molecule is bound and are more effective than endogenous
microtubule-associated proteins at stabilizing the microtubule (16, 17). There are several
drug categories within this class, including taxanes, epothilones, and laulimalide binding
site agents (18). Representative drugs in this class can be found in Figure 1-2.
Taxanes. The taxane binding site is located at the lumen of the β tubulin subunit
in the intact heterodimer. Taxanes use the H6/H7 loop on β tubulin as a hinge to
translocate from an intermediate position on the outside of the microtubule to the final
binding site on the lumen of the microtubule (19). This motion is supported by a
hydrogen bond in Ser277 in the M loop present in most tubulin isoforms. However, in the
class βIII isoform, this Ser277 is replaced by an arginine residue, and overexpression of
the βIII tubulin isoform is associated with resistance to taxanes, which will be further
explained in greater detail (19, 20). The first stabilizing agent identified, paclitaxel
(Taxol), was approved by the FDA in 1992 and has been available clinically since 1996
(17). Docetaxel (Taxotere), a semi-synthetic analog of paclitaxel, is another early
generation taxane that was FDA approved for breast cancer in 1996, non-small-cell lung
cancer in 1999, metastatic hormone-refractory prostate cancer in 2004, and head and neck
cancer in 2006 (21). While these drugs achieved much success in treating various
cancers, the development of drug resistance often limits their efficacy. Another issue
hindering the clinical efficacy of taxanes is their limited solubility. Formulations such as
Cremaphor EL and polysorbate are vehicles that allow for the solubilization of
hydrophobic drugs but can induce a range of negative biological side-effects in patients
(22). Development of Abraxane, also known as paclitaxel protein-bound, is a delivery
method that has mitigated this problem to some degree. High toxicity,
immunosuppression, and peripheral neuropathy that accompany long-term use of taxanes
prove that there is still a great need to develop agents with higher specificity, improved
efficacy, and minimal off-target toxicities for this class of drugs (23).
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Figure 1-2. Examples of different classes of microtubule stabilizing and
destabilizing agents.
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Pothilones. Epothilones make up another class of tubulin targeting agents that
are distinct from taxanes, though they share a common binding site. While epothilones
compete with paclitaxel for β tubulin binding, their common pharmacophore differs in
that each class exploits the binding pocket in an independent manner and involves
distinct amino acids (24, 25). Epothilones, originally isolated from the myxobacterium
Sorangium cellulosum, are more amenable to synthetic modifications than taxanes, more
potent in taxane-resistant and sensitive cell lines, and are poor substrates for Pglycoprotein (P-gp) drug efflux pumps (26). Epothilones contain a macrolide ring with a
methylthiazole side chain, and naturally occurring epothilones are characterized as either
epoxides (epothilone A, B, E, F) or olefins (epothilone C, D) (27). Semi-synthetic
compounds have been developed to improve their pharmacologic properties and
biological activities. For example, Ixabepilone, a second-generation derivative of
Epothilone B, is less susceptible to degradation by carboxylesterase and has increased
water solubility. It was the first epothilone derivative to be FDA approved for cancer
treatment (25). Sagopilone is the first fully synthetic analog of Epothilone B and has
reached phase II clinical trials (28, 29).
Laulimalide Binding Site Agents. Another binding site on tubulin is the
laulimalide binding site. This site was discovered when it was observed that laulimalide
possessed a similar mode of action as taxanes but was completely unable to inhibit the
binding of [3H] paclitaxel or Flutax-2, paclitaxel derivative to tubulin, confirming that it
did not compete with the taxane binding site (30, 31). Peloruside A also directly binds to
tubulin without competing with paclitaxel but can be displaced by laulimalide, supporting
that Peloruside A shares a binding site with laulimalide (32, 33). Both laulimalide and
Peloruside A synergistically enhanced microtubule assembly induced by stabilizing
agents, including discodermolide, dictyostatin, paclitaxel, Epothilones A and B,
eleutherobin, and cyclostreptin (32). Furthermore, laulimalide and Peloruside A stabilize
the M loop at the taxoid binding site, which contributes to crosstalk and explains the
observed synergism between these agents and taxane site ligands (34).
Destabilizing Agents
The other class of microtubule targeting agents are the destabilizing agents and
include drugs that bind to the vinca alkaloid binding site and colchicine binding site.
Their major mechanism of action is to interfere with tubulin dynamics, as opposed to just
reducing overall polymerization. Representative drugs in this class can also be found in
Figure 1-2.
Vinca Alkaloids. Vinca alkaloids are a natural product or semi-synthetic
extraction derivative from the periwinkle plant, Catharanthus roseus (35). The major
vincas in clinical use are vinblastine, vincristine and semisynthetic derivatives
vinorelbine, vindesine, and vinflunine. The last two are only approved for use in Europe,
while the rest are FDA approved in the US. In addition to their microtubule
depolymerizing effects, vincas have also been reported to increase oxidized glutathione,
alter lipid metabolism and membrane lipid content, elevate cAMP, and inhibit cAMP
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phosphodiesterase (36). Vincas bind near the exchangeable GTP site and inhibit GTP to
GDP hydrolysis and GDP exchange, causing a change in the tubulin dimer from the
straight conformation (which is favored for polymerization) to the curved confirmation
(23). Maytansinoids and halichondrins also induce depolymerization of microtubules at
the vinca site, while dolastatins, spongistatins, and cryptophycins bind to the “peptide
site” of the vinca binding domain (23, 37). Though vincas are amongst the most
commonly used microtubule targeting agents, they also are susceptible to development of
drug resistant mechanisms and toxic side effects.
Colchicine Binding Site Agents. The final major category of tubulin inhibitors
are colchicine binding site agents. Colchicine, from the meadow saffron Colchicum
autumnale L., was the first agent discovered in this group as a tubulin depolymerizing
agent. The colchicine binding domain is located at the interface between the α and β
tubulin dimer. When colchicine binds in the binding domain, it displaces the M loop and
then the bound colchicine-tubulin complex becomes incorporated into microtubule and
interferes with the formation of lateral contacts at the end of protofilaments. This causes
steric clashes and the tubulin can no longer maintain a straight conformation (38). As the
concentration of colchicine increases, more lateral contracts are broken, ultimately
leading to destabilization of microtubules. Colchicine and colchicine binding site
inhibitors are therefore able to suppress tubulin dynamics at lower concentrations and
induce destabilization of microtubules are higher concentrations. Colchicine itself is an
approved drug for the treatment of gout and has implications in other inflammatory
conditions such as familial Mediterranean fever pericarditis and Behçet's disease.
However, there are currently no colchicine binding site agents that have been approved
for cancer therapy due to limitations such as poor drug solubility, narrow therapeutic
window, and harsh side effects including neurotoxicity. Despite these shortcomings,
colchicine binding site agents have several advantages over other tubulin agents targeting
different binding sites. First, drugs binding to the colchicine binding pocket may
overcome mechanisms of drug resistance, which will be discussed herein. Also,
colchicine binding site inhibitors can target tumor vasculature and prevent formation of
new blood vessels or disrupt existing microvessels (39, 40). For these reasons, the
colchicine binding site is an attractive target for the development of chemotherapeutic
drugs and numerous scaffolds are being investigated.
Combretastatins are naturally occurring stilbenoid phenols isolated from the bark
of Combretum caffrum (41). Combretastatins A-4 (CA-4) demonstrates cell-cycle
dependent arrest, potent antiangiogenic activity, and cytotoxicity by apoptosis rather than
necrosis (42, 43). The water soluble phosphate prodrug, CA-4P, phenostatin, and many
other CA-4 derivatives have been developed to optimize its potency, vascular disrupting
potential, drug-like properties, and anticancer efficacy (44). Based on the knowledge
gained from combretastatin and phenostatin, 1,1-diarylethene isomers of combretastatin
A were developed called isocombretastatin A (45). CC-5079, an isocombretastatin A
analog, was determined to be an inhibitor of tubulin polymerization and TNFα. It showed
cell cycle arrest in G2/M phase, increased phosphorylation of G2/M checkpoint proteins,
and stimulated apoptosis. Additionally, its effect on TNFα production also diminished
phosphodiesterase type 4 enzymatic activity (46). Alkenyldiarylmethanes are a class of
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non-nucleoside reverse transcriptase inhibitors that are structurally related to CC-5079,
and several compounds in this class also demonstrate potent tubulin destabilization (47).
2-Methoxyestradiol (2-ME), a metabolite of estradiol-17β, suppresses
microtubule dynamics at the colchicine binding site, induces G2/M phase arrest, inhibits
blood vessel formation at several stages in the angiogenic process, and has potent
anticancer activity (48, 49). It inhibits tubulin assembly in a concentration-dependent
manner, and higher concentrations are needed to depolymerize microtubules. In addition
to showing efficacy in a variety of cancer types (breast, ovarian, lung, prostate, and
colorectal carcinomas), 2-ME is active against estrogen-dependent and -independent
cancerous cells. In addition to disrupting microtubule dynamics, 2-ME also acts through
triggering the apoptotic cascade via reactive oxygen species, superoxide dismutase, and
nitric oxide synthase (50).
Nocodazole is another natural product that inhibits tubulin polymerization by
binding to the colchicine binding site as a reversible inhibitor (51). It also binds with
varying affinities to the different tubulin isotypes, with the weakest affinity for βIII
tubulin (52). Nocodazole did not advance through clinical trials due to toxic side effects,
however, it is frequently used in cell culture to block mitosis and as a reference
compound for colchicine binding site agents (16, 53). Several colchicine binding site
agents have made it to clinical trials including ABT-751, BNC105 and verubulin (36, 54).
One of the hallmarks of colchicine binding site agents is that they accommodate a wide
range of structurally diverse scaffolds, and there is still much room for improvement to
limit toxicities, improve solubility, and increase efficacies. Future directions for
colchicine binding site agents aim to optimize structural based design, utilize targeting
strategies, and increase specificity.
Mechanisms of Multidrug Resistance
One of the major hurdles that continues to limit current anticancer agents is the
development of drug resistance. Multidrug resistance (MDR) is the simultaneous
resistance to a number of structurally and functionally unrelated chemotherapeutic drugs
and is a substantial obstacle impeding the success of anticancer agents (55). Many
cancers initially respond well to chemotherapy early on during treatment but
subsequently develop acquired resistance, and more than 90% of patients with metastatic
cancer fail to respond to or relapse from chemotherapeutics (56). For these reasons,
rigorous efforts have been devoted to elucidating both inherent and acquired MDR
mechanisms over the past few decades. Although a complete understanding of MDR is
still far from being uncovered, two major mechanisms have been proposed: non-cellular
and cellular mechanisms.
Non-cellular drug resistance is the inherent capacity of tumor cells to survive
chemotherapy. It is always mediated by the tumor microenvironment and is typically
associated with the unique properties possessed by solid tumors, such as heterogeneous
tumor vasculature, high interstitial fluid pressure, acidic microenvironment, and increased
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presence of non-cycling tumors caused by insufficient supply of nutrients and oxygen
(57-61). Cellular MDR mechanisms arise inside solid tumors, and compared to noncellular MDR mechanisms, cellular MDR mechanisms are more important for novel drug
development. Some examples in which cellular mechanisms are modified to escape drug
action include elevated DNA repair, increased drug metabolism, altered apoptotic
pathways to bypass drug targets, loss or change of drug target proteins, and increased
efflux of anticancer drugs (e.g. altered activities of membrane transporters such as ATPbinding cassette transporters)(62, 63) (Figure 1-3). Metabolic changes of drugs that
promote drug degradation are also critical to MDR. For instance, overexpression
glutathione, an important metabolic antioxidant, promotes MDR by converting drugs to
drug-conjugates or by generating inactive metabolites that expel as waste (64). Mutation
of key apoptotic regulators is another primary reason for cellular MDR. Tumor
suppressor protein p53 is crucial to many physiological processes, especially in
regulating apoptosis. Several studies have shown that mutation of p53 and overexpression
of BAX, an anti-apoptotic protein in the Bcl-2 family, are involved in MDR (62, 65).
Among all the MDR mechanisms, the increase of drug efflux mediated by ATPbinding cassette (ABC) transporters is the most significant factor leading to MDR. Many
studies demonstrated that the ABC transporters comprise seven distinct classes of
structurally related membrane proteins including ABCB, ABCC and ABCG.
Overexpression of ABC transporters in tumor cells promotes MDR by reducing sufficient
accumulation of anticancer drugs through increasing drug efflux. P-gp, encoded by the
ABCB1/ MDR1 gene, is the best characterized transporter protein mediating drug
resistance and many drugs (e.g. docetaxel, paclitaxel, doxorubicin, etoposide, vinblastine,
vincristine, and teniposide) are susceptible to resistance incurred from elevated P-gp (6567). P-gp overexpression was reported to lead to failure of chemotherapy in various
cancers, such as ovarian, lung, breast and acute myeloid leukemia cancer (68).
ABCC1/Multidrug Resistance-Associated Protein 1 (MRP1) is responsible for
transporting organic anions and phase II metabolic products and causes resistance to
anticancer agents. It was first shown to be overexpressed in a doxorubicin-resistant cell
line, but also accommodates a wide range of substrates in addition to doxorubicin,
including anthracyclines, epipodophyllotoxins, vinca alkaloids, and camptothecins (69).
Finally, ABCG2/Breast Cancer Resistant Protein (BCRP) is a well-defined efflux
transporter first identified in a breast cancer cell line selected for resistance to
mitoxantrone. Similar to the other MDR transporters, BCRP serves as an efflux pump for
many diverse scaffolds of xenobiotics, including 7-ethyl-10-hydroxycamptothecin (SN38)(70), tyrosine kinase inhibitors (71), methotrexate (65, 72), and is involved in drug
resistance in colon, breast cancer and gastric carcinomas (73, 74).
Strategies to Overcomer Multidrug Resistance
Strategies to overcome inherent or acquired drug resistance are essential to the
treatment of cancers. Using inhibitors of ABC transporters is one of the common
approaches to overcome P-gp-mediated MDR, rendering tumor cells more sensitive to
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Figure 1-3. Drug-resistance mechanisms in tumor cells.
1) Loss or change of surface receptor. 2) Mutations in drug targets. 3) Enzymatic
deactivation. 4) Altered drug metabolism. 5) Change in apoptotic pathways. 6) Increased
drug efflux. 7) Decreased drug influx (solute carriers). 8) Increased DNA repair.

9

chemotherapeutics. Some strategies for overcoming MDR include developing novel
anticancer drugs that are not the substrates of P-gp, suppressing the MDR-related genes
through destruction of mRNAs by using microRNA and RNA interference (75, 76),
decreasing intracellular GSH levels via hammerhead ribozymes against glutamate
cysteine ligase or L-buthionine-(S,R)-sulfoxime to repress glutathione synthesis (77, 78),
targeting P-gp to reverse MDR with anti-P-gp monoclonal antibodies (e.g. MRK16 and
MRK17), and using nanotechnology to deliver anticancer drugs to specific targets
efficiently (79). Development of novel drugs that overcome MDR continues to be a major
area of research in drug discovery and development. Herein, we briefly summarize some
strategies in developing tubulin inhibitors that overcome MDR.
Taxane Binding Site. Paclitaxel and docetaxel, members of taxane family, are
chemotherapeutics used to treat patients with various solid tumors, including ovarian,
breast, head and neck, lung, and prostate cancers. However, severe adverse effects and
development of MDR have largely compromised the use of paclitaxel and docetaxel. In
addition to transporter-mediated resistance, overexpression of the class III β-tubulin
isoform also limits efficacy of many taxanes. Differences between βI-tubulin, the most
commonly represented and constitutively expressed isotype, and βIII-tubulin are limited
to substitution within only a 13 amino acid region, where βIII has an Arg277 instead of
the Ser277 present in βI-tubulin (80). This substitution prevents stable paclitaxel binding
and creates more dynamic microtubules, minimizing the polymerization-inducing activity
of taxanes and increasing resistance to stabilization (81). Creation of newer generations
of taxanes that are poor substrates of P-gp such as cabazitaxel, drug combination therapy,
and drug conjugates for tumor-targeted delivery are all strategies that attempt to address
the issue of MDR and develop more effective treatments (21).
Ixabepilone (BMS-247550), an epothilone derivative, was first marketed under
the trade name Ixempra for the treatment of drug-resistant metastatic breast cancer. The
efficacy of ixabepilone in resistant tumors may result from its low susceptibility to
alteration in tubulin isotypes, tubulin mutations, and overexpression of P-gp/MDR1 drug.
In a phase II clinical trial of metastatic breast cancer patients treated with 40 mg/m2
ixabepilone as a 3-hour infusion every 3 weeks, ixabepilone demonstrated promising
antitumor activity and had an acceptable safety profile (82, 83). Taccalonolides are
taxol-like microtubule stabilizing agents isolated from plants of the genus Tacca that
increase the density of cellular microtubules, block mitotic progression, and induce
apoptosis. Similar to ixabepilone, taccalonolides can circumvent MDR mechanisms due
to their low susceptibility to P-gp overexpression and tubulin alteration-mediated
resistance (84, 85). Recently, new taccalonolides AF and AJ were obtained and
demonstrated potent IC50 values of 23 nmol/L and 4 nmol/L in HeLa cell lines.
Taccalonolides AF and AJ were generated from their parent taccalonolides A and B, by
epoxidizing the C22–C23 double bond. This simple epoxidation dramatically increased
the potency over 200- and 700-fold, respectively (86). Due to the unique structural
characteristics and mechanism of taccalonolides, Susan l. Mooberry’s group modified the
precursor structure and reported on a semi-synthetic derivative, taccalonolide AI, which
showed an IC50 below 1 nM (87, 88). These studies are particularly informative for the
synthesis of taccalonolide derivatives. Due to their strong cytotoxicity and unique
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mechanisms of covalent bonding, taccalonolide semi-synthetic derivatives are a very
promising generation of irreversible tubulin inhibitor for resolving the drug resistance
dilemma.
Vinca Alkaloid Binding Site. Hemiasterlin, a natural product, is a member of tripeptides derived from marine sponges. Hemiasterlin and its analog HTI-286 bind to
vinca-peptide site in tubulin, disrupt normal microtubule dynamics, and trigger the cell
apoptotic process (89). Total synthesis of hemiasterlin and its analogs has been
accomplished and the SAR studies have been explored. HTI-286 showed potent activity
with an IC50 of about 2 to 5 nM against a panel of tumor cell lines and was less sensitive
to the P-gp drug transporter pump than current anti-microtubule agents including
paclitaxel, docetaxel, vinorelbine, and vinblastine (90). Additionally, resistance to HTI286 was not detected in cells overexpressing the multi xenobiotic resistance drug pump.
However, side effects of HTI-286 included neutropenia, hair loss, and pain, which
ultimately terminated phase II trials. Further optimization is needed to address the current
limitations of anticancer therapies and side effects.
Tubulysins, originally isolated from myxobacterial cultures, are tetrapeptides
composed of D-methylpipecolate, L-isoleucine, L-tubuvaline, and L-tubuphenylalanine
residues (91). Tubulysin D demonstrated the most potent activity, exceeding other
marketed chemotherapeutics such as Ixabepilone, vinblastine, and paclitaxel, by 20- to
1000-fold. The mechanisms of action of tubulysins resembled dolastatin-10 and
hemiasterlin, which bind to the vinca domain site, arrest cancer cells in the G2/M phase,
and trigger subsequent cell apoptosis (92, 93). Tubulysins are highly active in MDR cell
lines that either overexpress P-gp pumps or have tubulin mutations, providing an
alternative solution to treating MDR cancers.
Colchicine Binding Site. While microtubule targeting agents often face
shortcomings due to the development of resistance, colchicine binding site agents have
several advantages over other classes of tubulin inhibitors. First, many drugs in this class
are less susceptible to MDR mechanisms that limit the efficacy of so many other tubulin
inhibitors (54, 94). For example, one of the main mechanisms of drug resistance is due to
the overexpression of the class III β tubulin that alters the conformation of the taxane
binding site but does not confer resistance to colchicine binding site agents (95). Humans
have at least 7 expressed β tubulin isoforms, and alterations in their expression are linked
to acquired drug resistance (95). Furthermore, paclitaxel-resistant mutants often show
elevated sensitivity to drugs that bind to alternative tubulin sites, such as colchicine site
agents (95). There is also evidence that the efficacy of the vinca drug, vinorelbine, is
reduced when βIII tubulin is overexpressed, whereas colchicine binding site agents were
unaffected, suggesting that that the resistance from βIII tubulin isoforms are binding site
specific (81, 96). This offers an advantage for chemotherapeutic drugs targeting the
colchicine binding site.
To address conventional multidrug resistance to many microtubuleinhibiting agents, there have been numerous efforts to develop colchicine binding site
inhibitors because of their therapeutic advantages over taxanes and vinca alkaloids.
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Recently, 2-aryl-4-benzoyl-imidazoles ABI-274 and ABI-231 were discovered by Miller
and Li’s group and they specifically target the colchicine binding site (97, 98). The
compounds exhibited similar potency to MDR cells compared to corresponding parent
cells. (99). They also demonstrated synergistic action through the combination of ABI274 and vemurafenib to overcome vemurafenib-acquired resistance in BRAF(V600E)
melanoma. The combination treatment effectively decreased the levels of phosphorylated
and total AKT, activated the apoptosis cascade, and reduced cleaved caspase-3 and
cleaved PARP (100). These contributions offer new strategies to alleviate the problem of
drug-resistance and they provide practical implications for further investigation of
colchicine binding site agents. Bai et al. reported a similar colchicine binding site
inhibitor, BZML, that showed potent cytotoxic activity against both A549 and
A549/Taxol-resistant cells (99). Mechanistic studies showed that BZML decreased P-gp
expression at the protein and mRNA levels. Cell morphology changes and the expression
of apoptosis-related proteins denoted that BZML induced mitotic catastrophe to
A549/Taxol-resistant cells in a p53-independent, apoptotic-like pathway, whereas BZML
caused apoptosis to A549 cells (99). Verubulin (MPC-6827) is a quinazoline derivative
that showed potent antineoplastic activities against diverse tumors and promoted
apoptosis in both sensitive and MDR cancer cell phenotypes (101). Other verubulin
analogs have been developed in attempt to maintain potency and avoid resistance, and
these compounds have reported vascular disrupting activities and low IC50 values against
various cancer cells (102). Several other colchicine binding site inhibitors investigated
include indanocine, millepachine, SSE15206, IMB5046, D4-9-31, and their respective
synthetic derivatives. Indanocine is a derivative of indanone and a selective inducer of
apoptosis to stationary multidrug-resistant cancer cells. One approach to eradicate tumor
cells involved combination therapy with indanocine, which was selectively cytotoxic to
non-cycling, multidrug-resistant cells and other chemotherapeutic drugs, which targeted
abnormalities of cell cycle tumors (103). Yang et al. reported the ability of millepachine
to evade multidrug resistance in an A2780CP (P-gp overexpressing) model and
demonstrated that it irreversibly interacted with the colchicine site of β-tubulin and
retained full activity toward MDR cells (104). SSE15206 also circumvented drug
resistance in KB-V1 and A2780-Pac-Res cell lines that overexpressed P-gp (105).
IMB5046 was not a P-gp substrate and displayed potent cytotoxicity against a panel of
tumor cell lines and multidrug-resistant cell lines that were resistant to colchicine,
vincristine and paclitaxel treatment (106). D4-9-31, a pyridine-pyrimidine amide, showed
strong efficacy in isogenic paclitaxel-resistant breast cancer cells and also evaded P-gpmediated drug efflux (107). Another major mechanism of drug resistance to tubulin
inhibitors that is a critical clinical concern is due to the overexpression of certain βtubulin isoforms. Humans have at least 7 expressed β-tubulin isoforms, and alterations in
their expression is linked to acquired drug resistance (95). Studies have shown that
overexpression of class III β-tubulin reduces the efficacy of taxanes and vinca alkaloids,
but drugs that target the colchicine binding site may circumvent resistance (81).
Further efforts evaluating novel tubulin inhibitors will help elucidate the drug
resistance mechanisms and thus guide drug design that can overcome inherent or
acquired drug resistance. In addition, discovery of tubulin inhibitors with different
inhibition mechanisms (such as targeting two pathways with one compound) will open
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alternative avenues to bypass the problem of drug resistance. Another strategy involves
utilizing antibody-drug conjugates of tubulin inhibitors for targeted drug delivery to
circumvent MDR, improve the therapeutic window, and limit toxicities (108). While
significant strides have been made to address MDR, resistance is often multifactorial and
heterogeneous. Therefore, efforts to gain insight into tumor dependence and the
relationship of the individual drug resistance effectors may assist in combating the
complex phenomenon of MDR (109).
Microtubule Targeting Agents’ Potentiation of Immune Response and Implications
in Cancer
Dendritic Cells: Induction of Maturation and T Cell Priming
In addition to their antimitotic effects, microtubule targeting agents can also affect
many non-mitotic mechanisms, including eliciting an immune response following the
disruption of intact microtubules. The perturbance of microtubules from anti-tubulin
agents can then induce anti-inflammatory responses and leukocyte action (110). For
example, dendritic cells (DC) are antigen-presenting cells and are important regulators in
the initiation of innate and adaptive immunity. While they have long been heralded for
their defensive action to foreign pathogens, they are more recently being appreciated for
their role in regulation of antitumor response. However, tumor-altered DC differentiation
can interfere with their ability to potentiate an immune response (111). This can lead to
DCs and their precursors accumulating in the tumor microenvironment and exacerbate
the immunosuppressive action of the tumor. Therefore, intervening and converting the
immature DCs to mature antigen presenting cells is an important target for immunetherapy based cancer treatment (112). Microtubule destabilizing agents including
ansamitocin P3, dolastatin, and antibody-drug conjugates containing dolastatin 10
analogs have been shown to induce functional DC maturation and activation, and also
increase the capacity of priming antigen-specific CD4+ and CD8+ T cells (113, 114). It
has also been reported that other classes of microtubule-destabilizing agents can activate
DCs, unlike microtubule stabilizing agents which only invoked minimal activation in
murine cells and caused no observed effect in DCs (112). Another group also investigated
the effects of microtubule destabilizing agents on DC maturation and T-cell activation in
relation to immunogenic tumor cell death. They reported that dendritic cell vaccines
pulsed with colchicine- or 2-phenyl-4-quinolone analog- treated cell lysates mitigated
tumor growth, revealed cytotoxic T-lymphocyte activity in tumors, and extended survival
of treated mice inflicted with tumor xenografts (115).
Inflammation
Inflammation can play a role in malignant transformation, cancer progression and
pathogenesis in numerous tissues. For example, inflammatory bowel diseases such as
ulcerative colitis and Crohn’s disease contribute to the development of colon cancer,
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because chronic inflammation can endorse the production of tumors. It has been reported
that the use of nonsteroidal anti-inflammatory drugs lowers mortality caused by sporadic
colon cancers, representing a link between cancer and inflammation (116-118). The
interaction of tumor cells with a variety of aspects within the tumor microenvironment,
including macrophages, B and T cells, mast cells, fibroblasts, myofibroblasts and
extracellular matrix components, has been shown to propagate tumor progression.
Furthermore, tumors are capable of secreting cytokines, chemokines, growth factors, and
proteases to remodel the stroma microenvironment (119). Inflammation is driven by these
soluble factors from the tumor cells or from cells recruited to the tumor microenvironment such as macrophages and mast cells, which can then drive tumor cell growth,
interfere with differentiation, and increase cancer cell survival. Elevated influx of
angiogenic cytokines from the surrounding immune cells to the tumor microenvironment
can also contributing to tumor metastasis (120). Since levels of cytokines such as Tumor
necrosis factor α (TNFα), IL-8, IL-6 and vascular endothelial growth factor are often
elevated in the serum of colorectal carcinoma patients, they represent potential anticancer
therapeutic targets (121, 122). Oncogenic signaling pathways are also activated by
cytokines that induce NF-κB signaling and turn on oncogenic mediators that promote
inflammation (119). While aberrantly expressed inflammation is linked to cancer
promotion and disease progression, targeting pro-apoptotic signals from an inflammatory
immune response to induce apoptosis of tumor cells could utilize these targets in
anticancer treatment. Cell death imposed by an immune response can be from cell killing
by cytotoxic T cells and natural killer cells, and can also be stimulated by apoptotic
ligands, such as TNFα. There have been reports on microtubule targeting agents
sensitizing cells to TNFα and other inflammatory apoptotic ligands (123, 124). AK301, a
colchicine binding site tubulin inhibitor, was found to cause treated cells to express
elevated levels of TNF receptor 1 (TNFR1) on the cell surface and increase caspases-8, 9, and -3 activation in the presence of TNFα. It also induced Fas- and Tumor necrosis
ligand -dependent apoptosis (123). Interestingly, it caused greater TNFα sensitization
than other tubulin binding agents including colchicine, nocodazole, and vincristine,
though it achieved a lower degree of tubulin polymerization inhibition from tubulin
binding assays. Nonetheless, these studies explore the relationship between microtubules
and apoptotic ligand-sensitizing agents and how these agents can exploit immune
response elements for cancer therapy. This may be particularly useful for colon or other
cancers that have high levels of inflammatory cell infiltrate or following treatment with
an immune stimulant or vaccines.
Colchicine, which is historically used in the treatment of gout, has been shown to
induce an anti-inflammatory response through destabilization of microtubules, which
subsequently interferes with the assembly of the NOD-like receptor pyrin domain
containing 3 (NLRP3) inflammasome (125). Activation of the NLRP3 inflammasome
within macrophages is commonly implicated in innate immune inflammatory response
(125). NLRP3 uses a mitochondrially-bound adaptor protein (apoptosis-associated
speck-like protein) containing a caspase recruitment domain to recruit caspase-1 to the
complex, followed by autocatalytic processing and activation, ultimately facilitating the
cleavage of pro-inflammatory cytokines IL-1β and IL-18 to their activated forms (126).
The generation of optimal sites for activation of the NLRP3 inflammasome, correct

14

localization, and its direct activation is mediated by microtubules, and microtubule
disrupting agents block inflammasome activation (127).
Polyploidy and Micronucleation
Another way that microtubule targeting agents may provoke an immune response
is related to their ability to cause polyploidization (128-130). This can happen through a
process called mitotic slippage, where cells arrested in the M phase can enter interphase
without undergoing proper chromosome segregation and cytokinesis, resulting in
tetraploid multinucleated cells (131). An increase in the number of chromosome sets (>4)
has been shown to elevate endoplasmic reticulum stress and cause translocation of
calreticulin to the cell surface. This exposure promotes phagocytosis of stressed cells by
macrophages and dendritic cells of the immune system and stimulates
immunosurveillance (130).
Microtubule targeting agents induce mitotic arrest via disruption of the
mitotic spindle, and interestingly, they have achieved greater success than mitosisspecific inhibitors. This may be in part attributed to their multifaceted roles in other
interphase functions including intracellular trafficking, migration, angiogenesis, and
cell signaling, suggesting that their anticancer efficacy is due to their roles in both
mitotic and non-mitotic events (132, 133). A relatively new theory as to why tubulin
targeting agents, particularly those in the taxane class, have achieved greater clinical
success than mitosis-specific inhibitors is their capacity to promote multiple
micronuclei (134). These form from chromosome segregation errors during mitosis
and recruit a nuclear envelope during telophase which does not incorporate into the
main nucleus. This phenomenon happens when cells are treated with subtoxic drug
concentrations that fail to induce complete mitotic arrest. These micronuclei formed
from double stranded DNA breaks can initiate the activation of cyclic GMP–AMP
synthase (cGAS) inflammatory signaling (135). While this may only occur in a small
population of dividing cells, it can have substantial implications on whole tumor
regression through amplified inflammatory activation. Micronucleated cells can
accumulate within the tumor and are not cleared by phagocytosis in the same manner
as apoptotic cells. Fragmented DNA is exported through nuclear pores into the
cytoplasm and binds to the cytosolic DNA sensor cGAS. CGAS consequently turns
on the endoplasmic reticulum membrane protein STING through the synthesis of
2′3′-cGAMP (136). This activation triggers the transcription factors NF-κB and IRF3
through the kinases IKK and TBK1, eventually leading to the activation of
inflammation. The cGAS-STING pathway activation has been shown to restrain
oncogenes and increase pro-inflammatory genes in cancer cells (137). Ultimately,
cGAS–STING-dependent inflammatory signaling can play a role in antitumor drug
response.
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Summary
Because of their major role in mitosis and other critical cellular processes,
targeting microtubules is an excellent strategy for developing anticancer agents. While
some microtubule targeting agents that exploit the taxane and vinca alkaloid binding sites
have been FDA approved for cancer treatment, there are still many hurdles to overcome
to find a more satisfactory treatment. Targeting the colchicine binding site on tubulin may
circumvent many MDR mechanisms affiliated with taxanes and vinca alkaloids, such as
overexpression of drug efflux pumps and alterations in β tubulin isoforms. Although
there are currently no marketed anticancer agents that target the colchicine binding site,
immense efforts have been made to advance small molecules in this class. Additionally,
drugs targeting this site often are effective as vascular disrupting agents and can
accommodate a large range of structurally diverse scaffolds. While these drugs show
promise for the future of anticancer therapeutics, poor solubility, metabolic stability, and
dose limiting neural and cardiotoxicities continue to be major issues limiting their clinical
potential. While the search for acceptable compounds targeting microtubules continues,
newer generations of tubulin inhibitors will need to optimize efficacy, capitalize on
combination therapies, and effectively escape the shortcomings of current anticancer
drugs.
Hypotheses for Novel Tubulin Inhibitors
In the following Chapters 2-4, we disclose the properties and anticancer activities
of newly synthesized tubulin inhibitors with the following hypothesis in mind: Tubulin
inhibitors that target the colchicine binding site will be able to potently inhibit tubulin
polymerization and disrupt microtubule dynamics, interfere with cellular processes such
as migration and proliferation, evade multidrug resistance, and show strong efficacy in
animal models harboring cancer xenografts and taxane-resistant tumors. This is the
overall goal for each of the different series of compounds evaluated, but we specifically
tested different scaffolds in each of the chapters.
In Chapter 2, we investigated two novel indolyl-imidazopyridines. These new
analogs were designed from diaryl-ketone chemotypes that were shown to possess
tubulin polymerization inhibition properties (138-142). To optimize this scaffold, the
ketone was cyclized to a pyridine ring and further introduced an imidazole, leading to a
series of series of indolyl-imidazopyridines. We previously reported that the lead
compounds in this series caused substantial cytotoxicity against several cell lines and
enhanced the metabolic stability in liver microsomes (143). Therefore, based on those
initial findings, we were determined to expand our biological assessment and explore the
drugability of the two most promising compounds, DJ95 and DJ101. We hypothesized
that these compounds would show broad anticancer action in expanded cell lines and
disrupt microtubule networks and mitotic spindle formation. We also hypothesized that
they would optimally target the colchicine binding site, maintain a low resistance index
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against ABC transporter overexpressing cell lines, and show significant efficacy against
taxane-resistant tumors in animal models.
In Chapter 3, we explored a different scaffold in a similar manner. Previously, we
reported the discovery of the 2-aryl-4-benzoyl-imidazole (ABI) scaffold (140).
Subsequent structural optimization of the benzoyl moiety, the aryl moiety, and the
imidazole fragment in this scaffold resulted in analogs with improved antiproliferative
activities and tubulin inhibiting properties (98, 141, 143, 144). ABI-231 (VERU-111)
was determined to be the most potent from those modifications, and it is currently under
clinical development by VERU Healthcare. We hypothesized that we could improve on
VERU-111 by focused structural-based optimization of the indole moiety and the 3,4,5trimethoxyphenyl moiety. In doing so, we hypothesized we could obtain analogs with
lower IC50s, enhanced tubulin depolymerization capabilities, and strong efficacy against
melanoma and taxane-resistant prostate cancer xenograft tumors in mice without causing
toxicity or eliciting off-target adverse reactions.
In Chapter 4, we unveil the final anti-tubulin series we evaluated, which was
based off the Azixa (Verubulin/MPC-6827) scaffold (101). We chose this scaffold
because of Azixa’s potent tubulin depolymerization properties and its vascular disrupting
attributes (39, 40, 101, 102). Other reported indole derivatives of Azixa demonstrated
significant disturbance of tumor vasculature and induced necrosis (102). We selected our
starting point from an Azixa derivative with reduced conformational flexibility compared
with other Azixa analogs (145). Because it showed strong potency and tubulin
depolymerization action but poor metabolic stability and high toxicity, it provided us
with an opportunity for significant improvement. Therefore, we hypothesized that we
could optimize this scaffold and identify novel compounds with greater metabolic
stabilities and reduced toxicities. We also surmised that these compounds would
demonstrate significant efficacy against clinically relevant MDR xenograft models and
display drastic morphological changes to tumor vasculature, similar to other vascular
disrupting agents.
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CHAPTER 2. INDOLYL-IMIDAZOPYRIDINES DJ95 AND DJ101 ARE
TUBULIN INHIBITORS THAT OVERCOME MULTIDRUG RESISTANCE1
Introduction to DJ95 and DJ101
Microtubules are cytoskeletal structures that are essential for a multitude of
cellular events including movement, intracellular transport, cell signaling, and mitosis
(146-149). Microtubules are composed of α- and β-tubulin proteins, which readily
undergo polymerization and depolymerization in a phenomenon known as dynamic
instability (150). They also form the highly dynamic mitotic spindles that are responsible
for the alignment and segregation of chromosomes in the cell during mitosis (151).
Interference with microtubule dynamics consequently disrupts mitotic progression and
ultimately leads to apoptosis and cell death (152). Therefore, interfering with microtubule
dynamics by targeting tubulin is a validated anticancer strategy, and many agents are
already used clinically or are undergoing development (148, 153-155).
Tubulin inhibitors can be broadly classified as stabilizing or destabilizing agents.
Currently, all approved tubulin inhibitors for cancer therapy target the taxane or vinca
alkaloid binding site. However, many tubulin inhibitors, including paclitaxel (Taxol®),
are associated with MDR mechanisms such as overexpression of drug efflux pumps or
the βIII tubulin isoform (54, 156-158). Drug efflux mediated by ABC transporters is the
most commonly observed mechanism responsible for inhibiting the intracellular
accumulation of therapeutic agents in resistant cell lines (72). Of the known human ABC
transporters, resistant melanoma cells have been shown to overexpress ABCB1 (MDR1,
P-gp), ABCC1 (MRP1), ABCC2 (MRP2), and ABCB5 amongst others (159-162).
ABCG2 (BCRP) is also well-characterized and its overexpression causes resistance to a
variety of anticancer drugs including paclitaxel and docetaxel(163, 164). Extensive
research efforts have addressed the issue of MDR, and numerous studies have
demonstrated that colchicine binding agents can overcome ABCB1 overexpression and
βIII tubulin-mediated drug resistance (81, 94, 97, 165-169). While colchicine is not
employed as an anticancer agent due to its toxic side effects, other colchicine binding
inhibitors have demonstrated promising potential and some are currently being
investigated as anticancer candidates (23, 54).
More recently, there has been increasing interest in the vascular-disrupting
capabilities possessed by some microtubule binding agents (40, 170, 171). It is wellknown that tumor progression is dependent on blood vessels to supply oxygen, essential
nutrients, and growth factors. Vascular disrupting agents act on the tumor endothelium
and induce destructive changes that decrease blood flow, promote vascular collapse,
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Modified with permission from American Association for Cancer Research. Kinsie E. Arnst, Yuxi Wang,
Dong-Jin Hwang, Yi Xue, Terry Costello, David Hamilton, Qiang Chen, Jinliang Yang, Frank Park, James
T Dalton, Duane D. Miller and Wei Li. A Potent, Metabolically Stable Tubulin Inhibitor Targets the
Colchicine Binding Site and Overcomes Taxane Resistance. Cancer research. 2018; 78(1): 265-277.
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initiate hypoxia within the tumor, and cause necrosis (171). There is accumulating
evidence that microtubule binding agents can act selectively on tumor endothelial cells,
and this supports the pursuit of targeting tumor vasculature (170).
We previously reported the discovery of diaryl-ketone chemotypes, including a
phenyl ring as linker (I-387) (138), 4-substituted methoxybenozyl aryl thiazoles
(SMART)(142), phenylaminothiazoles (PAT) (139), arylbenzoylimidazoles (ABI) (98),
and reverse arylbenzoylimidazoles (RABI)(141), that interfere with tubulin
polymerization by binding to the colchicine domain. While these compounds displayed
potent anticancer activity in human melanoma and prostate cancer cell lines, the ketone
moiety in their structure presented a metabolically labile site (172). Further structural
optimization to incorporate this metabolic soft spot into a stable ring produced a novel
class of indolyl-imidazopyridines, with DJ95 and DJ101 representing the two most
promising drug candidates in this series (structures shown in Figure 2-1) (143, 173).
DJ95 and DJ101 not only possessed excellent metabolic stability as designed, they also
showed improved anticancer potency in initial cytotoxicity testing and strong
polymerization effects in a cell-free tubulin assay(143, 174, 175).
To further preclinically evaluate the DJ compounds, we expanded our
investigation to additional malignant melanoma cell lines, the NCI-60 cell line panel,
taxane-resistant cell lines, and ABC-transporter overexpressing cell lines. We also
evaluated their effect on cancer cell migration, clonogenic potential, and endothelial cell
tube formation in vitro. Their depolymerization effects were demonstrated through
visualization of the microtubule networks as well as mitotic spindles formation. The
binding of both DJ95 and DJ101 to the colchicine site was confidently confirmed through
X-ray crystallographic analyses. Prior to in vivo studies, compounds were screened by
separate pharmacological profiling services to identify potential off-target interactions to
physiologically important targets. Antitumor efficacy was demonstrated for both
compounds in a melanoma xenograft model, and DJ101 was also evaluated in a
metastatic melanoma model and taxane-resistant prostate cancer xenograft model. To
determine if the compounds possess vascular disrupting properties,
immunohistochemistry (IHC) analysis of the tumor sections was utilized to determine
alterations to the tumor endothelium.
Materials and Methods
Cell Culture and Reagents
Human melanoma cell lines, A375, RPMI-7951, WM-164, WM115 and SKMEL-1, and adult primary dermal fibroblasts cells (American Type Culture Collection or
ATCC, Manassas, VA, USA) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Corning, Manassas, VA) supplemented with 10% (v/v) fetal bovine serum
(FBS) (Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic/antimycotic mixture
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Figure 2-1.

Structures of compounds DJ95 and DJ101
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(Sigma-Aldrich, St. Louis MO). Murine melanoma B16F10 cells (ATCC, Manassas,
VA, USA) were cultured in Minimum essential medium (Invitrogen, Carlsbad, CA),
supplemented with 5% heat-inactivated Hyclone FBS (Thermo Scientific, Rockford, IL),
1% antibiotic-antimycotic mixture (Sigma-Aldrich, St. Louis MO), 1% Mem-sodium
pyruvate (Invitrogen, Carlsbad, CA), 1% Mem-vitamin (Invitrogen, Carlsbad, CA), LGlutamine (2 mM final concentration) (Invitrogen, Carlsbad, CA), and 1% Mem NEAA
(Invitrogen, Carlsbad, CA). Parental prostate cancer PC-3, its paclitaxel-resistant
daughter line PC-3/TxR, parental prostate cancer DU-145, and its docetaxel-resistant
daughter line DU-145/TxR were gifts from Dr. Evan Keller at the University of Michigan
Medical School. PC-3 and DU-145 cell lines were cultured in RPMI 1640 media
(Gibco® by Life Technologies, Carlsbad, CA) supplemented with 10% (v/v) fetal bovine
serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic/antimycotic
mixture (Sigma-Aldrich, St. Louis MO). Taxane-resistant PC-3/TxR and DU-145/TxR
cell lines were cultured in the same media and additionally supplemented with 10 nM
paclitaxel or docetaxel, respectively. Paclitaxel or docetaxel was not included in the
media for PC-3/TxR or DU-145/TxR for at least one week prior to in vitro and in vivo
testing. HUVECs were cultured in Endothelial Cell Growth Medium containing growth
supplement (Promocell, Heidelberg, Germany) and 1% antibiotic/antimycotic mixture
(Sigma-Aldrich, St. Louis MO). The human epidermoid carcinoma cell line KB-3-1, its
drug-selected ABCB1-overexpressing KB-C2 cell line (maintained in medium with 2
Pg/mL colchicine) and ABCC1-overexpressing KB-CV60 cell line (maintained in
medium with 1 mg/mL of cepharanthine and 60 ng/mL of vincristine) (176) were kindly
provided by Dr. Shinchi Akiyama at Kagoshima University, Japan. The human nonsmall cell lung cancer cell line NCI-H460 and its mitoxantrone-selected ABCG2overexpressing NCI-H460/MX20 cells (maintained in medium with 20 nM of
mitoxantrone) (177), and the transfected cell lines HEK293/pcDNA 3.1,
HEK293/ABCB1, HEK293/ABCC1, and HEK293/ABCG2-R482 were kindly provided
by Drs. Susan E. Bates at Columbia University, NY, and Robert W. Robey (NIH,
Bethesda, MD). These cell lines were established by transfecting HEK293 cells with
either the empty pcDNA3.1 vector or the vector containing full length ABCB1, ABCC1,
and wild type ABCG2, respectively(178). These cell lines were cultured in DMEM,
penicillin/streptomycin (Corning, Manassas, VA) and FBS or Hyclone bovine calf serum
(GE Healthcare Life Science, Pittsburgh, PA). All cell lines were authenticated by ATCC
by short tandem repeat profiling. Cultures were maintained to 80-90% confluency at 37
°C in a humidified atmosphere containing 5% CO2. Compounds were dissolved in
dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) to make a stock solution of
20 mM. Compound solutions were freshly prepared by diluting stocks with cell culture
medium before use.
Cytotoxicity Assays
The cytotoxic effect against melanoma and fibroblast cell lines was previously
described (179). Briefly, cells were seeded in 96-well plates at a density of 1,000–3,500
cells per well, depending on the growth rate of the cell line. After overnight incubation,
test compounds were added to the wells at 10 concentrations ranging from 0.03 nM to 1
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μM plus a media-only control for 72 hrs in four replicates. Following treatment, the MTS
reagent (Promega, Madison, WI) was added to the cells and incubated in dark at 37 °C
for at least 1 hour. Absorbance at 490 nm was measured using a plate reader (BioTek
Instruments Inc., Winooski, VT).
IC50 values were calculated by nonlinear regression analysis using GraphPad
Prism (GraphPad Software, San Diego, CA). In addition, DJ101 and DJ95 were
evaluated in one dose and five dose assays against the NCI-60 cell line panel by the
National Cancer Institute Developmental Therapeutics Program (NCI/DTP).
The cytotoxic effects of DJ95 to KB-3-1, KB-C2, KB-CV60, NCI-H460 and
NCIH460/MX20 cell lines, and the transfected cell lines HEK293/pcDNA3.1,
HEK293/ABCB1, HEK293/ABCC1, and HEK293/ABCG2-R482, was obtained by ZiNing Lei (St. John’s University). The IC50 was determined using the MTT reagent
(Thermo Fisher Scientific Inc., Haverhill, MA) as previously described (180). Known
tubulin inhibitors with different mechanisms of actions, including paclitaxel
(microtubule-stabilizing agent, targeting the taxane-binding site in tubulin), colchicine
(microtubule-destabilizing agent, targeting the colchicine-binding site in tubulin), and
vincristine (microtubule-destabilizing agent, targeting the vinca alkaloid-binding site in
tubulin) (148, 166), were selected as positive controls for comparison with DJ59.
Paclitaxel, colchicine and vincristine, which are existing substrates of ABCB1 and
ABCC1(181-183), also served as positive substrate controls for the experiments
involving ABCB1- or ABCC1-overexpressing cell lines in this study. Mitoxantrone, a
known substrate of ABCG2(184), was used as positive substrate control in ABCG2overexpressing cells. Cisplatin was used as negative control since it is not a substrate of
ABCB1, ABCC1 or ABCG2 (180).
Colony Forming Assay
Two plating methods were used. To test the effects of DJ95, A375 cells were
seeded in 6 well plates at a density of 500 cells/well (n=4). To test the effects of DJ101,
A375 and RPMI-7951 cells were seeded in 24 well plates at a density of 200,000
cells/well (n=4). After overnight incubation in at 37 °C cells were treated with the
compound or media only control and incubated for 10 days. Cells were then fixed with
methanol and stained with 0.5% crystal violet. Images were taken, and colony area was
quantified with ImageJ software (NIH, Bethesda, MD).
Scratch Migration Assay
A375 and RPM-I7951 cells were seeded in 24 well plates (200,000 cells/well) in
replicates of four and incubated overnight. A 200 μL pipette tip was used to scratch a
straight line through the cell monolayer to remove an area of cells, then washed several
times to remove any debris and uprooted cells. Media was replaced containing equivalent
vehicle (DMSO) control or DJ compounds at 25 nM concentrations. Images were
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obtained at the start of the experiment and after 24 hrs with Evos Fl Imaging System
(LifeTechnologies, Carlsbad, CA). The analysis was performed with ImageJ software
(NIH, Bethesda, MD).
Endothelial Cell Tube Formation Assay
Matrigel (Corning, Manassas, VA) was thawed on ice overnight then diluted with
serum-free media for a final concentration of 10 mg/mL. Matrigel was plated in 48 well
plates and incubated at 37 °C for 1 hour. Low passage number HUVECs (<5) in
logarithmic growth phase were trypsinized and suspended in endothelial cell growth
media. Cells (7 x104) were plated on the Matrigel plates in quadruplicate containing the
desired drug concentrations. Images were captured after 6 hr incubation with Evos Fl
Imaging System (LifeTechnologies, Carlsbad, CA). Analysis was performed with
angiogenesis tool plug-in with ImageJ software (NIH, Bethesda, MD).
Immunofluorescent Staining
A375, RPMI-7951, or WM-164 cells were seeded 2.5x105 - 5x105 on glass
coverslips in 6 well plates and incubated overnight. Media was changed, and cells were
treated with DJ95, DJ101, paclitaxel, docetaxel or media only control for 18 hrs. Cells
were then fixed with 4% paraformaldehyde, permeabilized in 0.1% Triton X (SigmaAldrich, St. Louis MO) in Phosphate Buffered Saline (PBS) (Thermo Fisher Scientific
Inc., Haverhill, MA) and blocked with 3% Bovine serum albumin (Cell Signaling
Technology, Danvers, MA) prior to staining. Microtubules and mitotic spindles were
visualized after incubating with anti-α-tubulin antibody (Thermo Scientific, Rockford,
IL) and Alexa Fluor 647 goat anti-mouse IgG (Molecular Probes, Eugene, OR). The
coverslips were mounted with Prolong Diamond Antifade mounting media containing
DAPI (Invitrogen, Eugene, OR) and images acquired with a Keyence BZ-X700
fluorescence microscope and BZ-X analyzer software (Keyence, Osaka, Japan).
X-Ray Crystallography
Protein Expression and Purification. X-Ray crystallography was performed by
Dr. Yuxi Wang (Sichuan University, in China). The clones of the stathmin-like domain of
RB3 and TTL were generous gifts provided by Dr. Benoît Gigant (CNRS, France) and
Dr. Michel O. Steinmetz (PSI, Switzerland). The stathmin-like domain of RB3 (RB3SLD) from rat was transformed into and overexpressed in E. coli. The protein was
purified by anion-exchange chromatography and gel filtration chromatography. The peak
fractions from the gel filtration column were concentrated to 10 mg/mL and stored at -80
°C (51, 154, 185). The TTL protein from chicken was expressed and purified from an E.
coli expression system as described previously (186). Briefly, the protein was expressed
in E. coli using LB, purified through Ni-NTA affinity chromatography and gel filtration
chromatography (buffer: Bis-Tris Propane pH 6.5, 200 mM NaCl, 2.5 mM MgCl2, 5 mM
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βMe, 1% glycerol). The peak fractions were concentrated to 20 mg/mL and saved at -80
°C. The SDS-PAGE was performed to check the purity of RB3 and TTL. Porcine brain
tubulin (Catalog # T-238P) (Cytoskeleton Inc., Denver, CO) was supplied at 10 mg/mL
in G-PEM (General tubulin buffer:80 mM PIPES pH 6.9, 2 mM MgCl2, 0.5 mM EGTA
and 1 mM GTP) as a frozen liquid and saved at -80 °C until use.
Crystallization and Crystal Soaking. The previously published process of
obtaining crystals of the tubulin-RB3_SLD-TTL (T2R-TTL) complex was applied (186,
187). In brief, tubulin (10 mg/mL), TTL (20 mg/mL) and RB3 (10 mg/mL) were mixed at
the molar ratio of 2:1.3:1.2 (Tubulin: RB3_SLD: TTL) and incubated on ice with 1 mM
AMPPCP, 5 mM tyrosinol and 10 mM DTT, and the mixture was concentrated to 20
mg/mL at 4 °C. The crystallization of the T2R-TTL complex was carried out at 20 °C
using the sitting-drop vapor diffusion method by mixing an equal volume of protein
complex and crystallization buffer containing 6% PEG 4000, 5% glycerol, 0.1 M MES,
30 mM CaCl2, 30 mM MgCl2, pH 6.7. Seeding was used to obtain the well diffracting
crystals. Initial crystals were observed after two days of incubation and reached a final
length of 200-300 Pm within 3-5 days. Morphologically superior crystals were selected,
cryoprotected with crystallization buffer containing 20% glycerol, and flash frozen in
liquid nitrogen.
X-Ray Data Collection and Structure Determination. Diffraction data were
collected at 100K on the beamlines BL19U1 at Shanghai Synchrotron Radiation Facility
(SSRF) in Shanghai, China. The native dataset was collected at a wavelength of 0.97853
Å using MX225 CCD detector. Data were indexed, integrated and scaled using HKL2000
(188). The initial phase was determined by molecular replacement using the apo
structure T2R-TTL (PDB code: 4I55) as the searching model. The structure of T2R-TTLDJ95 was determined by molecular replacement using the previously published T2R-TTL
structure (PDB ID: 4I55) as a search model. The rotation and translation function
searches were performed by the program PHASER (189). The model was further built
with Coot (190) and refined using the phenix.refine module Phenix (191). The model
quality was checked with PROCHECK and shows a good stereochemistry according to
the Ramachandran plot. PyMol was used to generate the figures. Analysis was
determined in coordination with Dr. Stephen White’s group (St. Jude Children’ Research
Hospital).
Pharmacological Profile Screening
Screening of potentially significant off-target effects to DJ95 binding and enzyme
targets was performed via SafetyScreen44 offered by Eurofins Cerep-Panlabs. DJ95 was
tested at 1.0E-07 M. Compound binding was calculated as a % inhibition of the binding
of a radioactively labeled ligand specific for each target. Compound enzyme inhibition
effect was calculated as a % inhibition of control enzyme activity. Results showing an
inhibition (or stimulation for assays run in basal conditions) higher than 50% are
considered to represent significant effects of the test compounds. Results showing an
inhibition (or stimulation) between 25% and 50% are indicative of weak effects. Results
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showing an inhibition (or stimulation) lower than 25% are not considered significant and
mostly attributable to variability of the signal around the control level. In each
experiment, the respective reference compound was tested concurrently with DJ95, and
the data were compared with historical values determined at Eurofins. The experiment
was accepted in accordance with Eurofins validation Standard Operating Procedure.
Assessment of potentially significant off-target effects of DJ101 to 47 major physiologically important targets was performed by DiscoverX (DiscoverX Corporation,
Fremont, CA) in 78 assays using its Safety47™ Panel and standard protocols. DJ101 was
assayed at 1 μM concentrations in two replicates. Hit responses < 70% are considered
negligible.
LC-MS/MS Plasma Concentration Analysis
LCMS/MS Parameters. The LC-MS/MS data was obtained by Dr. Dejian Ma
(UTHSC). The LC-MS/MS system comprised a Sciex (Framingham, MA) 5500 triple
quadrupole mass spectrometer, equipped with a Turboionspray™ ionization interface and
Analyst software version 1.6.3. Chromatographic separation was carried out using a
ZORBAX SB-C18 column of 150 x 4.6 mm i.d., and 3.5 μm particle size (Agilent
Technologies, Santa Clara, CA) maintained at 35°C using Shimadzu (Columbia, MD)
Nexera XR HPLC system and SIL-20ACXR autosampler. The mobile phase (A: Milli-Q
water, B: methanol) was eluted at a flow rate of 0.5 mL/min. The gradient started at 50%
of mobile phase B and maintained for 0.5 min, then linearly rose to 100 % B over 1 min.
Subsequently, the eluent composition was maintained at 100% B from 1.5 to 6 min
before it was decreased to initial condition 50 % mobile phase B for re-equilibration in
0.1 min. The total run time was 6.5 min plus a pre-equilibrate of 0.5 min. A switching
valve directed the mobile phase to the MS system between 4.5 and 6.1 min. The
electrospray ion source was operated in a positive ionization mode for all the
experiments. The typical parameters were: capillary 5.5 kV; entrance potential (EP) 10 V;
channel electron multiplier (CEM) 1800 V; source temperature 600°C.
LC/MS Sample Preparation. Protein precipitation was used to extract DJ95
from plasma. Plasma (50 μL) was added in 150 μL precipitation solution, methanol
including 26.5 nM ABI-231 as IS, vortexed for 15 seconds, and then centrifuged for 15
minutes at 4°C (circa 12,000 rpm). Supernatant (120 μL) was then transferred to a 96well plate and 1 μL sample was injected into the LC-MS/MS system. Calibration
standards were prepared by mixing DJ95 stock solution in pooled human plasma,
resulting in matrix concentrations of 1, 10, 100, 200, 1000, 2000, 10,000 nM. Blank
samples were prepared using blank plasma. All samples were stored at -20⁰C prior to use.
The lowest standard of 1 nM was not detected. The LLOQ was determined to be 10 nM.
In Vivo Mouse Models and Treatments
All animal experiments were carried out in accordance with the Guide for the
Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National
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Institutes of Health and were approved by the Institution’s Animal Care and Use
Committee (IACUC) at the University of Tennessee Health Science Center (UTHSC,
Memphis, TN). All animals were maintained in a room with a 12 h light/dark cycle and
provided food and water ad libitum.
Plasma Concentration and Pharmacokinetic Analysis. Thirty CD-1 ICR mice
from Charles River Laboratories (Wilmington, MA) of approximately 6 weeks of age
were used for the study. Both males and females were used, and at least one animal of
each sex was collected at each time point. Animals (n=3 per time point) were dosed with
15 mg/kg DJ95 via intraperitoneal injection and drug vehicle was PEG300 (SigmaAldrich, St. Louis MO) and PBS at a 1:1 ratio.
Blood was collected at the following time points: 0, 15, 30, 60, 90, 180, 360, 480,
720 and 1440 min. A blood volume of 0.6 mL was collected from each mouse at
respective time point via cardiac venipuncture using heparinized syringes and collected
into lithium heparinized tubes. Samples were centrifuged at 3,000 rpm for 10 min.
Plasma was collected into 1.5 mL centrifuge tubes and frozen at -80C until analysis by
LC/MS. Pharmacokinetic parameters area under the curve (AUCinf), half-life (t1/2),
clearance, volume of distribution and maximum concentration (Cmax) were measured.
MTD and Xenograft Studies. We first performed an acute maximum tolerable
dose (MTD) study for DJ101 formulated in the vehicle (equal parts PEG300: PBS) by
progressively increasing daily injection doses via i.p. route to ICR mice (n=2) (Evigo
Corporation, Denver, CO), and estimated the MTD to be at least 65 mg/kg. To ensure a
safety margin during the repeated treatment, the dose was scaled down to 30 mg/kg in the
animal experiments. We also performed a longer MTD study by subjecting nude mice
(Evigo Corporation, Denver, CO) to 30 mg/kg doses of DJ95 or DJ101 formulated in the
vehicle by i.p. injection for 5 consecutive days. Because mice receiving DJ95 treatment
began to show signs of toxicity beyond this time point, we scaled the dose back farther to
15mg/kg for the xenograft study.
Nude mice, age 6–8 weeks old, were purchased from Evigo Corporation (Denver,
CO) for the xenograft studies. Logarithmic growth phase A375, PC-3, or PC-3/TxR cells
were prepared in phenyl red-free, FBS-free media and mixed with thawed matrigel prior
to injecting into mice. Tumors were established by injecting 100 μL of matrigel/cell
suspension containing 2.5×106 cells subcutaneously in the hind flank of each mouse.
After tumors were established, mice were ranked on tumor size and randomized into
control or treatment groups, with each group receiving half males and half females. 100
μL of the drug treatment or vehicle control solution was administered via i.p. injection 5x
a week for the duration of the studies.
Tumor volume was measured three times a week with a caliper and calculated by
using the formula a×b2×0.5, where a and b represent the larger and smaller diameters,
respectively. Tumor growth inhibition (TGI) at the conclusion of the experiments was
calculated as 100 – 100 ×((T − T0)/(C − C0)), where T, T0, C and C0 are the mean
tumor volume for the specific group on the last day of treatment, mean tumor volume of
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the same group on the first day of treatment, mean tumor volume for the vehicle control
group on the last day of treatment and mean tumor volume for the vehicle control group
on the first day of treatment, respectively (100). Animal activity was monitored, and body
weights were recorded throughout the study to assess potential acute toxicity. At the end
of the experiment, mice were sacrificed, and the tumors were dissected out, weighed, and
fixed in in 10% neutral buffered formalin solution prior to pathology staining analysis.
B16F10 Melanoma Lung Metastasis Model. C57BL/6 mice from Charles River
Laboratories International, Inc., age 7–8 weeks old, were used to study the inhibition
effect of DJ101 on lung metastasis of melanoma cells. Murine B16F10 melanoma cells
growing in a logarithmic growth phase were suspended in the conditioned media at a
density of 1 × 106 per mL. Each mouse was inoculated with the tumor cells (100 μL
containing 1 × 105 cells) via the lateral tail vein. The treatment started on the third day
after the inoculation to ensure the initiation of metastasis before beginning treatment.
DJ101 (30 mg/kg) and vehicle were formulated as described above. Doses (100 μL) of
DJ101 or vehicle solution were administered via i.p. injection every other day for 2
weeks. Animal activity and body weights were monitored during the entire experiment
period to assess acute toxicity. Mice were sacrificed 15 days after the initiation of the
experiment, and the lungs were separated, expanded and preserved in 10% neutral
buffered formalin. The number of lung metastasis nodules was recorded. Major organs
were also preserved in the same manner for subsequent toxicological examination.
Histology and Immunohistochemistry
The fixed tumor xenograft tissues were embedded in paraffin. Serial sections were
obtained for Hematoxylin and Eosin (H&E) and immunohistochemistry (IHC) analysis.
Staining was performed with rabbit anti-cleaved caspase 3 antibody (Cell Signaling
Technology Inc., Danvers, MA) and rabbit anti-CD31 (Cell Signaling Technology Inc.,
Danvers, MA) following ABC-DAB methods. Antigen retrieval was performed with H3300 antigen unmasking solution (Vector Laboratories, Burlingame, CA). Images were
captured with a Keyence BZ-X fluorescent microscope (Keyence Corporation, Itasca, IL)
at 10x and 20x magnification. Five representative fields of view from three tumors per
group at 20x magnification were analyzed in ImageJ to calculate positive stained area.
Pathological tissue sections from major organs (heart, liver, kidney, lung and spleen)
were examined similarly to identify any potential drug-related effects by Dr. Frank Park
(UTHSC). Images were obtained with EVOS XL Core microscope (Life Technologies,
Carlsbad, CA).
Statistical Analysis
Data were analyzed using Prism Software 5.0 (GraphPad Software, Inc., San
Diego, CA). IC50 values were calculated by nonlinear regression. The statistical
significance (P < 0.05) was calculated by one-way analysis of variance (ANOVA)
followed by Dunnett’s multiple comparison test, comparing each treated group to the
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corresponding control group for studies comparing 3 or more groups. An unpaired
Student’s t-test was used to calculate significance for studies comparing two groups.
Results
Potency Against Malignant Melanomas and the NCI-60 Cell Panel
Our preliminary studies showed that DJ101 and DJ95 have potent cytotoxic
activity against a variety of melanoma and prostate cancer cell lines (143). To expand
upon this observation and determine their in vitro efficacy against additional metastatic
melanoma cell lines that harbor clinically relevant mutations, we first performed
cytotoxicity assays for the DJ compounds against a panel of human metastatic melanoma
cell lines including A375, RPMI-7951, WM-164, WM115, and SK-MEL-1 (Table 2-1).
These cell lines possess diverse genetic complexity and contain genomic mutations in one
or more of the following genes: BRAF, CTNNB1, CDKN2A, PTEN, and TP53. DJ101
demonstrated comparable potency against these lines to colchicine, with IC50 values
ranging from 7-12 nM in each of the tested cell lines. DJ95 was the most potent against
A375 cells, though less potent than DJ101 or colchicine.
DJ95 and DJ101 were also tested in the NCI-60 cell panel, assaying a diverse
selection of cancer types, in a single-dose and 5-concentration assay to see if they were
effective against other kinds of cancer (Appendix Figures A-1 and A-2). DJ compounds
were highly active and demonstrated low GI50 values for the majority of melanoma cell
lines, and were especially potent against leukemia, colon, CNS, and prostate cancers. The
average total growth inhibition (TGI) and LC50 was greatest for colon cancer and
melanoma. The dose-response curves of each individual melanoma cell line tested
revealed that the cell lines most sensitive to DJ95 treatment were LOX IMVI and SKMEL-5 and to DJ101 were MDA-MB-435 and also SK-MEL-5.
DJ Compounds Overcome Taxane Resistance and ABC Transporter-Mediated
Resistance
In addition to melanoma cell lines, we also tested DJ compounds against prostate
cancer cell lines, including parental PC-3 and DU-145, paclitaxel-resistant PC-3 (PC3/TxR) and docetaxel-resistant DU-145 (DU-145/TxR) cell line pairs to understand if
DJ95 can overcome mechanisms associated with taxane resistance (Table 2-2). In the
PC-3 cell line, DJ95 and DJ101 were mildly less toxic (8.5 ± 0.7 and 17.0 ± 2.6 nM) than
the colchicine-treated cells (5.31 ± 1.86 nM). Paclitaxel and docetaxel treatment
demonstrated greater cytotoxicity, with IC50s of 3.7 ± 0.3 and 0.5 ± 0.1 nM, respectively.
However, in the paclitaxel-resistant PC-3/TxR cell line, DJ101 and DJ95 were much
more potent than in the parental cell line (8.5 ± 0.7 and 4.8 ± 1.7 nM) and even
outperformed colchicine (28.1 ± 1.2 nM). There was a drastic reduction in efficacy for
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Table 2-1.
Cytotoxic effects of DJ compounds against malignant melanoma
cancer cell lines.
Treatment

IC50 ± SEM (nM)
A375

RPMI-7951

WM-164

WM115

SK-MEL-1

DJ95

19.2 ± 2.3

46.0 ± 6.5

92.2 ± 12.7

92.2 ± 12.7

62.5 ± 9.9

DJ101

7.6 ± 0.5

10.1 ± 0.9

12.1 ± 2.4

10.3 ± 1.8

9.6 ± 0.4

Colchicine

11.7 ± 0.4

17.8 ± 1.9

7.8 ± 0.9

7.8 ± 0.9

8.3 ± 1.9

Table 2-2.
Cytotoxic effects of DJ95 and DJ101 against parental and taxaneresistant prostate cancer cell lines.
IC50 ± SEM (nM)
Treatment

IC50 ± SEM (nM)
a

PC-3

PC-3/TxR

DJ95

17.0 ± 2.6

4.8 ± 1.7

DJ101

8.5 ± 0.7

Colchicine

RI

RI

DU-145

DU-145/TxR

0.3

32.4 ± 9.7

222.9 ± 28.0

6.9

6.4 ± 0.3

0.75

18.2 ± 0.9

63.3 ± 7.2

3.5

8.0 ± 0.8

28.1 ± 1.2

3.5

25.7 ± 1.4

>1,000

>40

Paclitaxel

3.7 ± 0.3

110.7 ± 3.7

30

1.1 ± 0.1

>1,000

>1,000

Docetaxel

0.5 ± 0.1

27.9 ± 1.1

55.8

0.10 ± 0.01

352.3 ± 118.2

>3,523

a

RI: resistance index is calculated by dividing the IC50 value of compound in resistant
cell lines by the IC50 in the corresponding parental cell lines.
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the taxanes, showing 30-fold increase in resistance to paclitaxel and a 55.8-fold increase
for docetaxel. The DJ compounds demonstrated substantially better resistance indexes
(RI) of 0.3 for DJ95 and 0.8 for DJ101. Similar results were observed in the DU-145 and
DU-145/TxR cell pair except that the differences were more profound: while paclitaxel
and docetaxel had IC50s of 1 nM or less, and the DJ compounds were slightly less potent
than in the PC-3 cell lines, the taxanes showed greater than 1000 fold decrease in
efficacy to the DU-145/TxR cells while DJ101 had only a slight increase in the resistance
index to 3.5. DJ95 showed some resistance, but much less than colchicine, which showed
more than a 40-fold increase in resistance DU-145/TxR compared to the parental cells.
These results demonstrate that DJ compounds, particularly DJ101, can overcome some
mechanisms of taxane resistance that developed by cancer cells.
Because we were particularly interested in the ability of DJ95 to overcome
transporter-mediated drug resistance, we tested DJ95 against genetically engineered
HEK293 cells lines, that stably transfected full length ABCB1, ABCC1, wild type
ABCG2, or the pcDNA3.1 blank vector. Cisplatin, which is not a substrate for any of
these ABC transporters, was used as negative control. Greater than 100-fold resistance
was observed for the ABCB1 overexpressing HEK293 cells against paclitaxel,
colchicine, and vincristine (Table 2-3). On the other hand, HEK293/ABCB1 resistant
cells showed virtually no resistance to DJ95. Slight resistance (RI= 3.7) was revealed for
the ABCC1 overexpressing HEK293 transfected cells against DJ95 compared to the
vector-only cells, but all other microtubule targeting drugs that were tested (paclitaxel,
colchicine, vincristine) demonstrated significantly increased resistance, with IC50s greater
than 10 μM against HEK293/ABCC1. Similarly, against the HEK293/ABCG2-R482
cells, resistance was evident for all tubulin inhibitors, though less resistance was
developed against the DJ95 compound (about 8.7-fold). This was still lower than
mitoxantrone, a known substrate of ABCG2, showing about 11.2-fold decrease in
potency in the ABCG2 overexpressing cell line.
We also wanted to assess the effects of DJ95 against drug-selected resistant cell
lines. From the parental epidermoid carcinoma cell line KB-3-1, the colchicine
resistant/ABCB1-overexpressing (KB-C2) cell line and vincristine resistant/ABCC1overexpressing (KB-CV60) cell line were developed. The mitoxantrone-selected
ABCG2-overexpressing cell line NCI-H460/MX20 was generated from the parental nonsmall cell lung cancer cell line NCI-H460 and utilized to further evaluate the effects
against ABCG2 upregulation. Compared to the existing tubulin inhibitors paclitaxel,
colchicine and vincristine, DJ95 exhibited greater cytotoxicity against drug-selected
ABCB1-overexpressing KB-C2 cells and ABCC1-overexpressing KB-CV60 cell lines,
with IC50 values of 719.54 ± 181.48 nM and 35.90 ± 4.50 nM, respectively (Table 2-4).
Although there was still some increase in resistance against the KB-C2 (colchicine
selected/ABCB1 overexpressing) cells compared to the parental KB-3-1 cells, both KBC2 and KB-CV60 were much less resistant to DJ95 than they were against the three other
tubulin inhibitors tested. Since no resistance to DJ95 was revealed from ABCB1
transfected cell line, the increase in resistance observed for DJ95 against the colchicineselected KB-C2 may be related to mechanisms affiliated with the colchicine binding site
and not solely ABCB1 overexpression.
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Table 2-3.
Cytotoxic effects of DJ95 against gene transfected ABCB1-, ABCC1or ABCG2-overexpressing cancer cell lines.
IC50 ± SD (nM)
Treatment

HEK293/
pcDNA3.1

HEK293/
ABCB1

HEK293/
ABCC1

HEK293/ABCG2
-R482

DJ95

330.0 ± 44.1

314.7 ± 73.1

1213.9 ± 241.6

2869.2 ± 123.3

Paclitaxel

34.6 ± 6.3

3496.0 ± 657.8

>10000

>10000

Colchicine

112.1 ± 41.5

>10000

>10000

>10000

Vincristine

99.4 ± 23.1

>10000

>10000

>10000

Mitoxantrone

108.0 ± 27.5

—

—

1209.7 ± 111.4

Cisplatin

2510.1 ± 362.6

2583.1 ± 474.5

2584.1 ± 151.8

2475.3 ± 127.4

Data obtained by Zi-Ning Lei (St. John’s University).

Table 2-4.
Cytotoxic effects of DJ95 against parental and drug-selected ABCB1-,
ABCC1- or ABCG2-overexpressing cancer cell lines.
IC50 ± SD (nM)
Treatment
KB-3-1

KB-C2
(ABCB1)

KB-CV60
(ABCC1)

NCI-H460

NCIH460/MX20
(ABCG2)

DJ95

23.5 ± 2.2

719.5 ± 181.5

35.9 ± 4.5

673.0 ± 111.7

5361.5 ± 645.5

Paclitaxel

9.2 ± 2.1

1918.5 ± 106.3

120.0 ± 14.6

>10000

>10000

Colchicine

23.9 ± 4.9

7445.3 ± 446.3

91.7 ± 7.7

>10000

>10000

Vincristine

1.3 ± 0.2

748.8 ± 99.8

218.6 ± 1.9

>10000

>10000

Mitoxantrone

—

—

—

118.7 ± 40.2

2456.5 ± 420.4

Cisplatin

2024.5 ± 463.7

2871.2 ± 115.3

1796.5 ± 198.8

2226.6 ± 179.5

2870.6 ± 281.7

Data obtained by Zi-Ning Lei (St. John’s University).
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In both NCI-H460 and its mitoxantrone-selected ABCG2 overexpressing cell line,
DJ95 demonstrated better anticancer activities than paclitaxel, colchicine and vincristine,
with IC50 values of 673.04 ± 111.71 nM and 5361.50 ± 645.45 nM, respectively, whereas
IC50 values of the three other tubulin inhibitors were higher than 10,000 nM in both cell
lines. However, low resistance against DJ95 was observed in NCI-H460/MX20 cell line
compared to its parental cell line (about 8-fold resistance), though the resistance index
was not as high as that of the substrate control mitoxantrone (about 20-fold resistance).
The results from the drug-selected resistant cells are consistent with those obtained from
transfected ABCG2-overexpressing cell line HEK293/ABCG2-R482 and its vector
control, which indicated that DJ95 might be a weak substrate of ABCG2. Further study is
needed to verify if ABCG2 would be a factor mediating resistance to DJ95.
Interaction at the Colchicine Binding Site on Tubulin
We previously reported the design and synthesis of DJ95 and DJ101(143) and a
number of potent tubulin inhibitors related to this scaffold (98, 141, 142). While
mechanistic studies suggested that these agents produce their antitumor activities by
interacting with the colchicine binding site on tubulin, the detailed molecular interactions
had not previously been fully elucidated. Recently, high-resolution (<3.0 Å) crystal
structures of tubulin in complex with several known colchicine site inhibitors were
reported (51, 192). Using these newly established procedures, we obtained the highresolution X-ray crystal structure of DJ101 in complex with DE-tubulin (deposited to the
Protein Databank with PDB code: 5H7O, resolution 2.8 Å). This high-resolution crystal
structure confirms the direct binding of DJ101 in the colchicine binding site (Figure
2-2A). DJ101 forms three hydrogen bonds with the DE-tubulin dimer: one hydrogen bond
from T179 in loop five in the D-monomer to the imidazole nitrogen, one hydrogen bond
from N349 in loop nine in the E-monomer to the indole nitrogen, and one hydrogen bond
between the oxygen of the 4-methoxyl moiety and the thiol moiety in C241 in helix seven
of the E-monomer (Figure 2-2B). A tight hydrophobic “sandwich” formed by sidechains
from C241, L255, L248, and N258 wraps the trimethoxyphenyl and the imidazopyridine
moieties firmly in the colchicine binding domain. Additionally, the sidechain M259 in
helix eight of the E-monomer serves as a “wedge” between sheet 9 and DJ101 to lock its
curved conformation. It is also evident that DJ101 overlaps with colchicine at its binding
site (Figure 2-2C). These results provide the first direct evidence of DJ101’s direct
interaction with the colchicine binding site in tubulin to inhibit tubulin polymerization.
We also determined the crystal structure of the T2R-TTL complex bound with
compound DJ95 at 2.5 Å resolution, and the coordinates and structure factors have been
deposited in the Protein Data Bank with the PDB ID: 6C77. In the crystal structure, the
compound is bound only at the interface of the first D- and E-tubulin heterodimer, unlike
colchicine where the interfaces of both D- and E-tubulin heterodimers were occupied
(Figure 2-2D). In the case of the unliganded T2R-TTL complex reported earlier, the ET7 loop of E-tubulin at the interface of the D- and E-tubulin heterodimer is in a closed
conformation (PDB ID: 4I55). The DJ95 binding pocket is created by the outward
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Figure 2-2. X-ray crystal structures of DJ101 and DJ95 in complex with tubulin protein.
A) Surface representation of the overall structure of α-tubulin (black) and β-tubulin (grey). DJ101 is shown in sphere representation
(cyan). B) Detailed molecular interactions between the DJ101 molecule (cyan) and the tubulin dimer. Hydrogen bonds are indicated
with black dash lines. C) Superimposition of the binding sites for DJ101 (cyan)-tubulin complex (5H7O) with colchicine (yellow)tubulin complex (4O2B). D) Cartoon showing the organization of D-tubulin (green), E-tubulin (salmon), RB3-SLD (cyan), TTL (grey)
proteins, GTP, GDP, and DJ95. E) 2Fo-Fc electron density map for DJ95 contoured at 1 sigma shown as blue mesh, and hydrogen
bonds are shown as red dashed lines. F) Superimposed tubulin–DJ95 (green sphere) complex and tubulins as found in straight
protofilaments (PDB ID: 1JFF; cyan) showing that binding is not compatible with the straight conformation. Conformational changes
of the secondary elements are labeled. Crystallographic data obtained by Yuxi Wang (Sichuan University, China) and interpreted by
Dr. Stephen White and Dr. Gyanendra Kumar (St. Jude Children’s Research Hospital).
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movement or opening of this loop and the same motion has previously been observed
when colchicine binds (PDB ID: 4O2B). Looking closely at the bound DJ95, we find that
the 3-methoxyphenyl group of DJ95 occupies a deep pocket in the E-tubulin subunit that
is lined with residues Val236, Cys239 and Leu253 (Figure 2-2E). The side chain of
Leu253 makes a pi-H interaction with the phenyl ring of 3-methoxyphenyl group. The
imidazopyridine ring forms two hydrogen bond interactions; a nitrogen atom with the
main chain NH of E-tubulin Asp249 and an NH with the main chain carbonyl oxygen of
Thr179 from D-tubulin across the interface. Finally, the indole ring of DJ95 sits in a
pocket lined by Asn347, Lys350, Asn256 and Met257 of E-tubulin and Val181 from Dtubulin. The electron density is consistent with this ring having two conformations
rotated by ~180° – one where the nitrogen faces the Met257 from E-tubulin, and the other
where the nitrogen faces the Val181 from D-tubulin. The refinement suggests that the
latter conformation is preferred 2:1 over the former. Comparison with the unliganded
T2R-TTL complex revealed that a significant conformational change not only occurs in
loop β-T7 to accommodate DJ95 but also in loop α7(Figure 2-2F). These two loop
conformations are incompatible with the ‘straight’ structure of the tubulin filament and
are therefore consistent with DJ95 acting as a destabilizer of filament formation.
Disruption of Microtubule Networks and Spindle Formation
To characterize their effects on microtubule networks and cell morphology, we
used confocal microscopy to visualize several melanoma cell lines treated for 18 hours
with either DJ compounds or a microtubule stabilizing agent such as paclitaxel or
docetaxel, which promote polymerization. The alteration in microtubule rearrangement in
the treated cells can clearly be observed (Figure 2-3A). Control cells appeared to exhibit
well-organized microtubule networks extending throughout the cell to the cell periphery.
Treatment with DJ95 or DJ101 led to fragmented microtubule networks and an increase
in soluble, cytoplasmic tubulin. At higher concentrations, there appeared to be very little
polymeric tubulin framework left intact. These observations are consistent with a
mechanism of action of tubulin depolymerization. In contrast, taxane-treated cells
demonstrated highly condensed, polymeric tubulin. With increasing concentrations, the
aggregation of the filaments was more pronounced, consistent with increased
stabilization of microtubules.
Microtubules also make up the mitotic spindle and utilize the dynamic properties
for chromosome segregation during mitosis (151). Therefore, tubulin targeting agents
also interfere with the formation and organization of mitotic spindles (193-196). We
investigated the effects of DJ95 in a concentration-dependent manner compared to
untreated control cells (Figure 2-3B). While control cells exhibited normal, bilateral
spindle formation extruding from centrosomes, DJ95 treatment caused aberrant spindle
development as evidenced by multi-polar and disorganized spindle morphology. These
abnormalities were exacerbated with increasing drug concentrations. This is further proof
that DJ95 inhibits the progression of mitosis by interfering with microtubule dynamics.
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Figure 2-3. DJ compounds interfere with microtubule networks and mitotic
spindle organization.
A) Microtubule networks of melanoma cells (either A375, RPMI-7951, or WM-164)
after treatment with DJ101, DJ95, docetaxel or paclitaxel at 40x magnification. The
concentration of the drug treatment is indicated in the bottom of each image. The top row
of images are the untreated control cells for comparison. B) The effect on mitotic spindle
organization of cells undergoing mitosis obtained at 63x magnification. All confocal
images of all cells were obtained after 18 hr drug treatment. Tubulin (red) is visualized by
α-tubulin primary antibody and Alexa Fluor 647 secondary antibody and DNA (blue) is
stained with DAPI.
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Inhibition of Colony Growth and Cell Migration
DJ95 and DJ101 were tested separately in colony-forming assays to evaluate the
long-term inhibitory growth effects on different melanoma cell lines. We first tested the
ability of DJ95 to inhibit colony formation in a concentration-dependent manner
compared to untreated A375 control cells. (Figure 2-4A). A significant decrease was
observed for all treated cells, and concentrations as low as 10 nM caused a 26.78 ± 1.9%
inhibition of colony area compared to control (P < 0.001) and higher concentrations of 25
nM and 50 nM inhibited colony formation by 44.73 ± 1.9% and 65.01 ± 3.08%,
respectively (P <0.0001). At 100 nM, DJ95 almost completely eliminated colony
formation, and only 1.25 ± 0.07% of the area compared to the control remained.
We also tested DJ101 and colchicine in both A375 and RPMI-7951 cells lines
using lower concentrations (Figure 2-4B and 2-4C). Treatment with 4 nM of DJ101
resulted in colonies covering only 30.6% ± 0.8% of the total surface area, representing a
59.5% ± 2.0% inhibition compared to the untreated control cells, which inhabited 75.6%
± 3.7% of the total area. Colchicine was used as a reference control because its ability to
potently and persistently inhibit colony formation is well-documented (197, 198). The
effect of DJ101 on A375 cell colony formation was similar to colchicine at the same
concentration, which had colonies covering a total area of 34.7% ± 1.5% (54.1% ± 3.5%
inhibition). Control RPMI-7951 cells formed colonies occupying a surface area of 83.2%
± 2.1% and comparable reductions in colony formation were measured for treated cells,
where DJ101-treated cells occupied 47.1% ± 5.7% (43.5% ± 11.8% inhibition) and
colchicine-treated cells covered 50.9% ± 3.4% (38.8% ± 7.0% inhibition). Higher
concentrations (20 nM) of DJ101 or colchicine resulted in complete colony obliteration.
Dunnett’s multiple comparison tests after one-way ANOVA analysis gave an overall P
value of less than 0.0001 for each treated group compared to the control, indicating that
they are statistically different.
To demonstrate that the DJ compounds interfere with cell migration through
microtubule destabilization, we performed scratch migration assays against A375 and
RPMI-7951 cell lines. Cells were treated with 25 nM of the drug and images were taken
at 0, 12 and 24 hours (Figure 2-4D and 2-4E). After 24 hours, untreated A375 cells
migrated into 83.8% ± 6.1% of the wound channel, nearly closing the gap. DJ101 and
DJ95 treated cells migrated into only 40.8% ± 6.0% and 35.6% ± 1.4%, respectively. A
greater reduction in cell migration was observed in the RPMI-7951 cell line, where
control cells reclaimed 86.4% ± 10.5% of the wound channel and DJ compound treated
cells occupied less than 25% of gap area. Similar but less inhibition of the scratch area
was observed colchicine-treated cells, achieving 52.0% ± 2.7% closure for the A375 cell
line and 52.3% ± 3.4% for the RPMI-7951 cell line. One-way ANOVA analysis of both
cell lines gave P values in both cell lines were less than 0.0001. There was no significant
difference in the scratch channel area for each group at the beginning of the experiment
(time 0), and the % closed was based on this average area. Taken together, these in vitro
studies demonstrate that the DJ compounds strongly reduce aberrant cancer cell
proliferation at low concentrations and hinder cell migration at least as efficiently as
colchicine in these melanoma cell lines.
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Figure 2-4. Inhibition of cell proliferation and migration.
A) Colony formation assay of A375 cells treated with DJ95 or colchicine (n=3). Colony area was quantified by VisionWorks software
and represented by total area (in pixels) ± SD. B) Colony assay formation of A375 and C) RPMI-7951 cells treated with DJ101 or
colchicine (n=4). Colony area is represented as percent of the total surface area ± SD as determined by ImageJ software. Colony
assays were treated for 10 days in 6-well plates. D) Scratch migration assay of A375 and E) RPMI-7951 cell lines (n=4). Cell
migration is presented as mean percent of the area closed ± SD after 24 hrs compared to the scratch area at time 0. ImageJ software
was used to calculate the total scratch area at each of the time points. Scale bar = 1000μm. Statistical significance was determined by
one-way ANOVA followed by Dunnett’s multiple comparison test, comparing each treatment group to the control group for the above
experiments. (**p< 0.01, ***p< 0.001, ****p< 0.0001).
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Anti-Angiogenic Activity on HUVEC Tube Cell Formation
In recent years, there has been extensive research on the vascular disrupting
properties of tubulin targeting agents and their ability to selectively target tumor
vasculature (39, 40, 97, 199-201). To see whether DJ95 would exhibit these
characteristics, we tested the in vitro effect on the formation of capillary-like networks of
human umbilical vein endothelial cells (HUVECs) plated on Matrigel. The Matrigel
basement membrane allows endothelial cells to form tubules with tight cell-to-cell and
cell-to-membrane contacts (202). After 6 hrs of incubation in the presence of the test
compounds, it was clearly observed that both DJ95 and colchicine disrupted the tube cell
formation in a concentration-dependent manner (Figure 2-5). At concentrations of 100
nM and 200 nM, DJ95 disrupted networks by 35.7% ± 5.6% and 51.8% ± 3.3% based on
total calculated network length (P < 0.01 and 0.0001, respectively). This was similar to
the effect observed from colchicine treatment at the same concentrations, inhibiting
HUVEC tube cell formation by 60.4% ± 9.0% and 81.6% ± 8.0%, respectively (P <
0.0001). Since this result was observed in a short timeframe, we expect that the drug
action on tube cell formation was not a result of antiproliferative activity but rather from
anti-angiogenic action.
Pharmacological Profiling
In vitro pharmacological profiling is increasingly being used to identify
undesirable off-target activity profiles early in the drug discovery process. It involves
screening the compound of interest against a wide range of targets such as receptors, ion
channels, transporters and enzymes other than the intended therapeutic target in order to
identify specific interactions that may elicit adverse drug-related side effects (203). About
3/4ths of all adverse drug reactions are dose-dependent, and pharmacological profiling of
the drug of interest can predict the risk and help reduce drug attrition rate. To further test
for potentially significant off-target effects and determine the drug safety profile, DJ101
was evaluated at 1 μM in the Safety47™ Panel using functional assays for human targets
(Figure 2-6A). This in vitro pharmacological profiling service includes the assessment of
the functional response of 47 major physiologically important targets across 78 assays to
the drug of interest, normalized to respective controls. Only a value higher than |70%|
response is considered significant. DJ101 only showed hit responses in 2 of the 78 assays,
namely norepinephrine transporter (NET) blocking and glucocorticoid receptor (GR)
antagonism. Since the concentration tested was about 100 times greater than the average
IC50 value for DJ101, which is expected to be well above its practical physiological
concentration, results from this Safety47™ Panel screening strongly suggest that DJ101
has minimal potential off-target effects.
DJ95 also underwent pharmacological profiling for off-target assessment but was
screened through a different safety panel. DJ95 was evaluated in binding and enzyme
uptake assays performed by Eurofins Cerep Panlabs. DJ95 demonstrated nominal specific
binding inhibition or stimulation against 37 radioactive labeled ligand targets (Figure
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Figure 2-5. In vitro inhibition of angiogenesis.
Representative images of HUVEC capillary-like formation on Matrigel taken after 6 hr incubation with indicated concentrations of
DJ95 or colchicine. Quantification of total tube length was performed with ImageJ analysis and expressed as mean ± SD (n=4).
Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparison test. (**p< 0.01, ****p<
0.0001).
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Figure 2-6. Pharmacological profiles for DJ95 and DJ101.
A) Assessment of DJ101 in the Safety47™ panel. Graph represents mean percent
response ± SD. Values in between -70% and +70% (indicated with dashed lines) are
considered insignificant. B) Assessment of DJ95 in the SafetyScreen 44 panel. DJ95
binding was calculated as a % inhibition of the binding of a radioactively labeled ligand
specific for each target. Compound enzyme inhibition effect was calculated as a %
inhibition of control enzyme activity. Results showing an inhibition or stimulation less
than 50% are considered insignificant. Both screens were performed in duplicate at 1μM
concentrations.

40

2-6B). Additionally, DJ95 did not induce significant alterations in enzyme function for
COX1, COX2, PDE3A, PDE4D2, Lck kinase or ACHE. Results showing an inhibition
or stimulation higher than 50% are considered significant in this panel, none of which
were observed at any of the targets studied in this screening. These results from 2
separate off-targeting screening services suggest that the DJ compounds minimally
interact with some of the key off-target liabilities responsible for cessation of clinical
drug development.
Pharmacokinetics and Plasma Concentration
Based on the preliminary in vitro data suggesting that DJ compounds are potently
active against melanoma cell lines and do not significantly interfere with off-targets, we
investigated their in vivo anticancer activity. We determined that concentrations up to 30
mg/kg of DJ95 or DJ101 administered by i.p. injection daily was well-tolerated for at
least 5 days in nude mice, but additional treatments with DJ95 caused a decrease in
mouse weight and decline in behavioral activity. Therefore, we scaled back the dose to 15
mg/kg of DJ95 for the pharmacokinetic and xenograft study. To determine if DJ95 could
reach therapeutically relevant biological concentrations at doses of 15 mg/kg, we
collected blood samples from 15 minutes to 24 hrs following i.p. injection of the drug and
analyzed the plasma concentrations by LC-MS methods. The Cmax for DJ95 was 13.65
uM and the detected concentrations stayed above 13 uM for at least 1.5 hrs in mouse
plasma (Figure 2-7A). While the concentration of DJ95 gradually decline over the course
of the 24 hrs during when samples were collected, there was still an average of 126.5 nM
at 12 hrs and 8.1 nM at 24 hrs. This data, along with the AUC (50500 hr*nM) suggests
acceptable exposure for DJ95 over the course of a day. We also determined additional
pharmacokinetic parameters including half-life (3.28 hrs), volume of distribution to (3.51
L/kg), and clearance (0.744 L/hr/kg). We reasoned that these results supported a dosing
regimen of 5 treatments/week, allowing for 2 recovery days to avoid accumulating
toxicities.
Tumor Growth Inhibition and Reduction of Metastasis in Melanoma Models in
Mice
The antitumor efficacy of the DJ compounds was determined in an A375
xenograft model in nude mice. Tumors were established by subcutaneous inoculation of
A375 cells, and treatment began after viable tumors developed. Groups were dosed by
i.p. injection with either 15 mg/kg treatments of DJ95, 15 or 30 mg/kg of DJ101, or
vehicle solution only. After 2 weeks and a total of 10 treatments, the group of mice
receiving 15 mg/kg doses of DJ95 or DJ101 had an average tumor growth inhibition
(TGI) of 61.4% and 66.4%, respectively (Figure 2-7B). At the higher doses 30 mg/kg of
DJ101, the treatment group averaged 92.8% inhibition compared to vehicle control.
Dunnett’s multiple comparison test indicated that treatments with 15 mg/kg of DJ95 (P <
0.01), 15mg/kg of DJ101 (P < 0.001), and 30 mg/kg doses of DJ101 (P < 0.0001), were

41

Figure 2-7. Inhibition of tumor growth and metastasis in melanoma mouse
models.
A) Plasma concentrations at each timepoint following i.p. injection 15 mg/kg
concentration of DJ95 shown as individual replicates connected by mean (n=3 per time
point). B) A375 melanoma xenograft model in nude mice. Mice were dosed by i.p.
injection 5 times a week for 2 weeks with 15 mg/kg DJ95, 15 or 30 mg/kg of DJ101, or
vehicle solution only. Statistical significance was determined using one-way ANOVA
followed by Dunnett’s multiple comparison test for the final tumor volumes compared to
the control. C) Mean mouse weight change ± SD in the xenograft model. D) B16F10
melanoma lung metastasis model in C57BL/6 mice. Mice were dosed by i.p. injection 5
times a week for 2 weeks with 30 mg/kg of DJ101 or vehicle solution only. Graph
represents mean number of nodules with individual number for each mouse plotted ± SD
(n=11). Representative photos of lungs with melanoma nodules (black dots) are shown
below. Statistical significance (P=0.0001) was determined with an unpaired student’s ttest. E) Mean mouse weight change ± SD in the metastasis model.
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significantly better than the vehicle based on the percent increase in final tumor volume.
Animal behavior and mouse body weights were measured and recorded throughout the
course of the experiment to assess for acute toxicities, and major deviations were not
observed (Figure 2-7C). This in vivo study demonstrates the antitumor efficacy of DJ
compounds in a melanoma xenograft model, and DJ101 for further in vivo experiments
because of its enhanced antitumor activity without dose-limiting toxicities.
Since a major obstacle in treating melanoma is tumor metastasis, we next assessed
the efficacy of DJ101 in suppressing melanoma metastasis using a B16F10 experimental
lung metastasis model in mice. After two weeks of treatment with 30 mg/kg doses of
DJ101, the average number of tumor nodules that developed on the lungs was 1.7 ± 0.3,
whereas the vehicle-treated group averaged 10.5 ± 2.0 nodules, demonstrating a 6.2-fold
decrease in lung metastasis for those receiving DJ101 treatment (Figure 2-7D). An
unpaired Student’s t-test gave a P value of < 0.001, representing a significant decrease in
lung metastasis for the treatment group. Body weights and physical activities of mice
were normal in both groups (Figure 2-7E). These results demonstrate that DJ101 is welltolerated for doses up to 30 mg/kg in mice and can efficiently reduce the potential for
lung metastasis of murine melanoma.
Overcoming Paclitaxel Resistance In Vivo
We next compared the efficacy of DJ101 and paclitaxel in vivo using both PC-3
and PC-3/TxR xenograft models. Both paclitaxel (15 mg/kg) and DJ101 (30 mg/kg)
inhibited tumor growth in the parental PC-3 xenograft model as determined by average
tumor volume (Figure 2-8A, left panel). The TGI for the group receiving paclitaxel
treatment was 101.1% and 78.8% for the DJ101 treated group in PC-3 xenografts (P
values of < 0.0001). Their efficacy against tumors was also evident based on final tumor
weight (Figure 2-8B) and representative tumor images (Figure 2-8C), where the DJ101and paclitaxel-treated groups showed a 47.1% (P < 0.001) and 79.3% (P < 0.0001)
reduction in tumor weight compared to the control group, respectively. No acute
toxicities were observed based on physical activity and body weights (Figure 2-8D). In
contrast, using the same dosing regimen and frequency as we did in the parental PC-3
model, DJ101 caused a TGI of 104.0%, remarkably demonstrating an overall reduction in
tumor volume in the PC-3/TxR xenograft model, whereas paclitaxel only modestly
inhibited tumor growth by 37.8% (Figure 2-8A, right panel). These results were
corroborated by final tumor weights, where DJ101 caused a 77.3% reduction (P <
0.0001) and paclitaxel showed only a 35.6% reduction (P < 0.05) compared to the control
group (Figure 2-8B). No acute toxicities were observed in this model based on body
weight (Figure 2-8D).
Elevated Apoptosis and Vascular Disruption in Xenograft Tumors
Hematoxylin and eosin (H&E) stains of representative tumor sections in the
vehicle control group showed aggressive growth with numerous mitotic cells in different
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Figure 2-8. Inhibition of taxane-resistant prostate cancer tumors in mouse
models.
A) Tumor volumes for PC-3 (left panel) and PC-3/TxR (right panel) xenograft model in
nude mice. Graphs represent mean tumor volume percent increase ± SEM (n=7). B) Final
tumor weights ± SEM for PC-3 and PC-3/TxR mice. C) Representative images for PC-3
and PC-3/TxR tumors. D) Mouse weight change ± SEM for PC-3 and PC-3/TxR mice.
One-way ANOVA analysis was performed for final tumor volumes and weight followed
by Dunnett’s multiple comparison test of each treated group with the corresponded
results of vehicle group. (*p< 0.05, **p< 0.01, ****p< 0.0001)
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stages (Figure 2-9A). The increase of metaphase cells and decrease of anaphase cells in
the DJ101 treatment groups indicate mitotic blocking in the G2/M phase, consistent with
our previous cell cycle analysis (143). Tumor sections from both low and high dose
treatment groups showed significantly less proliferation, and there were abundant
apoptotic cells showing dense nuclear pyknosis and cytoplasmic karyorrhexis. There was
also extensive central tumor necrosis in the treatment groups. Additionally, CD31 labeled
endothelial cells in the vehicle control tumor sections exhibited well-developed networks
of capillaries or small blood vessels around tumors, while the DJ101 treatment groups
displayed severely distorted blood vessels or absence of CD31 positive stains, suggesting
potential vascular disrupting properties of DJ101. Finally, cleaved caspase-3 IHC staining
of tumor sections in the control group showed very few positive regions, but tumor
sections from the DJ101 treatment groups showed a profound increase in positive labeled
cells, confirming enhanced apoptosis due to DJ101 treatment.
Separate and more extensive analysis of tumor vasculature was performed on the
DJ95 treated xenografts. CD31 staining of tumor sections revealed the change in
microvessels of the DJ95 treated group compared to the control group (Figure 2-9B).
The control group displayed more abundant and in-tact microvessels throughout the
tumors, whereas DJ95 treatment tumors showed vessel fragmentation and decreased
overall density and occupied area. Quantification of the positive CD31-stained area
revealed that there was a 50.5% decrease in total microvessel area, representing a
significant difference (P= 0.0038) (Figure 2-9C). These findings validate the in vitro
results and suggest that the anti-vascular capacities portrayed by DJ95 and DJ101 may
contribute to their anticancer efficacy.
Toxicology Analysis of Major Organs
To assess whether DJ101 treatment produces potential organ toxicities,
pathological analysis was performed on major organs collected from both melanoma in
vivo studies including the heart, kidney, liver, lung and spleen. H&E stained sections
revealed no apparent drug-related injury or pathological changes in the cellular structure
of the various tissues in the melanoma xenograft mouse models (Figure 2-9D) and the
experimental lung metastasis mouse model (Figure 2-9E), providing further support of
an overall acceptable safety profile.
Discussion
Importance of Overcoming Drug Resistance
Melanoma is the most aggressive form of skin cancer and is one of the most
rapidly increasing cancers worldwide (204). Malignant melanoma is characterized by
resistance to chemotherapy and is incurable in most affected patients (205, 206). Despite
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Figure 2-9. Immunohistochemistry analysis of tumors and pathological assessment of major organs.
A) IHC of DJ101 treated A375 tumors. H&E insert (2 fold) shows white arrows indicating metaphase and black arrows indicating
anaphase. CD31 expression shows blood vessel disruption and expression of cleaved caspase-3 is indicative of apoptosis. B)
Representative IHC images of DJ95 treated tumors stained with CD31 (10x magnification). C) CD31 area represented as mean pixels
± SD. Statistical significance was determined by student’s t test (20x magnification,5 images per tumor, 3 separate tumors per group)
(**p< 0.01). D) Representative images of H&E stained sections of major tissues (heart, kidney, liver, lung, and spleen) from the A375
xenograft and E) B16F10 lung metastasis study.
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recent advances in treating melanoma with targeted therapies and immunotherapies,
significant obstacles still exist for finding satisfactory treatments. Intrinsic and acquired
resistance are the major causes of treatment failure, and it is crucially important to
discover and develop agents that can overcome drug resistance, improve response rates,
and extend survival for melanoma patients.
Interfering with tubulin dynamics is a validated approach for anticancer treatment
and many antimitotic microtubule stabilizers and destabilizers are widely used clinically
or are undergoing clinical development (207). However, many of these agents cause
neurotoxicity, exhibit chemical instability, or have elevated metabolic clearance (172).
Additionally, the clinical efficacy of many FDA approved tubulin inhibitors is often
limited by drug efflux pumps or overexpression of certain tubulin subtypes, most notably
the βIII tubulin isotype (54). Design and development of new tubulin inhibitors targeting
the colchicine binding site represent an attractive approach for improving and advancing
tubulin inhibitors.
We previously identified DJ95 and DJ101, small-molecule tubulin destabilizing
agents, synthesized from a series of indolyl-imidazopyridines, that demonstrated high
potency and improved metabolic stability in vitro (143). Because genetic heterogeneity
among cancer cell lines of the same cancer type has emphasized the necessity to study
multiple cell lines in a panel, we expanded our investigation of the compounds in a more
extensive array of malignant melanomas with varying degrees of genetic complexity
based on genomic mutations (BRAF, CTNNB1, CDKN2A, PTEN, or TP53)(208). The
DJ compounds were also screened in the NCI-60 panel, which includes numerous
extensively characterized cell lines from nine different tumor types, providing additional
evidence to support their broad-spectrum anticancer efficacy.
While taxanes are some of the most clinically effective chemotherapy drugs
available, their clinical success is often limited by the emergence of intrinsic and acquired
drug resistance (209). One of the major culprits responsible for contributing to MDR is
the overexpression of ABC transporters such as ABCB1 (MDR1), ABCC1 (MRP1), and
ABCG2 (BCRP) (210). Agents that target the taxane and vinca binding sites of tubulin
are particularly susceptible to resistance from the overexpression ABCB1 and are
effectively extruded from the cell (209, 211-213). These agents are also substrates to
MRP and BCRP proteins that also decrease their intracellular concentrations (214). We
discovered that DJ95 had a lower resistance index than the other tested tubulin inhibitors
in both the drug-selected and gene-transfected cell lines overexpressing ABCC1. While it
did not show resistance to the transfected ABCB1 overexpressing cells, it did display
some resistance to KB-C2 drug-selected cell line overexpressing ABCB1. This might be
due to the more complex MDR mechanisms in drug-selected MDR cells in comparison
with gene-transfected cells. As KB-C2 cells were established by continuous selection
with colchicine (2 μg/mL), they may have incurred additional drug-resistance
mechanisms besides ABCB1 upregulation. For example, mutations to the colchicine
binding domain could account for the cross-resistance to DJ95 or other agents targeting
this site.
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We also investigated the effect of DJ compounds against drug-selected taxane
resistant cell lines. In the paclitaxel-resistant PC-3/TxR prostate cancer cell line, more
than 200 genes are upregulated, in addition to P-gp overexpression, which representing
numerous paclitaxel resistance mechanisms (174, 175). Both DJ compounds maintained
potency in the resistant PC-3/TxR cell line and had significantly lower resistance indexes
to both PC-3/TxR and DU-145/TxR cells than did colchicine and paclitaxel. We also
demonstrated the excellent potency of DJ101 against PC-3/TxR xenograft tumors in
mice. Other groups have reported elevated sensitivity of paclitaxel resistant cancer cells
to colchicine binding site drugs. One such study investigated a variety of microtubule
targeting agents that bind to the taxane site, vinca alkaloid binding site, and colchicine
binding site for docetaxel resistant MCF-7 breast cancer cells. They reported that while
MCF-7TXT cells demonstrated cross-resistance to vinca alkaloids, they were more
sensitive to colchicine binding site agents, including 2MeOE2, ABT-751, CA-4P, and
colchicine, than the non-resistant counterpart MCF-7 cells (215). This also supports the
notion that colchicine binding agents such as the DJ compounds, particularly DJ101, may
be an alternative treatment when tumors acquire resistance to treatment by taxanes.
Optimizing Scaffolds Through X-Ray Crystallography
Tubulin inhibitors interacting with the colchicine binding site have widely diverse
structures. Thus, it has been very challenging to reliably decipher the molecular
interactions between an inhibitor and tubulin using molecular modeling with crystal
structures containing a different class of tubulin inhibitors. Furthermore, available X-ray
crystal structures often have low resolution which further impedes reliable molecular
modeling studies.
We obtained the high-resolution X-ray crystal structures of DJ101 and DJ95,
showing their interaction with colchicine binding pocket at the interface of D- and Etubulin heterodimer. These X-ray crystallography results not only provide the structural
basis for the anticancer mechanism of action of the DJ compounds, they underline the
benefit of utilizing high-resolution crystal structures over molecular modeling in guiding
structure optimizations for tubulin inhibitors interacting at this site. For example, three
hydrogen bonds formed between DJ101 and the tubulin dimer and additional strong
hydrophobic interactions from surrounding residues firmly anchored DJ101 in this
colchicine binding site. Interestingly, our previous molecular modeling studies using the
crystal structure of 1SA0 showed a different binding pose for DJ101, in which the top
portion of DJ101 was rotated (143). Examination of the crystal structures of 1SA0 and
the current DJ101 complex clearly revealed significant conformational changes for the
T4 loop in the tubulin α-subunit and T7 loop in the tubulin β-subunit. It is apparent that
the “closing up” of the T4 loop to the colchicine binding pocket in the 1SA0 structure
prevented the top moiety of DJ101 in adopting its true binding pose, and thus forced its
top moiety to rotate 180 degrees.
It is well known that while the colchicine site can accommodate a wide variety of
structurally distinct molecules, and seemingly insignificant changes to many of these
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compounds can result in a total loss of activity (54, 94). These results highlight critical
contributions to the optimal bindings of different scaffolds at the colchicine site in
tubulin. The detailed crystallographic analysis presents opportunities for designing better
analogs of these compounds that may show improved potency.
Targeting Microtubule Dynamics
The main function of microtubule targeting agents is to inhibit mitosis through
disruption of microtubule dynamics, leading to mitotic arrest and eventual apoptosis.
Paclitaxel and docetaxel are microtubule stabilizing agents that target the taxane site
within the lumen of polymerized microtubules and alter their conformation to the more
stable GTP-bound β-tubulin structure, thereby locking them in the polymerized state (23)
The DJ compounds are destabilizing agents that bind to the colchicine site, which causes
interdimer bending and promotes destabilization (23). To further confirm the mechanism
of action of the DJ compounds and evaluate the physical change in microtubule networks,
we performed immunofluorescent imaging studies of melanoma cells that had been
treated with the DJ compounds or taxanes. In the untreated cells, the microtubule
networks displayed an arrangement of organized, fibrous microtubules extending
throughout the elongated cells. Treatment with the DJ compounds led to fragmented
microtubules and a dramatic decrease of visible tubulin filaments. On the contrary,
paclitaxel treated cells demonstrated rigid and condensed polymeric microtubules. The
immunofluorescent images clearly differentiated the stabilizing and destabilizing effects
on microtubule structure and cellular framework by these two opposing classes of
compounds.
Microtubules constitute the mitotic spindle in cells undergoing mitosis. Disruption
of the mitotic spindle through suppression of treadmilling and dynamic instability are the
primary means by which microtubule inhibitors thwart cellular functions and induce
apoptosis (216). Typical features of mitotic spindle suppression and aberrant formation
such as multiple asters in mitotic cells were evident in the DJ95 treated cells, whereas the
control cells demonstrated polar spindle formation and centrally aligned chromosomes.
In addition to their well-defined roles in supporting cellular structure and their
involvement in mitosis, microtubules are also implicated in cell migration and motility. It
has been suggested that the dynamic instability imposed on the microtubules by
suppressing and interfering with tubulin behavior causes cell immobility, as the cell is
less able to remodel and respond to change the cell shape demanded for cell migration
(198). The antimitotic and anti-migratory effects of the DJ compounds were
demonstrated by their ability to inhibit anchorage-dependent colony propagation and
suppress cell motility in a wound healing assay. The cessation of colony formation and
cell movement was attributed to disruption of microtubule dynamics, though additional
studies are needed to further elucidate the mechanism of microtubule binding drugs on
different facets of cellular function.
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Minimizing Failure in Drug Development
Off-target adverse drug reactions often contribute to the high attrition rate in the
drug discovery and development process. Reducing the failure rate of potential
pharmaceutical drug candidates is an important step in drug discovery and development
and will help to mitigate the risk of expensive failure in late stages. Identification of offtarget, adverse drug reactions for drug candidates to important pharmacological targets
such as GPCRs, drug transporters, ion channels, nuclear receptors, kinases and nonkinase enzymes through the use of predictive safety panels is supported by major
pharmaceutical companies such as AstraZeneca, GlaxoSmithKline, Novartis and Pfizer
(203). DJ101 and DJ95 underwent this pharmacological profiling in two separate panels
(DiscoveRx Safety47™ Panel and Eurofins SafetyScreen44™ Panel). DJ95 did not show
significant inhibition or activation to of the receptors or enzymes tested in the screening,
DJ101 only elicited a functional response to NET and GR antagonism when tested at
concentrations significantly higher than its IC50. This suggests that the DJ compounds
minimally interact with or activate some of the key targets that potentially cause adverse
drug reactions, suggesting a good safety profile for this scaffold.
Anticancer Efficacy
We proceeded with in vivo studies and found that the DJ compounds were able to
hinder melanoma tumor growth at doses of 15 mg/kg, and at higher concentrations of 30
mg/kg, DJ101 dramatically inhibited tumor growth and reduced metastasis without
causing signs of toxicity.
DJ101 was able to induce tumor regression in a taxane-resistant prostate cancer
xenograft models in mice, whereas paclitaxel had almost no effect. Other groups have
also reported elevated sensitivity of resistant cancer cells to colchicine binding site drugs.
One such study investigated a variety of microtubule targeting agents that bind to the
taxane site, vinca alkaloid binding site, and colchicine binding site for docetaxel resistant
MCF-7 breast cancer cells. They reported that while MCF-7TXT cells demonstrated crossresistance to vinca alkaloids, they were more sensitive to colchicine binding site agents
including 2MeOE2, ABT-751, CA-4P, and colchicine than the non-resistant counterpart
MCF-7 cells (215). This also supports the notion that colchicine binding agents such as
DJ101 may be an alternative treatment when tumors acquire resistance to treatment by
taxanes.
Because antimitotic drugs exploit different sites on tubulin and microtubules,
synergistic combinations could be investigated to optimize their clinical usefulness. This
assertion is supported by several reported studies that combined paclitaxel with other
tubulin targeting drugs (217-220). It will also be important to combine novel tubulin
inhibitors such as the DJ compounds with agents exploiting different cancer targets.
Towards this end, we previously demonstrated that strong synergy can be achieved by
combining ABI-274 (a less metabolically stable analog of DJ101) and vemurafenib in a
BRAF inhibitor resistant-melanoma xenograft model (100). Continued exploration of
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combination therapies is warranted to maximize the clinical potential of the DJ
compounds.
Dual Inhibitors of Tubulin and Tumor Vasculature
It is well-appreciated that tumor growth and metastasis require a reliable system
of blood vessels to support the tumor microenvironment, and interfering with this process
is an attractive strategy for inhibiting tumor growth (39, 221). This has prompted research
in the development of anti-angiogenic and vascular disrupting agents, and many tubulin
inhibitors that target the colchicine binding site demonstrate this capability (39, 40, 97,
222). Microtubule stabilizing agents such as paclitaxel, Peloruside A, and laulimalide
also have reported vascular disrupting properties, but they have other shortcomings, such
as the development of resistance and dose-limiting toxicities (223-226). We demonstrated
that DJ95 treatment suppressed capillary-like networks in vitro in HUVECs in a
concentration-dependent manner. We also discovered vascular disrupting action evident
in mouse xenografts after treatment with the DJ compounds, where there was significant
disturbance of endothelial vasculature and an overall decrease in microvessel area for
these treatment groups compared to control tumors. These in vitro and in vivo data
support the dual role of the DJ compounds as tubulin inhibitors and vascular disrupting
agents, and they may exert their anticancer effects through multiple mechanisms.
Conclusions
In our examination of DJ101 and DJ95, we found that they were potent against a
variety of melanoma cell lines and other cancer types and were able to overcome ABCtransporter mediated drug resistance and acquired taxane resistance. We obtained the
high-resolution crystallography of both compounds in complex with tubulin, confirming
their direct interaction with the colchicine binding domain and demonstrated their
depolymerizing effect microtubule morphology, which was distinct from stabilizing
agents. Both compounds show antitumor efficacy in melanoma xenograft models without
causing apparent toxicity to major organs and display good pharmacological safety
profiles. DJ101 treatment also reduced lung metastasis nodules in a metastatic model and
caused tumor reduction in the paclitaxel-resistant xenograft model. The DJ compounds
also disrupted endothelial cells and tumor vasculature, indicating that they may play a
role as vascular disrupting agents in addition to tubulin inhibitors. There are currently no
colchicine binding site inhibitors approved for chemotherapy, and intervention with the
DJ compounds could prove to be an effective alternative treatment when other tubulin
inhibitors fail to show efficacy due to MDR.
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CHAPTER 3.

OPTIMIZING VERU-111 ANALOGS FOR IMPROVED
ANTICANCER EFFICACY2
Introduction to VERU-111 Analogs

The microtubule targeting agents have achieved great success in cancer treatment
in the last decade. However, acquired drug-resistance is often developed over the course
of treatment and becomes a tremendous obstacle. It is estimated that 22 million new
cancer cases will be diagnosed worldwide in the coming two decades, and therefore an
urgent need exists to develop new anticancer agents to treat resistant phenotypes (157,
227). Mechanisms that mediate drug-resistance against microtubule targeting agents
include, but are not limited to, the overexpression of membrane-bound drug efflux
proteins, such as P-glycoprotein; the overexpression of β-tubulin isotypes; and
microtubule mutations (146, 228).
Colchicine binding site inhibitors target tubulin at the interface between α and βtubulin heterodimers and mechanistically decrease cellular motility, alter cell
morphology, impair protein assembly, and arrest mitosis (229, 230). Colchicine has widescope mechanisms of action, but unfortunately, it induces systemic toxicities and
multiorgan dysfunction that have prevented its clinical use for cancer treatment (229).
Other colchicine binding site inhibitors have also been disclosed in the last decade.
Encouragingly, extensive preclinical studies have proven that drugs targeting the
colchicine binding site may suppress overexpression of tubulin isotypes and surmount
drug-resistance mediated by P-gp, MRP1, and MRP2 (81, 94, 231).
The 3,4,5-trimethoxyphenyl (TMP) is a common moiety shared by many drugs
targeting the colchicine site and is crucial for maintaining suitable molecular
conformations that are needed for optimal interactions with tubulin and for producing the
maximum antiproliferative activities (232). Attempts to modify this TMP moiety usually
lead to significantly reduced anticancer potency (94, 97, 165, 233). For example,
substituting the methoxy with a bulky group or demethylating the methoxy on the TMP
moiety of colchicine were reported to reduce the potency (234, 235). In addition,
removing or adding methoxy to TMP significantly impaired the antimitotic activity (>10fold) (236). However, some isosteric modifications of the TMP in colchicine or CA-4
have been shown to maintain the potency to that of parent natural products. For instance,
Semenov et al. have demonstrated that isosteric replacement of the TMP of CA-4 with
[1,3]dioxole or [1,4]dioxane did not significantly reduced antimitotic activity (236).
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Cornigerine, a [1,3]dioxole analog of colchicine, displayed equipotent antimitotic activity
to that of the parent compound (237).
In our prior reports, we described the discovery of several scaffolds of potent
tubulin inhibitors, including the discovery of a 2-aryl-4-benzoyl-imidazole (ABI) scaffold
(140). Subsequent structural optimization of the benzoyl moiety, the aryl moiety, and the
imidazole fragment in this scaffold resulted in analogs with improved potency (98, 141,
143, 144). VERU-111 is the best analog from that series of structural optimizations.
VERU-111 is currently under clinical development as 3rd line hormonal therapy by
VERU Healthcare. Interestingly, it also exhibits potent antiproliferative activities against
melanoma cell lines and acts as a colchicine binding site tubulin inhibitor. Due to an
unproductive chemical synthesis, its in-depth medicinal programmatic investigation was
nevertheless hampered. The TMP moiety in VERU-111, like many other colchicine
binding site inhibitors with this shared moiety, is critical for its high binding affinities to
tubulin.
In this chapter, we report the extensive structure-activity relationship (SAR) study
of VERU-111 analogs by focusing modifications to the indole moiety and TMP moiety,
leading to the identification of the 3 most potent compounds, 10ab, 10bb, and 13f.
Mechanism studies confirmed that the new VERU-111 analogs inhibit tubulin
polymerization and promote microtubule fragmentation and disassembly. Direct binding
to the colchicine binding domain on tubulin is revealed through X-ray crystallography,
and specific molecular interactions and overlay with colchicine are detailed. The
compounds demonstrated good in vitro metabolic stability, and 10bb and 13f showed
significant anticancer efficacy in melanoma mouse models without demonstrating
toxicity to animals or significantly inducing off-target interactions based on
pharmacological safety screening. Finally, 10bb was highly effective in a taxane-resistant
prostate cancer xenograft model, suggesting its ability to overcome resistant mechanisms.
Overall, these data demonstrate great potential for these VERU-111 analogs as anticancer
drug candidates.
Materials and Methods
Cell Culture and Reagents
Human melanoma carcinoma cell lines A375, M14, RPMI-7951, and WM-164
(American Type Culture Collection or ATCC, Manassas, VA, USA) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Corning, Manassas, VA) supplemented
with 10% (v/v) fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) and
1% antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis MO). Murine melanoma
B16F10 cells (ATCC, Manassas, VA, USA) were cultured in Minimum essential medium
(Invitrogen, Carlsbad, CA), supplemented with 5% heat-inactivated Hyclone FBS
(Thermo Scientific, Rockford, IL), 1 % antibiotic-antimycotic mixture (Sigma-Aldrich,
St. Louis MO), 1% Mem-sodium pyruvate (Invitrogen, Carlsbad, CA), 1% Mem-vitamin
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(Invitrogen, Carlsbad, CA), L-Glutamine (2mM final concentration) (Invitrogen,
Carlsbad, CA), and 1% Mem NEAA (Invitrogen, Carlsbad, CA). Parental prostate cancer
PC-3, its paclitaxel-resistant daughter line PC-3/TxR, parental prostate cancer DU-145,
and its docetaxel-resistant daughter line DU-145/TxR are gifts from Dr. Evan Keller at
the University of Michigan Medical School. PC-3 and DU-145 cell lines were cultured in
RPMI 1640 media (Gibco® by Life Technologies, Carlsbad, CA) supplemented with
10% (v/v) fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) and 1%
antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis MO). Taxane resistant PC3/TxR and DU-145/TxR cell lines were cultured in the same media and additionally
supplemented with 10 nM paclitaxel or docetaxel, respectively. Drugs were not included
in the media for PC-3/TxR or DU-145/TxR for at least one week prior to in vitro testing.
All cell lines were authenticated by ATCC by short tandem repeat profiling. Cultures
were maintained to 80-90% confluency at 37 °C in a humidified atmosphere containing
5% CO2. Compounds were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St.
Louis, MO) to make a stock solution of 20 mM. Compound solutions were freshly
prepared by diluting stocks with cell culture medium before use.
Cytotoxicity Assays
Logarithmic growth phase cells were seeded in 96-well plates at a concentration
of 1,000–5,000 cells per well, depending on growth rate of the cell line. After overnight
incubation, the media was replaced, and cells were treated with the test compounds at 10
concentrations ranging from 0.03 nM to 1 μM plus a vehicle control for 72 h in four
replicates. Following treatment, the MTS reagent (Promega, Madison, WI) was added to
the cells and incubated in dark at 37 °C for at least 1 h. Absorbance at 490 nm was
measured using a plate reader (BioTek Instraments Inc., Winooski, VT). Percentages of
cell survival versus drug concentrations were plotted, and the IC50 (concentration that
inhibited cell growth by 50% of untreated control) values were obtained by nonlinear
regression analysis using GraphPad Prism (GraphPad Software, San Diego, CA). The
resistant index (RI) was calculated by dividing the IC50 of the resistant cell line with the
IC50 of the parental cell line.
X-Ray Crystallography
Protein Expression and Purification. X-Ray crystallography was performed by
Dr. Yuxi Wang (Sichuan University, in China). Porcine brain tubulin (Catalog # T-238P)
was obtained from Cytoskeleton, Inc. The stathmin-like domain of RB3(RB3-SLD) was
transformed into and overexpressed in E. coli. The protein was purified by anionexchange chromatography and gel filtration chromatography. The peak fractions from gel
filtration column were concentrated to 10 mg/mL and stored at -80 Ԩ (51, 154, 185).
TTL protein was expressed and purified from E. coli expression system as described in
the previous reference (186). Briefly, the protein was expressed in E. coli using LB,
purified through Ni-NTA affinity chromatography and gel filtration chromatography
(buffer: Bis-Tris Propane pH 6.5, 200 mM NaCl, 2.5 mM MgCl2, 5 mM β- Me, 1 %
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Glycerol). The peak fractions of the target protein were collected and concentrated to 20
mg/ml and saved at -80 Ԩ. Porcine brain tubulin was supplied at 10 mg/ml in G-PEM
(General tubulin buffer: 80 mM PIPES pH 6.9, 2 mM MgCl2, 0.5 mM EGTA and 1 mM
GTP) as a frozen liquid and saved at -80 Ԩ until use.
Crystallization and Crystal Soaking. The process to getting crystals of T2RTTL followed the previously reported procedure (186, 187). Briefly, the complex
containing tubulin (10 mg/ml), TTL (20 mg/ml) and RB3 (10 mg/ml) at the molar ratio of
2:1.3:1.2 (tubulin:RB3:TTL) was incubated on ice with additional 1 mM AMPPCP, 5
mM tyrosinol and 10 mM DTT, and then the final sample was concentrated to 20 mg/ml
at 4 Ԩ. Crystallization of T2R-TTL complex was carried out at 20 Ԩ using the sitting
drop vapor diffusion method by mixing equal volumes of the protein complex and
crystallization buffer containing 6% PEG, 5% glycerol, 0.1 M MES, 30 mM CaCl2, 30
mM MgCl2, pH 6.7. Seeding was used to optimizing the crystal conditions. Initial
crystals were observed after two days and crystals reached their final size of 200-300 μm
within 3-5 days. For crystal soaking, 0.1 μl of the ligand solution (13f dissolved in 100%
DMSO) was added to the 2μl crystal-containing drop for 12 h at 20 °C. The best crystals
were selected and frozen in liquid nitrogen in the presence of cryoprotectant
(crystallization buffer containing 20ˁ glycerol).
X-Ray Data Collection and Structure Determination. Crystals of the T2RTTL-13f complexes were mounted in nylon loops and flash-cooled in a nitrogen stream
at 100 K. The diffraction data were collected on beamlines BL19U1 at Shanghai
Synchrotron Radiation Facility (SSRF) in Shanghai, China. Data were indexed,
integrated and scaled using the HKL2000 program package (188). The structure of T2RTTL-13f complex was solved by molecular replacement using the previously published
T2R-TTL structure (PDB ID: 4I55) as the search model. The rotation and translation
function searches were performed by the program PHASER. The model was manually
built with Coot (190) and then refined using the phenix refine module of the Phenix
program (191). The model quality was checked with the PROCHECK program showed
good stereochemistry according to the Ramachandran plot. Analysis was determined in
coordination with Dr. Stephen White’s group (St. Jude Children’ Research Hospital).
Tubulin Polymerization Assay
Bovine brain tubulin (3 mg/ml final concentration) (Cytoskeleton, Denver, CO)
was mixed with 10 μM of the test compounds and incubated in 100 μL of general tubulin
buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, and 1 mM GTP) at pH 6.9. The
absorbance of wavelength at 340 nm was monitored every 1 min for 40 min by the
SYNERGY 4 Microplate Reader (Bio-Tek Instruments, Winooski, VT). The
spectrophotometer was set at 37 °C for tubulin polymerization.
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Fluorescence Microscopy
WM-164 cells were seeded and allowed to adhere on glass coverslips in 6 well
plates (500,000 cells/well) overnight. Cells were incubated for 18 hrs with 50 nM of
10ab, 10bb, or docetaxel. DMSO was added to the cells in equivalent volume as a
negative control. Microtubules were visualized with anti-α-tubulin antibody (Thermo
Scientific, Rockford, IL) and Alexa Fluor 647 goat anti-mouse IgG (Molecular Probes,
Eugene, OR). The coverslips were mounted with Prolong Diamond Antifade mounting
media with DAPI (Invitrogen, Eugene, OR) and images acquired with a Zeiss 710
Confocal microscope and Zen imaging software (Zeiss, Thornwood, NY).
Colony Forming Assay
Cells were seeded in triplicate in 6 well plates at a density of 500 cells/well in full
cell culture media and incubated at 37 °C overnight. Media was changed and cells were
treated with 5 nM of the test compound and incubated for another week. At the end of
this period, cells were fixed with chilled methanol (5 min), stained with 0.5% crystal
violet solution (4 hrs), rinsed with sterile water, and air-dried overnight. Images were
taken UVP ChemiDoc-It imager (Bio-Rad, Hercules, CA) and colonies were quantified
with the corresponding VisionWorks software.
Scratch Migration Assay
A375 and RPMI-7951 cells were seeded in 24 well plates in 4 replicates at a
concentration of 200,000 cells/well and incubated overnight. This concentration allowed
a confluent monolayer to form in the wells. Using a 200 μL pipette tip, a straight line was
scratched through the cell monolayer to remove an area of cells. The plates were then
washed several times with media to remove any debris and uprooted cells. Cells were
treated with 25 nM of 10ab, 10bb or vehicle control. Images were obtained immediately
after drug treatment and again after 18-22 hours with Evos Fl Imaging System
(LifeTechnologies, Carlsbad, CA). Analysis was performed with ImageJ software (NIH,
Bethesda, MD).
Liver Microsomes Stability Assay
Liver microsome assays were performed by Dr. Lei Yang (St. Jude Children’s
Research Hospital). The NADPH regenerating agent solutions A (catalog#: 451220) and
B (catalog#: 451200) and mouse liver microsomes (CD-1, mixture of male,
catalog#:452701, and female, catalog#: 452702) were obtained from BD Gentest
(Woburn, MA). Liver microsomes stability assay was conducted following literature
reports (238, 239). For each test compound, the mouse liver microsomal solution was
prepared by adding 0.058 ml of concentrated mouse liver microsomes (20 mg/ml protein
concentration) to 1.756 ml of 0.1 M potassium phosphate buffer (pH 7.4) containing 5 μL
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of 0.5 M EDTA to make a 0.6381 mg/ml (protein) microsomal solution. Each test
compound (2.2 μL of 10 mM DMSO solution) was added directly to 1.79 ml of mouse
liver microsomal solution and 90 μL was transferred to wells in 96-well plates (0, 0.25,
0.5, 1, 2, and 4 h time points each in triplicate). The NADPH regenerating agent was
prepared by mixing 0.113 ml of NADPH regenerating agent Solutions A, 0.023 ml of
solution B and 0.315 ml of 0.1 M potassium phosphate buffer (pH 7.4) for each tested
compound. To each well of the 96-well plate, 22.5 μL of the NADPH regenerating agent
was added to initiate the reaction, and the plate was incubated at 37 °C for each time
point (0, 0.25, 0.5, 1, 2, and 4 h time points each in triplicate). The reaction was quenched
by adding 225 μL of cold acetonitrile containing warfarin (4 mg/ml) as internal control to
each well. All of the plates were centrifuged at 4000 rpm for 20 min and the supernatants
(100 μL) were transferred to another 96-well plates for analysis on UPLC–MS (Waters
Acquity UPLC linked to Waters Acquity Photodiode Array Detector and Waters Acquity
Single Quadrupole Mass Detector) on Acquity UPLC BEH C18 1.7 mm (2.1x50 mm)
column by running 90–5% gradient for water (+0.1% formic acid) and acetonitrile
(+0.1% formic acid) in 2 minutes. The area under the single ion recording (SIR) channel
for the test compound divided by the area under the SIR for internal control at 0 time
concentration was considered as 100% to calculate remaining concentration at each time
point. The terminal phase rate constant (ke) was estimated by linear regression of
logarithmic transformed concentration versus the data, ke = slope × (−ln 10). The half-life
t1/2 was calculated as ln 2/ke. The intrinsic clearance (CLint,app)= (0.693/in vitro t1/ 2) x
(1ml incubation volume/0.5 mg of microsomal protein) x (45 mg microsomal
protein/gram of liver) x (55 g of liver/kg body weight).
In Vivo Experiments
All animal experiments were performed in accordance with the NIH animal use
guidelines and protocol approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Tennessee Health Science Center (UTHSC, Memphis, TN).
Xenograft Models. Nude mice, 6–8 weeks old, were purchased from
Harlan/Evigo. Logarithmic growth phase A375 or PC-3/TxR (5 × 107 cells per ml) cells
were prepared in phenyl red-free, FBS-free cell culture media and mixed at a 1:1 ratio
with Matrigel. Tumors were established by injecting 100 μl of cell suspension
subcutaneously in the dorsal flank of each mouse (2.5×106 cells). After 2 weeks, mice
were randomly divided into control or treatment groups (n=8 for A375 model of 13f,
n=10 for A375 model of 10bb, and n=8 for PC-3/TxR model of 10bb). Test compounds
were dissolved in a 1:1 ratio of PEG300:PBS solution to produce desired concentrations.
100 μl of the drug solution corresponding to 15 or 30 mg/kg doses were administered via
i.p. injection once daily for the duration of the study. The control group was given only a
vehicle solution of the same preparation and injected at the same frequency.
Tumor volume was measured three times a week with a caliper and calculated by
using the formula a×b2×0.5, where a and b represented the larger and smaller diameters,
respectively. Tumor growth inhibition (TGI) at the conclusion of the experiments was
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calculated as 100 – 100 ×((T − T0)/(C − C0)), where T, T0, C and C0 are the mean tumor
volume for the specific group on the last day of treatment, mean tumor volume of the
same group on the first day of treatment, mean tumor volume for the vehicle control
group on the last day of treatment and mean tumor volume for the vehicle control group
on the first day of treatment, respectively (100). Animal activity and body weight were
monitored during the entire experiment period to assess potential acute toxicity. At the
end of the experiment, mice were sacrificed and the tumors and tissues were dissected out
and fixed in 10% buffered formalin phosphate solution for more than 1 week before
pathology staining analysis.
Lung Metastasis Model. C57BL/6 mice from Charles River Laboratories
International, Inc., age 7–8 weeks old, were used to study the inhibition effect of 10bb on
lung metastasis of melanoma cells. B16F10 melanoma cells growing in a logarithmic
growth phase were suspended in the conditioned media at a density of 1 × 106 per ml.
Each mouse was injected with 100 μL (1 × 105 cells) via the lateral tail vein. The
treatment started on the third day after the inoculation to ensure the initiation of
metastasis before beginning treatment. 10bb (30 mg/kg) was formulated as described
above. All the treatment solutions were kept in the same volume (100 μl) and
administered via i.p. injection for 2 weeks, 5 days a week. Vehicle control group was
treated by i.p. injection with 100 μL of PEG300 and PBS in a 1:1 ratio. Mice were
sacrificed after 15 days after the initiation of the experiment, and the lungs were
separated, expanded and preserved in 10% neutral buffered formalin. The number of lung
metastasis nodules was recorded. Major organs were also preserved in 10% neutral
formalin buffer for subsequent examination of potential toxicities. Animal activity and
body weight were monitored during the entire experiment period to assess acute toxicity.
Results and Discussion
SAR Investigation
VERU-111 Analogs of 3-Indolyls. To compare the cytotoxicity of VERU-111
that was reported previously, new VERU-111 analogs were evaluated for their cytotoxic
effect in human melanoma cell lines including A375, WM-164, and M14 or RPMI-7951.
Colchicine was used as a positive control, and VERU-111 was used as a prototype for
comparison. In the first series of compounds developed to optimize the potency and
investigate the SAR of VERU-111 analogs, a substitution at the 2-position of the indole
ring was introduced (Table 3-1). Compared to the prototype VERU-111, analog 10aa
containing a bulky phenyl group on the 2-position of indole moiety showed markedly
reduced activity and had IC50s more than 1 μM against three melanoma cell lines. This
indicated that bulky substituent on the indole might not be tolerated. We next compared 6
analogs with a substitution at the 4-position of the indole ring, including 10ab-10ag. The
best inhibitory effect was observed in 4-methyl analog 10ab, which had IC50s ranging
from 1.7-3.2 nM and was ~3-fold more potent than VERU-111. Analog 10ac had a small
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Table 3-1.
moiety.
Compound
scaffold

In vitro cytotoxicity of VERU-111 analogs modifying the indole

ID

R

VERU-111

IC50 ± SEM (nM)
A375

M14

WM-164

H

8.1 ± 1.6

5.6 ± 0.9

7.2 ± 0.9

10aa

2-Ph

>1000

>1000

>1000

10ab

4-CH3

1.8 ± 0.2

1.7 ± 0.2

3.2 ± 0.3

10ac

4-F

7.2 ± 0.7

8.2 ± 0.9

ND

10ad

4-Br

13.8 ± 1.7

10.4 ± 1.2

67.1 ±14.5

10ae

4-OCH3

>1000

>1000

>1000

10af

4-OBn

>1000

>1000

>1000

10ag

4-OH

9.2 ± 1.4

8.6 ± 0.8

19.1 ± 1.8

10ah

5-CH3

277.7 ± 36.3

177.4 ± 16.3

552.3 ± 108.3

10ai

5-F

19.2 ± 1.5

18.0 ± 1.3

80.9 ± 16.6

10aj

5-Cl

61.8 ± 9.3

64.9 ± 4.3

159.5 ± 24.1

10ak

5-Br

164.2 ± 16.7

104.3 ± 5.9

441.7 ± 110.0

10al

5-OBn

>1000

>1000

>1000

10am

5-OH

>1000

>1000

>1000

10an

6-CH3

21.1 ± 3.9

21.7 ± 4.7

23.7 ± 6.1

10ao

6-F

17.5 ± 3.0

5.8 ± 0.8

10.3 ± 1.2

10ap

6-Br

67.8 ± 10.5

41.2 ± 7.5

55.4 ± 7.4

10aq

6-OCH3

793.4 ± 89.9

879.8 ± 88.2

>1000

10ar

6-OBn

>1000

>1000

>1000

10as

6-OH

>1000

>1000

>1000

10at

7-CH3

13.1 ± 1.3

10.8 ± 1.0

61.3 ± 11.0

10au

7-OCH3

38.3 ± 3.7

34.1 ± 3.5

115.4 ± 25.0

10av

7-OBn

>1000

>1000

>1000

10aw

7-OH

>1000

>1000

>1000

10bb

4-indolyl

3.6 ± 1.0

3.7 ± 0.8

1.6 ± 0.3

10bc

5-indolyl

8.6 ± 3.3

18.5 ± 3.7

6.1 ± 1.2

10bd

6-indolyl

8.0 ± 1.0

6.1 ± 1.1

3.8 ± 0.5

10be

7-indolyl

285.5 ± 78.7

240.6 ± 38.1

435.8 ± 171.3

14.1 ± 2.2

16.6 ± 1.5

10.8 ± 1.9

Colchicine
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substituent (4-F) and displayed nearly equipotent antiproliferative activity to that of
VERU-111 with its IC50 ranging from 7.2-8.2 nM. In contrast, 10ad, an analog with a
larger halogen 4-bromo, was half as potent as VERU-111, having IC50s ranging from
10.4-67.1 nM. For analogs 10ae with a 4-methoxy group and 10af with a 4-benzoxy
group, considerable reductions of activities were observed, demonstrating IC50s of more
than 1 μM. However, hydrogenation to a 4-hydroxy in compound 10ag rescued activity,
with IC50s from 8.6-19.1 nM. 5-position substituted analogs (compounds 10ah-10am)
showed decreased antiproliferative activities in comparison with their corresponding 4position substituted counterparts. For example, the 5-fluoro analog 10ai and 5-bromo
analog 10ak were 2-fold and 10-fold less potent than 10ac and 10ad, respectively. We
also observed that the activity decreased with halogen size, where the order of potency
from F > Cl > Br substitutions on 10ai, 10aj, and 10ak, respectively. The activity 5methyl analog 10ah possessed approximately 100-fold decreased cytotoxicity compared
to 10ab. The best activity was observed in 5-substitution set was the 5-fluoro analog
10ai, which had IC50s ranging from 18.0-80.9 nM. Although a bulky benzyloxy led to
completely lost antiproliferative activity (analog 10al), hydrogenation of benzyloxy to
hydroxy (analog 10am) did not contribute to any improvement of activity, unlike what
was observed in 10ag. Next, we compared analogs with a substitution at the 6-position of
the indole ring and found analogs with bulky functional groups at this position such as
10aq and 10ar also resulted in significant loss of activity, and hydrogenation of the
benzyloxy to hydroxy on the 6-position (10as) did not provide any significant
improvement of activity. Smaller substituents, however, had better cytotoxicity. For
example, the best activity from a 6-position substitution was observed in the 6-fluoro
analog 10ao, with IC50s ranging from 5.8-17.5 nM. At the final position for this series of
3-indolyl analogs, 4 compounds were synthesized with substitutions at the 7-indole
position (10at-10aw). 10at, containing a small methyl substitution, possessed the most
potent inhibitory effect of the 7-indole substitutions, with IC50s ranging from 10.8-61.3
nM. Interestingly, 10au with a bulky 7-methoxy substituent showed significantly stronger
activity (IC50s of 34.1-115.4 nM) than its 4-methoxy and 6-methoxy counterparts (10ae
and 10ap). Taken these data together, small substituent (e.g. fluoro and methyl) is
preferred to bulky functional groups on the 3-indolyl moiety. By comparing different
positions of substituted analogs, it was determined that 4-position is the most amenable to
the introduction of a functional group.
VERU-111 Analogs with Indolyl Rotation. Hwang et al. have disclosed a series
of indolyl-imidazopyridines that are tubulin inhibitors, and their SAR study revealed that
indolyl rotation significantly affected the potency and antiproliferative activities. (143).
We hypothesized that this concept would also apply to VERU-111 analogs, considering
its structural similarity to indolyl-imidazopyridines. Therefore, we synthesized four
VERU-111 analogs 10bb-10be demonstrate their cytotoxicity in Table 3-1. In this series,
5- and 6-indolyl analogs 10bc and 10bd showed comparable antiproliferative activities to
that of VERU-111and had IC50s ranging from 6.1-18.5 and 3.8-8.0 nM, respectively,
while the 7-indolyl analog 10be showed a drastic decline in potency. 10bb, the 4-indolyl
analog, demonstrated greater cytotoxicity than VERU-111, with IC50s ranging from 1.63.7 nM against the tested cancer cell lines, and was one of the most potent of all the new
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analogs. Overall, these data suggest that rotating the indole moiety is feasible to improve
the antiproliferative activity of VERU-111.
VERU-111 Analogs with Modified 3,4,5-Trimethoxyphenyl Moiety. Based on
our recently reported high resolution crystal structure of DJ101 (Figure 2-2) (199), a
close analog of VERU-111, we discovered that: (1) only one methoxy of the TMP moiety
in DJ101 was involved in the formation of a hydrogen bond interaction with the βCys241 residue of tubulin; and (2) there is very limited space around the TMP moiety to
accommodate any larger moieties (179). We hypothesized that two of the three methoxys
of the TMP moiety could be modified to optimized activity without damaging the
interactions to tubulin. We carried out a focused SAR investigation of VERU-111 by
modifying the TMP moiety, specifically by linking two adjacent methoxy moieties into a
conformationally restricted ring system (Table 3-2).
The benzo[4,5]-dioxane analog 13a lacks the 3-methoxy present in the TMP of
VERU-111. It exhibited remarkable loss of cytotoxicity (IC50 ranges from 119 to 218
nM). The ring contraction of the six-member benzo[4,5]-dioxane ring to the five-member
benzo[4,5]-dioxole ring in analog 13b demonstrated showed comparable antiproliferative
activity to that of 13a. In contrast to 13c, the 3-methoxybenzo substituted analog of 13a,
demonstrated significantly increased potency, with IC50 values ranging from 11.3 to 29.2
nM. This is consistent with our previous SAR, where we discovered that removing one or
more of the methoxy groups in the TMP moiety negatively affects the antiproliferative
potency for this scaffold (98). Similarly, introducing the 3-methoxy to the benzo[4,5]dioxole analog 13b led to the formation of 13d, which restored the potency (IC50 ranges
from 3.5 to 5.6 nM, 30-fold more active than 13b). Interestingly, this five-membered ring
analog was ~4-fold more potent than the six-membered ring analog 13c. Thus, while the
3-methoxy was crucial for the activities of VERU-111 analogs, the size of the cyclic
rings on the phenyl moiety also played an important role (13c vs 13d). Consistent with
this, further increasing the ring size to a seven-membered ring resulted in 3methoxybenzo[4,5]dioxepin analog 13e, resulted in a moderate decrease in potency (IC50
ranging from 32.2 to 47.7 nM). By comparing 13c, 13d and 13e, it was revealed that the
activity for the size of this saturated ring is 5 > 6 > 7.
We next introduced an unsaturation to this ring by synthesizing 13f, a unique 3methoxybenzo[4,5]-dioxene analog. Interestingly, 13f exhibited the most potent
antiproliferative activity among the TMP-modified analogs (13a-13f), with IC50 values
ranging from 1.1 to 3.3 nM. To determine the combination modifications to both the
TMP and indole moieties on 13f, we further produced analogs 19 and 25 (Table 3-2).
While the 4-indolyl analog 19 exhibited ~ 11-fold reduced antiproliferative activity when
compared to 13f, the 4-methyl-3-indolyl analog 25 (IC50 values ranging from 6.1 to 8.8
nM) was only slightly less potent than 13f. Overall, our SAR result show that the TMP
moiety in VERU-111 can be modified without negatively impacting antiproliferative
activities.
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Table 3-2.
Compound
Scaffold

In vitro cytotoxicity of VERU-111 analogs modifying the TMP moiety.
ID

IC50 ± SEM (nM)

R
A375

M14

RPMI-7951

13a

158.7 ± 16.4

118.8 ± 14.3

213.7 ± 17.1

13b

190.6 ± 16.8

154.6 ± 10.4

235.6 ± 19.3

13c

21.0 ± 1.6

11.3 ± 0.8

29.2 ± 1.7

13d

3.5 ± 0.4

5.6 ± 0.6

5.6 ± 0.5

13e

32.2 ± 3.4

38.2 ± 3.5

47.7 ± 3.9

13f

1.1 ± 0.1

1.2 ± 0.2

3.3 ± 0.3

19

17.1 ± 1.1

13.8 ± 0.9

34.8 ± 2.2

25

6.1 ± 0.2

6.1 ± 0.2

8.8 ± 0.5

8.1 ± 1.6

5.6 ± 0.9

7.2 ± 0.9

VERU111
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Lead Compounds Show Improved Potency to Resistant Cell Lines
To expand our assessment of the biological activity of the lead compounds, we
chose the most potent compound from each modification series to move forward with for
additional analysis. This included 10ab from the 3-indolyls, 10bb from indole rotation
series, and 10f from TMP modification series. Since other colchicine binding site
inhibitors are reportedly less susceptible to taxane-related drug resistance, we wanted to
determine if our analogs would still be efficacious in taxane-resistant models (54, 199,
240). We tested our compounds against paclitaxel in PC-3, paclitaxel-resistant PC-3/TxR,
DU-145, and docetaxel-resistant DU-145/TxR prostate cancer cell lines (Table 3-3).
Paclitaxel was more potent in the parental PC-3 cell lines with an IC50 of 1.1 ± 0.2 nM
compared to 5.2 ± 0.4, 89.9 ± 6.3, and 15.2 ± 1.3 nM for 10ab, 10bb, and 13f, which is
not surprising given paclitaxel’s potency and clinical success. However, in resistant PC3/TxR cell lines, paclitaxel had a resistance index of 103.5 and an IC50 of 113.9 ± 4.3 nM
whereas 10ab, 10bb, and 13f all showed a resistance index of less than 1, meaning they
had improved potency against the resistant cell line. Along the same lines, paclitaxel was
highly potent against the sensitive DU-145 cell line (1.5 ± 0.2 nM), however, no effect
was observed at all against the paclitaxel-treated DU-145/TxR cells at concentrations up
to 1μM. In contrast, all 3 compounds showed remarkably improved resistance indices,
ranging from 1.8-2.2. These data support the continued investigation of this scaffold as an
alternative treatment for cancers resistant to taxane treatment.
Molecular Interactions of 10f with Tubulin
To understand the molecular basis for the strong interaction of the most potent
TMP-modified analog, 13f, with tubulin, we obtained the crystal structure of the T2RTTL (consisting of α/β-tubulin, the stathmin-like domain of RB3, and tubulin tyrosine
ligase) (186, 241) in complex with 13f at a resolution of 2.85 Å (PDB ID: 6D88). As
expected, 13f occupies the colchicine binding site at the interface of the α- and β-tubulin,
mostly confined in a deep pocket in β-tubulin opposite the GTP molecule that is bound in
a pocket in the α-tubulin (Figures 3-1A). There are two α/β-tubulin heterodimers in this
complex and both interfaces are occupied by the small molecule. In both heterodimers
(Chain A/B and C/D), 13f forms virtually identical interactions. First, it forms three
hydrogen bonds with the surrounding amino acids: an imidazole NH to carbonyl of
Thr179 (α-tubulin); an indole NH to Ser178 (α-tubulin) and Asn347 (β-tubulin) via a
water molecule; and a carbonyl linker to Asp249 (β-tubulin) (Figure 3-1B). Second, the
3-methoxybenzo[4,5]-dioxene moiety is stacked between Cys239 and Leu253 from βtubulin, the latter making a pi-H interaction with the ring. Finally, the imidazole ring is
surrounded by Leu246 and Asn256 from β-tubulin while the indole ring is surrounded by
both Lys350 and Met257 from β-tubulin and Val181 from α-tubulin. Colchicine targets
the β subunit and keeps the tubulin from adopting a straight conformation, thus inhibiting
microtubule assembly, and 13f also blocks the curved-to-straight conformational change
of tubulin by steric clashes with surrounding secondary structure elements (Figure 3-1C).
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Table 3-3.
In vitro cytotoxicity of 10ab, 10bb, and 10f against parental and
taxane-resistant prostate cancer cell lines.
IC50 ± SEM (nM)
treatment

IC50 ± SEM (nM)

a

RI

PC-3

PC-3/TxR

10ab

5.2 ± 0.4

3.9 ± 0.3

10bb

89.9 ± 6.3

10f

RI
DU-145

DU-145/TxR

0.8

13.8 ± 1.0

25.2 ± 2.0

1.8

66.9 ± 4.4

0.7

169.1 ± 4.4

379.1 ± 80.0

2.2

15.2 ± 1.3

7.6 ± 0.5

0.5

42.2 ± 3.6

81.5 ± 11.6

1.9

Colchicine

10.4 ± 0.5

37.4 ± 2.2

3.6

35.5 ± 3.5

>1,000

>28

Paclitaxel

1.1 ± 0.2

113.9 ± 4.3

103.5

1.15± 0.2

>1,000

>869

Docetaxel

0.5 ± 0.1

27.9 ± 1.1

55.8

0.10 ± 0.01

352.3 ± 118.2

>3,523

a

RI: resistance index is calculated by dividing the IC50 value of compound in resistant cell
lines by the IC50 in the corresponding parental cell lines.
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Figure 3-1. T2R-TTL in complex with 13f.
A) Surface representation of the 13f-tubulin complex. Various components are marked
with arrows. B) Close up view of first a/β-tubulin heterodimer interface occupied with
13f. The compound is shown in ball & stick model with orange carbons. Water and Mg
are shown in ball model, GTP in thick sticks and amino acids in thin sticks. 2Fo-Fc map
of the compound drawn at 1.0 Å. sigma is shown as green mesh. C) Interference of 13f
with the tubulin straight conformation. The close-up view of superimposition of the
tubulin-13f complex (blue ribbons-orange carbon balls, PDB ID: 6D88) and tubulin as
found in straight protofilaments (grey ribbons, PDB ID: IJFF) shows that 13f binding is
not compatible with the straight conformation. Conformational changes of the secondary
elements in both subunits upon binding of 13f are labeled. D) Conformational changes at
the colchicine-binding sites between colchicine (PDB: 4O2B), and 13f (PDB code:
6D88). Superimposition of tubulin bound with 13f bound (shown in yellow) and with
colchicine bound (shown in salmon). Crystallographic data obtained by Yuxi Wang
(Sichuan University, China) and interpreted by Dr. Stephen White and Dr. Gyanendra
Kumar (St. Jude Children’s Research Hospital).
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Finally, the superimposition of 13f and colchicine bound to tubulin demonstrates that it
overlaps well with colchicine in the binding pocket and supports a shared mechanism of
action between colchicine and 13f (Figure 3-1D).
Inhibition of Tubulin Polymerization and Microtubule Dynamics
To further validate their mechanism of action, we tested the effect of 10ab, 10bb,
and 10f on polymerization of purified tubulin in a cell-free assay. 10 μM concentrations
of 10ab, 10bb, and 10f were evaluated against vehicle-only control, colchicine, and
docetaxel, which is a well-documented enhancer of polymerization. All three new
VERU-111 analogs potently inhibited tubulin polymerization, while the vehicle
experienced an initial and rapid increase in polymerization and docetaxel strongly and
consistently promoted polymerization (Figure 3-2A). Colchicine, which was used as a
positive control, showed similar activity as the 3 new compounds in tubulin inhibition.
The effect on microtubule networks was then observed by immunofluorescence
via confocal microscopy. Microtubule morphology in WM-164 cells was visualized after
18 hrs of treatment of with 100 nM of 10ab, 10bb, docetaxel, or untreated control cells.
Unlike the control cells, 10ab and 10bb effectively disrupted microtubules, resulting in
fragmentation and disassembly (Figure 3-2B). Docetaxel demonstrated the opposite
effect, causing hyper-polymerization and resulting in the formation of dense, aggregated
bundles of microtubules. These mechanistic studies confirm that these compounds
maintain a mode of action by inhibiting tubulin assembly and interfering with
microtubule dynamics.
Inhibition of Cancer Growth and Migration
The long-term inhibitory growth effects of 10ab and 10bb were tested in A375
cells in an anchorage-dependent colony formation assay. While the control cells averaged
199.3 ± 10.7 colonies after 12 days, 5 nM concentrations of 10ab and 10bb decreased
colony number, resulting in an average of 81.7 ± 7.8 and 128.3± 9.1 colonies,
respectively (Figure 3-3A). These compounds even out-performed colchicine, which
averaged 150.0 ± 5.3 colonies. There was a significant reduction in colony number for
each compound-treated group, where colchicine, 10bb, and 10ab treatment resulted in a
24.7%, 35.6%, and 59.5% decrease, respectively. Tubulin and microtubule function are
also implicated in cell migration and motility. Therefore, we assessed the effect of 10ab
and 10bb in a wound healing assay. After removing a confluent monolayer of adherent
A375 or RPMI-7951 melanoma cells, cells were treated for 18-22 hrs with 5 or 25 nM of
10ab, 10bb, or colchicine and compared against an untreated control. The total closure
was calculated as a percentage of the total wound area after treatment compared to the
total area of removed cells immediately prior to treatment. In A375 and RPMI-7951 cell
lines, the control cells were able to efficiently migrate into the wound channel, recovering
60.7% ± 5.9% and 71.8% ± 1.8% of the area, respectively (Figure 3-3B). Following 5
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Figure 3-2. New VERU-111 analogs inhibit tubulin polymerization.
A) Polymerization of purified tubulin in a cell-free assay. Tubulin (3.33 mg/ml) was
exposed to vehicle control or 10 μM of the compounds (n=2). Absorbance at 340 nm was
monitored at 37 °C every minute for 40 min. B) Effect on microtubules of WM-164 cells
following 18h exposure to 100 nM of 10ab, 10bb, docetaxel or vehicle control. Confocal
microscopy was utilized to visualize the microtubules following immunofluorescent
staining. Microtubules are shown in red and DNA is shown in blue. Scale bar = 20 μm.
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Figure 3-3. Inhibition of colony proliferation and cancer cell migration.
A) A375 colony formation for control or treated cells represented as mean ± SD (n=3). B) Scratch migration assay for A375 (top) or
RPMI-7951 (bottom) cells after treatment with 5 or 25 nM concentrations of 10ab, 10bb, colchicine, or untreated control represented
as mean ± SD (n=3). Area of the wound channel was calculated using ImageJ software. Statistical analysis was performed by one-way
ANOVA followed by Dunnett’s multiple comparison test (*P < 0.05, ** P < 0.01, *** P < 0.001, ****P < 0.0001).
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nM treatment with 10ab, 10bb or colchicine, A375 cells only migrated into 49.4% ±
1.6%, 38.5% ± 3.9%, and 46.0% ± 2.5% of the wound area, respectively. At higher
concentrations of 25 nM, a greater inhibition was observed, where cells recovered 25.9%
± 2.8%, 27.5% ± 6.2%, and 20.7% ± 3.8% for each of the tested compounds (P <
0.0001). A significant difference was also observed in RPMI-7951 cells treated at 25 nM
of 10ab, 10bb or colchicine, leading to wound closure averaging 35.6% ± 6.6%, 35.0% ±
7.8%, and 42.8% ± 5.8%, respectively (P =0.0004). Averaging the results from both cell
lines, the average inhibition of migration of cells treated at 25 nM concentrations with
10ab, 10bb, and colchicine was 56.1%, 55.3%, and 34.0%. Taken together, these results
demonstrate that 10ab and 10bb potently inhibit proliferation and migration in vitro at
low nanomolar concentrations.
In Vitro Metabolic Stability of VERU-111 Analogs
To determine the most suitable candidates for in vivo studies, we examined the in
vitro metabolic stabilities of the most potent analogs by measuring their half-life upon
incubation with mouse, rat and human liver microsomes in the presence of an NADPH
regeneration system. The parent compound VERU-111 was used for comparison and
Verapamil was used as a positive control. Overall, all three new VERU-111 analogs
exhibited moderate to good stabilities in three different microsome species. (Table 3-4).
Compared to the parental compound, 10ab showed an improved half-life and clearance in
human liver microsomes (6.7 ± 0.8 hrs, 3.1 mL/min/kg), whereas VERU-111 showed a
half-life of 5.1 ± 0.3hrs and a clearance of 4.1 mL/min/kg. 10bb showed better stability
compared to VERU-111 in all 3 species and, compared to 10ab, demonstrated an almost
identical half-life and clearance in human liver microsomes and better metabolic
stabilities in mouse and rat liver microsomes. 13f showed a slightly less stable profile
than the other compounds (2.7± 0.3 hours and 7.7 mL/min/kg in human liver
microsomes) but still displayed greater stabilities than the reference control. Based on the
in vitro and stability assessment, we selected 10bb to undergo testing in animal models.
Because of its unique modification to the TMP moiety, 13f was also selected for in vivo
evaluation to determine if the strong anticancer efficacy demonstrated in vitro would also
be evident in animal models.
Anticancer Efficacy in Melanoma Mouse Models Without Toxicity.
The antitumor efficacies of 10bb and 13f were evaluated in two melanoma
xenograft mouse models. Nude mice bearing A375 melanoma tumors were treated every
other day via i.p. injection with 15 mg/kg or 30 mg/kg doses of 10bb, 13f, paclitaxel, or
given a vehicle solution only. The average TGI for the groups treated with 15 mg/kg and
30 mg/kg of 13f was 54.8% and 73.9%, respectively. These results were similar to the
paclitaxel-treated group, which showed an average TGI of 70.7% (Figure 3-4A). In a
separate in vivo study, the group receiving 15 mg/kg of 10bb achieved an average tumor
growth inhibition of 82.3% and the group receiving the higher dose of 30 mg/kg achieved
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Table 3-4.
In vitro metabolic stabilities of compound 10ab, 10bb, and 13f in liver
microsomes.

Compound

Metabolic Stability
(Human)
t1/2
Clint
(hr)
(mL/min/kg)

VERU-111 5.13 ± 0.26

Metabolic Stability
(Mouse)
t1/2
Clint
(hr)
(mL/min/kg)

Metabolic Stability
(Rat)
t1/2
Clint
(hr)
(mL/min/kg)

4.05

3.76 ± 0.24

15.20

6.74 ± 0.59

6.94

10ab

6.70 ± 0.82

3.10

2.42 ± 0.15

23.60

1.80 ± 0.09

25.98

10bb

6.72 ± 0.74

3.10

5.04 ± 0.30

11.34

29.93 ± 7.82

1.56

13f

2.69 ± 0.26

7.70

1.42 ± 0.14

40.30

3.57 ± 0.43

13.10

Verapamil

1.68 ± 0.16

12.41

0.94 ± 0.06

60.66

1.29 ± 0.09

36.18

Data obtained by Lei Yang (St. Jude Children’s Research Hospital).
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Figure 3-4. Anticancer efficacy of VERU-111 analogs in melanoma mouse models.
A) 13f and B) 10bb treatments in A375 xenograft models in nude mice represented as mean tumor volume ± SEM. (n=8 and n=10,
respectively). Statistical significance for final tumor volumes in both studies was determined by one-way ANOVA analysis followed
by Dunnett’s multiple comparison test for the treatment group compared with the corresponded results of the control group (*P < .05,
** P < 0.01, *** P < 0.001, ****P < 0.0001). C) 10bb inhibits B16F10 lung metastasis in C57BL/6 mice. The graph represents the
tumor index for mice (n=10) and error bars represent 95% CIs. An unpaired student’s t-test was performed to show statistical
significance between the groups (P= 0.0013). Mouse body weights are represented as a percent of weight change compared to initial
weight ± SEM for each study.
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a TGI of 90.6% (Figure 3-4B). Both groups achieved significantly greater tumor growth
inhibition than the paclitaxel group, which averaged a TGI of 68.6%. Because it showed
the most potent effect on tumor growth inhibition, we investigated the ability of 10bb to
inhibit metastatic potential in a lung metastasis mouse model at 30 mg/kg doses in
C57BL/6 mice against a vehicle control group (Figure 3-4C.) After inoculation with the
melanoma via the lateral tail vein, mice were treated for two weeks with the same dosing
regimen. The average tumor index based on lung metastasis nodule size and the number
was 13.6 ± 2.9 for the control group and 2.6 ± 0.6 for the 10bb treatment group. This was
significantly less than the control based on an unpaired student’s t test (P = 0.0013) and
represents an 80.9% decrease in metastasis. Mouse weight and activity were monitored
and for both xenograft models and the lung metastasis model, and major weight
deviations were not observed. Histopathology analysis was performed on major organs
collected from both in vivo studies to assess for acute toxicities from 10bb treatment.
H&E stained sections revealed no apparent drug-related injury or pathological changes in
the cellular structure of the various tissues from both the xenograft mouse model and the
experimental lung metastasis mouse model (Figure 3-5A). Additionally, in vitro
pharmacological profiling was utilized to identify undesirable off-target effects and
determine the safety profile. 10bb was evaluated at 1 μM in the Safety47™ Panel which
includes the assessment of the functional response of 47 major physiologically important
targets (Figure 3-5B). 10bb only showed positive responses (higher than |70%|) in 2 of
the 78 assays, which were norepinephrine transporter (NET) and serotonin receptor 2B
(HTR2B) antagonism.
Circumventing Taxane Resistance
Because of its promising in vivo antitumor potency and initial findings
demonstrating that taxane resistant cells were still highly sensitive to 10bb treatment, we
wanted to confirm that 10bb could be an effective treatment to taxane-resistant tumors.
We previously demonstrated that paclitaxel is an effective treatment against PC-3
xenograft tumors in a nude mouse model but was ineffective against the taxane resistant
PC-3/TxR xenograft tumors (previously shown in Figure 2-8A). We hypothesized that
10bb would show high efficacy in the resistant xenograft model and that paclitaxel would
fail, providing support for the development of 10bb in resistant chemotypes. Therefore,
we proceeded to test 10bb at the same dosing concentration and frequency as in the
previous models (30mg/kg, every other day via i.p. injection) in comparison to paclitaxel
at 15 mg/kg, a dose that was shown to be highly effective against non-resistant cancer
xenograft models. Paclitaxel showed a marked decline in anticancer capabilities, yielding
a TGI of only 37.8% and a modest reduction in tumor weight of only 34.5% (Figure
3-6A-C). In contrast, treatment with 10bb caused a significant reduction in tumor growth
by 83.8% and decreased average tumor weight by 62.8%. ANOVA analysis (P < 0.0001)
followed by Dunnett’s multiple comparison test confirmed a significant decrease in final
tumor volume and weight (P < 0.0001) for the 10bb treated groups without causing
significant loss of body weight or animal activity (Figure 3-6D). This further validates
10bb as an alternative treatment to taxane-resistant cancers.
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Figure 3-5. Toxicity and safety assessment for 10bb.
A) Pathological sections of major tissues (heart, kidney, liver, lung, and spleen) were
obtained from the A375 xenograft (top) and B16F10 lung metastasis (bottom) studies.
Organs were H&E stained, and representative images of the tissues were captured. B) In
vitro pharmacological profiling of 10bb to assess potential off-target effects to major
targets at 1μM concentrations using the Safety47™ Panel (n=2). Graph represents mean
% response ± range. Values in between -70% and +70% (indicated with dashed lines) are
considered insignificant.
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Figure 3-6. Antitumor efficacy of 10bb in a taxane-resistant xenograft model.
A) Tumor volumes for the PC-3/TxR xenograft model shown as mean volume ± SEM
(n=8). B) Final tumor weights for PC-3/TxR mice. Error bars represent 95% CIs.
Statistical significance for final tumor volumes and weights were determined by one-way
ANOVA analysis followed by Dunnett’s multiple comparison test (*P < .05, ****P <
0.0001). C) Representative images of resected tumors at the end of the study. D) Mouse
body weights represented as mean weight change as a percentage compared to initial
weight ± SEM.
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Conclusions
In this research, an extensive SAR investigation of VERU-111 focusing on the
modification of the indole moiety is reported, revealing that 10ab and 10bb are more
potent derivatives than prototype VERU-111. We also conducted SAR on the TMP
modification series. While modifying the TMP moiety of colchicine binding site
inhibitors is usually unsuccessful in improving antiproliferative activities, our results
showed that isosteric (conformationally restricted) replacement of the TMP is feasible to
significantly increase the potency in this scaffold. We identified the analog 13f,
containing a unique 3-methoxybenzo[4,5]-dioxene moiety, that demonstrated more potent
antiproliferative activity than VERU-111. Additionally, compared to paclitaxel, these
lead compounds showed significantly improved resistance indexes against taxaneresistance prostate cancer cell lines, suggesting their potential against drug-resistant
phenotypes.
The X-ray crystal structure of tubulin in complex with 13f, the visualization of
disrupted microtubule networks of cells after treatment with 10ab and 10bb, and the
potent inhibition of tubulin polymerization by all 3 compounds in a tubulin assay all
support that these compounds have the same mechanism of action as colchicine. The
crystallographic analysis is particularly valuable because it revealed that the interactions
between 13f and tubulin are centered on a hydrogen-bonding network, which provides
potential avenues for future modifications to improve potency.
10bb and 13f were selected for in vivo efficacy studies and drastically inhibited
tumor growth in melanoma xenografts. 10bb also reduced lung metastasis without
causing signs of toxicity. Finally, 10bb treatment was effective in a PC-3/TxR prostate
cancer model, suggesting its ability to circumvent certain MDR mechanisms that nullify
paclitaxel action. In conclusion, we have developed improved analogs of VERU-111 by
optimizing substitutions through SAR investigation and demonstrated the feasibility of
modifying the TMP moiety for enhanced activity. We confirmed their mechanism of
action and in vivo potency, supporting their development as potential new candidates
targeting the colchicine binding site for cancer treatment.
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CHAPTER 4. NOVEL TUBULIN INHIBITORS WITH A HETEROCYCLIC
PYRIMIDINE SCAFFOLD SHOW VASCULAR DISRUPTING PROPERTIES3
Introduction
Disrupting tubulin dynamics is a well-validated strategy for anticancer therapy
(54, 145, 172, 242-249). The three widely studied binding sites in tubulin are the
paclitaxel site, the vinca alkaloid site, and the colchicine site (39, 54). Currently, all FDA
approved tubulin inhibitors for cancer treatment target either the taxane site (e.g.
paclitaxel, docetaxel) or the vinca alkaloid site (e.g. vinblastine, vincristine). Colchicine
binding site agents have advantages over other classes of tubulin inhibitors, including
reduced susceptibility to MDR from ABC transporter overexpression and upregulation of
the βIII tubulin isoform (explained in detail in Chapter 1). However, the potential clinical
applications of many colchicine site tubulin inhibitors have been halted due to significant
toxicities, low solubility, and low bioavailability (23, 39, 54, 214, 244). There have been
extensive research efforts to identify new small molecules capable of acting at the
colchicine binding site with improved therapeutic indexes. Additionally, there have been
numerous reports that tubulin inhibitors targeting the colchicine binding site exhibit
promising vascular disrupting effects in addition to inhibiting tumor cell invasion and
metastasis (39, 98, 141, 145, 172, 243, 250). Vascular disrupting agents (VDAs) are
known to rapidly disrupt existing tumor vessels resulting in prompt vascular collapse and
tumor cell death (39, 40, 251). Thus, there has been substantial interest in this class of
tubulin inhibitors, since newer generations of tubulin inhibitors can be developed that can
overcome the limitations of the existing tubulin inhibitors by evading MDR and reducing
toxicity (39, 40).
A number of small molecule vascular disrupting agents targeting the colchicine
binding site are currently in clinical development as anticancer agents (Figure 4-1,
compounds 1a-1c) (39, 40). Out these VDAs, Azixa/Verubulin (1a) and its derivatives
have drawn considerable attention in the recent years (101). Azixa emerged a few years
ago as a very potent tubulin polymerization inhibitor, and it has been observed to act as a
VDA by introducing rapid shut down of tumor blood flow and consequently inhibits the
tumor growth (39, 40, 101, 102). Azixa has demonstrated low nanomolar potency against
diverse tumor models, including melanoma, brain cancer, ovarian cancer, small cell lung
cancer, and prostate cancer (102, 252, 253). Recently, Mueller et al. reported an indole
derivative of Azixa/Verubulin (1d) that induced significant vascular disruption in the
1411 HP germ cell xenograft tumors, leading to rapid tumor necrosis (102). Gangjee et
al. have reported Azixa derivatives (1e) that are dual inhibitors of tubulin and vascular
3

Modified with permission from American Chemical Society. Souvik Banerjee*, Kinsie E. Arnst*, Yuxi
Wang*, Gyanendra Kumar, Shanshan Deng, Lei Yang, Guo-bo Li, Jinliang Yang, Stephen W. White, Wei
Li, and Duane D. Miller. Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors
Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy
Journal of Medicinal Chemistry. 2018; 61 (4), 1704-1718.
*
Equally contributing authors.
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Figure 4-1. Recently developed VDAs that target the colchicine binding site.
Three are currently in clinical trials (1a, 1b, and 1c) and three reported derivatives of
Azixa/Verubulin are in pre-clinical development (1d, 1e, and 1f).
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endothelial growth factor receptor-2 (VEGFR2) (242). These dual actions produced
significant reduction in tumor size and disruption of vascularity in three mouse xenograft
models.
However, most of the quinazoline analogs reported by Xie et al. have shown low
metabolic stability in human liver microsomes (t1/2 ≤ 10 minutes) and substantial in vivo
toxicity, with MTDs less than 4 mg/kg (145). Although Azixa and many of its derivatives
are highly effective as tubulin inhibitors and VDAs, none of them have successfully made
it through clinical trials. One of major concerns limiting the clinical progression of Azixa
is the cardiovascular toxicities that it demonstrated in Phase I and Phase II studies (254).
The identified cardiovascular toxicities include grade 1-3 hypertension, atrial fibrillation,
grade 3-4 myocardial infarction, grade 4 non-ST-elevation myocardial infarction, and
grade 3 cerebral haemorrhage (254, 255). Additionally, while Azixa demonstrates
excellent potency against cancer cells, it also shows potential high toxicity to normal
tissues.
To the improve the therapeutic index of tubulin inhibitors based on the scaffolds
of Azixa or its reported analogs, we set the goal to design new Azixa analogs with: (a)
equal or higher potency than existing Azixa analogs; (b) substantially reduced toxicities
as tested in mouse models; (c) significantly improved metabolic stability; and (d) high
efficacy against clinically relevant MDR models. We selected our starting point based on
the 1f scaffold reported by Lee and Xie et al. because of its reduced conformational
flexibility compared with all other Azixa analogs (145). We revealed the structural
modifications from lead compound 1f that yielded highly potent heterocyclic pyrimidines
and their comprehensive in vitro and in vivo anticancer activities. Lead compounds 4a,
6a, 5a, and 5b were selected out of the series as the molecules with the greatest potential
and underwent additional biological investigation. To confirm the direct binding of these
new analogs to tubulin and determine their molecular interactions, we obtained the highresolution crystal structures of 4a, and 6a in complex with tubulin protein. To the best of
our knowledge, this is the was the first X-ray crystal structure reported for Azixa analogs
bound to tubulin. Importantly, contrary to all previously published molecular modelling
studies for Azixa or its analogs, these high-resolution X-ray crystal structures reveal a
different actual binding pose, along with significant conformational changes, in the
colchicine binding pocket in tubulin (102, 145, 167, 250, 256). Results from this study
provide important structural basis for the molecular interactions and enable future
structure-based optimization for the general Azixa scaffold. Additional mechanistic
studies of 4a, 6a, 5a and 5b reveal that they share the same mechanism of action as
colchicine as tubulin polymerization inhibitors that arrest cells in the G2/M phase of the
cell cycle, interfere with cellular functions such as migration and proliferation, and
enhance apoptotic cascades. 4a was evaluated in two animal models against melanoma
and paclitaxel-resistant tumors, emphasizing the potential of this scaffold to overcome
multidrug resistance for cancer therapy. Finally, we confirmed ability of 4a to elicit
vascular disrupting effects within tumors and against endothelial capillary-like network
formation.
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Materials and Methods
Cell Culture and Reagents
Human melanoma cell lines (A375, M14, RPMI-7951, WM-164, SK-MEL-1,
M14/MDR1) and breast cancer cell lines (MDA-MB-453, MDA-MB-231, MDA-MB468) (American Type Culture Collection or ATCC, Manassas, VA, USA) were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) (Corning, Manassas, VA)
supplemented with 10% (v/v) fetal bovine serum (FBS) (Atlanta Biologicals,
Lawrenceville, GA) and 1% antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis
MO). Human lung cancer cell lines (A549, H460, H1299) American Type Culture
Collection or ATCC, Manassas, VA, USA) were cultured in RPMI 1640 medium (Gibco
by Life Technologies, Carlsbad, CA) supplemented with 10% (v/v) FBS and 1%
antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis MO). Parental prostate cancer
PC-3, its paclitaxel-resistant daughter line PC-3/TxR, parental prostate cancer DU-145,
and its docetaxel-resistant daughter line DU-145/TxR were gifts from Dr. Evan Keller at
the University of Michigan Medical School. PC-3 and DU-145 cell lines were cultured in
RPMI 1640 medium supplemented with 10% FBS and 1% antibiotic/antimycotic
mixture. Taxane-resistant PC-3/TxR and DU-145/TxR cell lines were cultured in the
same medium and additionally supplemented with 10 nM paclitaxel or docetaxel,
respectively. Paclitaxel or docetaxel was not included in the medium for PC-3/TxR or
DU-145/TxR for at least 1 week prior to in vitro and in vivo testing. All cell lines were
authenticated by ATCC by short tandem repeat profiling. Cultures were maintained to
80–90% confluency at 37 °C in a humidified atmosphere containing 5% CO2.
Compounds were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis,
MO) to make a stock solution of 20 mM. Compound solutions were freshly prepared by
diluting stocks with cell culture medium before use.
Cytotoxicity Assays
Cells were seeded in 96-well plates at a concentration of 2000–5000 cells per
well, depending on growth rate of the cell line. After overnight incubation, the medium
was replaced, and cells were treated with the test compounds at 10 concentrations ranging
from 0.03 nM to 1 μM plus a vehicle (DMSO) control for 72 hrs in four replicates.
Following treatment, the MTS reagent (Promega, Madison, WI) was added to the cells
and incubated in dark at 37 °C for at least 1 hr. Absorbance at 490 nm was measured
using a plate reader (BioTek Instraments Inc., Winooski, VT). IC50 values were
calculated by nonlinear regression analysis using GraphPad Prism (GraphPad Software,
San Diego, CA).
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Microsomal Stability Assay
Liver microsome assays were performed by Dr. Lei Yang (St. Jude Children’s
Research Hospital). For each test compound, the human liver microsomal solution was
prepared by adding 0.058 mL of concentrated human liver microsomes (20 mg/mL
protein concentration) to 1.756 mL of 0.1 M potassium phosphate buffer (pH 7.4)
containing 5 μL of 0.5 M EDTA to make a 0.6381 mg/mL (protein) microsomal solution.
Each test compound (2.2 μL of 10 mM DMSO solution) was added directly to 1.79 mL
of human liver microsomal solution, and 90 μL was transferred to wells in 96-well plates
(0, 0.25, 0.5, 1, 2, and 4 h time points each in triplicate). The NADPH regenerating agent
was prepared by mixing 0.113 mL of NADPH regenerating agent solution A, 0.023 mL
of solution B, and 0.315 mL of 0.1 M potassium phosphate buffer (pH 7.4) for each
tested compound. To each well of the 96-well plate, 22.5 μL of the NADPH regenerating
agent was added to initiate the reaction, and the plate was incubated at 37 °C for each
time point. The reaction was quenched by adding 225 μL of cold acetonitrile containing
warfarin (4 μg/mL) as internal control to each well. All of the plates were centrifuged at
4000 rpm for 20 min, and the supernatants (100 μL) were transferred to another 96-well
plate for analysis on UPLC–MS (Waters Acquity UPLC linked to Waters Acquity
photodiode array detector and Waters Acquity single quadrupole mass detector) on
Acquity UPLC BEH C18 1.7 μm (2.1 mm × 50 mm) column by running 90–5% gradient
for water (+0.1% formic acid) and acetonitrile (+0.1% formic acid). The area under the
single ion recording (SIR) channel for the test compound divided by the area under the
SIR for internal control at 0 time concentration was considered as 100% to calculate
remaining concentration at other time points. The terminal phase rate constant (ke) was
estimated by linear regression of logarithmic transformed concentration versus the data,
where ke = slope × (−ln 10). The half-life t1/2 was calculated as ln 2/ke.
Tubulin Polymerization Assay
The polymerization reaction contains 100 ul of volume of Bovine brain tubulin (3
mg/ml) (Cytoskeleton, Denver, CO) and 10 μM of the test compounds in general tubulin
buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, and 1 mM GTP) at pH 6.9. The
absorbance of wavelength at 340 nm was monitored every 1 min for 50 min by the
SYNERGY 4 Microplate Reader (Bio-Tek Instruments, Winooski, VT). BioTek Gen5
data analysis software was used to calculate the Vmax values. The spectrophotometer was
set at 37 °C for tubulin polymerization.
Confocal Microscopy
WM-164 cells were seeded on glass coverslips in six-well plates (125 000
cells/well) and incubated overnight. Cells were treated with 100 nM compounds or
equivalent vehicle (DMSO) control for 18 h. Microtubules were visualized after
incubating with anti-α-tubulin antibody (Thermo Scientific, Rockford, IL) and Alexa
Fluor 647 goat anti-mouse IgG (Molecular Probes, Eugene, OR). The coverslips were
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mounted with Prolong Diamond Antifade mounting medium with DAPI (Invitrogen,
Eugene, OR) and images acquired with a Zeiss 710 confocal microscope and Zen
imaging software (Zeiss, Thornwood, NY).
X-Ray Crystallography Method
Protein Expression and Purification. X-Ray crystallography was performed by
Dr. Yuxi Wang (Sichuan University, in China). The stathmin-like domain of RB3(RB3SLD) was overexpressed in E. coli and purified by anion-exchange chromatography and
gel filtration chromatography. The final sample was concentrated to 10 mg/mL and
stored at -80 Ԩ. The TTL protein was also expressed and purified from an E. coli
expression system as described previously (Section 2.2.7-2.2.8.) The final sample was
concentrated to 20 mg/ml and saved at -80 Ԩ. The purity of RB3 and TTL were assessed
by SDS-PAGE. Porcine brain tubulin (Catalog # T-238P, Cytoskeleton, Inc.) was
supplied at 10 mg/ml in G-PEM (General tubulin buffer: 80 mM PIPES pH 6.9, 2 mM
MgCl2, 0.5 mM EGTA and 1 mM GTP) as a frozen liquid and saved at -80 Ԩ until use.
Crystallization and Crystal Soaking. Crystals of T2R-TTL were obtained by
vapor diffusion using the sitting-drop method following published protocols. Briefly, the
protein solution containing tubulin (10 mg/ml), TTL (20 mg/ml) and RB3 (6 mg/ml) at
the molar ratio of 2 : 1.3 : 1.2 (tubulin:RB3:TTL) was incubated on ice, supplemented
with 1 mM AMPPCP, 5 mM tyrosinol and 10 mM DTT, and then concentrated to 20
mg/ml at 4 Ԩ. Crystallization drops contained equal volumes (1.0 μl) of the T2R-TTL
protein solution and the precipitant solution (6% PEG, 5% glycerol, 0.1 M MES, 30 mM
CaCl2, 30 mM MgCl2, pH 6.7) and were incubated at 20 Ԩ. The seeding method was
used to obtain single crystals. Crystals appeared after two days and grew to 200-300 μm
within 3-5 days. Compounds were soaked into the crystals to obtain the complex
structures. Each compound (4a and 6a) was dissolved in DMSO at 10 mM concentration
and 0.1 μl was added to the mother liquor at 20 Ԩ for 12 h. The crystals were
cryoprotected in 20% glycerol (30 mM MgCl2, 30 mM CaCl2,0.1 M MES, 20% glycerol,
pH 6.7) and flash-frozen at 100 K for synchrotron X-ray data collection.
X-Ray Data Collection and Structure Determination. Crystals of the T2RTTL-ligand complexes were mounted in nylon loops and maintained at 100 K in a
nitrogen stream. Diffraction data were collected on beamlines BL17U1 and BL19U1 at
Shanghai Synchrotron Radiation Facility (SSRF) in Shanghai, China. Data were indexed,
integrated and scaled using HKL2000. Initial phases were determined by molecular
replacement using the previously published T2R-TTL structure (PDB ID: 4I55) as a
template. The initial model was completed manually using Coot and iteratively refined
with the phenix refine module of the Phenix program (191). The final quality of the
structure was checked and validated using the PDB validation server. Analysis was
determined in coordination with Dr. Stephen White’s group (St. Jude Children’ Research
Hospital).
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Colony Assay
To test the effects of clonogenic potential and proliferation, A375 cells were
seeded in 6 well plates at a density of 500 cells/well (n=4). After overnight incubation in
at 37 °C cells were treated with the compound or media only control and incubated for 10
days. Cells were then fixed with methanol and stained with 0.5% crystal violet. Images
were taken, and colony area was quantified with ImageJ software (NIH, Bethesda, MD).
Endothelial Cell Tube Formation Assay
Matrigel (Corning, Manassas, VA) was thawed on ice overnight then diluted with
serum-free media for a final concentration of 10 mg/mL. Matrigel (50 μl) was plated in
96 well plates and incubated at 37 °C for 1 hr. Low passage number HUVECs (<5) in
logarithmic growth phase were trypsinized and suspended in endothelial cell growth
media. Cells (1.5 x104 suspended in 50 μl) were plated on the Matrigel plates in
quadruplicate containing the desired drug concentrations. Images were captured after 4 hr
incubation with Evos Fl Imaging System (LifeTechnologies, Carlsbad, CA). Analysis
was performed with angiogenesis tool plug-in with ImageJ software (NIH, Bethesda,
MD).
Wound Healing Assay
A375 and RPMI-7951 cells were seeded in 12-well plates (200 000 cells/well) in
replicates of 3 and incubated overnight. Using a 200 μL pipet tip, a straight line was
scratched through the cell monolayer to remove an area of cells, and cells were washed
several times to remove any debris and uprooted cells. Medium was replaced containing
5 or 25 nM of 4a or colchicine. Control wells received medium without drug. Images
were obtained at 0 h and 18 h (RPMI-7951 cells) and 22 h (A375 cells) with Evos Fl
imaging system (Life Technologies, Carlsbad, CA). Analysis of the scratch area was
performed with ImageJ software (NIH, Bethesda, MD).
For real time cell migration analysis, A75 or M14 cells were seeded 96-well
Image-Lock plates (Essen bioscience, Ann Arbor, MI) at a density of 30,000 cells/well
and incubated overnight. The WoundMaker™ tool (Essen bioscience, Ann Arbor, MI)
was used to create uniform identical scratches in all the wells of a 96-well plate. After
creating the wound, the medium was aspirated, and the wells were washed twice with
fresh medium to remove any cell that had been uprooted from the scratched area. 100 μL
of medium containing the indicated concentrations of the 5a or colchicine were then
added to each well (n=4). The plate was fitted into the IncuCyte Imaging System
chamber, and images of the cell migration were recorded every 2 hours for a total
duration of 24 hours. The affiliated IncuCyte ZOOM™ live cell imaging software
calculated scratch closure in real time and determined the relative wound density within
the scratch-channel area at each time point. The relative wound density was calculated as
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the ratio of the occupied area compared to the total area of the initial scratched area. Rate
of change was calculated as % change in relative wound density/ hour.
Cell Cycle Analysis
To determine cell cycle distributions in the G2 and M phases, 1 x 106 cells A375
cells plated in 10 cm tissue culture-treated dishes, incubated overnight, and then serumstarved for 24 hours to synchronize. They were then treated for 24 hrs with 10 or 50 nM
of drug in full media. Cells were harvested with trypsin, fixed with 4%
paraformaldehyde, and stained using P-Histone H3 rabbit antibody (Cell Signaling
Technologies, Danvers, MA) and Alexafluor-488 secondary antibody AlexaFluor® 488
IgG (Invitrogen, Eugene, OR) followed by stained using PI/RNase solution (Sigma,
Sigma-Aldrich, St. Louis MO) for 30 minutes at room temperature and protected from
light. Data was collected with Bio-Rad ZE5 flow cytometer (Bio-Rad, Hercules, CA) and
the acquisition software used was Everest v2.1.07, plotting at least 20,000 events per
sample. Analysis was performed using FlowJo v10.3.
Apoptosis Assay
A375 cells were seeded, treated, and harvested in the same manner as described
above. Apoptosis analysis was performed using the Annexin V-FITC Apoptosis
Detection Kit (Abcam, Cambridge, MA) as per manufactures instructions utilizing
fluorochrome-conjugated annexin V and propidium iodide solution. Data was collected
with Bio-Rad ZE5 flow cytometer (Bio-Rad, Hercules, CA) and the acquisition software
used was Everest v2.1.07, plotting at least15,000 events per sample. Analysis was
performed using FlowJo v10.3.
Western Blot


1 x 106 cells A375 or M14 cells were seeded in 10 cm tissue culture-treated
dishes, incubated overnight, then treated for 24 hours with indicated compounds and
concentrations of 0, 15, 40, or 100 nM. Harvested cells were collected in RIPA lysis
buffer including protease inhibitors and sonicated. The lysates were centrifuged at 13,000
 g for 15 min at 4 °C. The concentration of total protein was measured using the BCA
assay method and absorbance was read at 562 nm on a plate reader (BioTek Instruments
Inc., Winooski, VT)(n=2). Protein samples were separated with 15% SDS-PAGE and
transferred onto the methanol-activated PVDF membranes. Primary antibodies PARP, cPARP, Akt, p-Akt, PH3, and GAPDH and secondary anti-rabbit and anti-mouse were all
obtained from Cell Signaling Technologies (Danvers, MA.) Images were obtained using
the ChemiDoc-It2 Imaging System (Bio-Rad, Hercules, CA).
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In Vivo Xenograft Studies
All animal experiments were performed in accordance with the NIH animal use
guidelines and protocol approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Tennessee Health Science Center (UTHSC, Memphis, TN).
Nude mice, 6–8 weeks old, were purchased from Envigo. We first estimated the acute
MTD for 4a and 6a formulated in PEG300. The MTD following a single dose was
estimated to be at least 100 mg/kg for 4a and at least 60 mg/kg for 6a. To ensure an
adequate safety margin for the xenograft study, the maximum dose was scaled down to
30 mg/kg for 4a and 15 mg/kg for 6a.
Logarithmic growth phase A375, PC-3, or PC-3/TxR was prepared in phenyl redfree, FBS-free medium and mixed with Matrigel immediately before injecting into mice.
Tumors were established by injecting 100 μL of this mixture subcutaneously in the dorsal
flank of each mouse (2 × 106 A375 cells or 2.5 × 106 prostate cancer cells). After tumor
volumes reached approximately 100 mm3 mice were randomized into control or
treatment groups (n = 8 for A375 and PC-3 model, n = 7 for PC-3/TxR xenograft model).
4a, 6a, or paclitaxel was dissolved in a 2:1 ratio of PEG300/PBS solution to produce
desired concentrations. The vehicle control solution was formulated with equal parts
PEG300 and PBS only. 100 μL of the drug treatment or vehicle control was administered
via i.p. injection every other day for 2–3 weeks.
Tumor volume was measured three times a week with a caliper and calculated by
using the formula a × b2 × 0.5, where a and b represented the larger and smaller
diameters, respectively. Tumor growth inhibition (TGI) at the conclusion of the
experiments was calculated as 100 – 100 × ((T – T0)/(C – C0)), where T, T0, C, and C0 are
the mean tumor volume for the specific group on the last day of treatment, mean tumor
volume of the same group on the first day of treatment, mean tumor volume for the
vehicle control group on the last day of treatment, and mean tumor volume for the vehicle
control group on the first day of treatment, respectively. Animal activity and body
weights were monitored during the entire experiment period to assess potential acute
toxicity. At the end of the experiment, mice were sacrificed and the tumors were
weighed. Tumors and tissues were dissected out and fixed in 10% buffered formalin
phosphate solution prior to pathology staining analysis.
Histology and Immunohistochemistry
The fixed tumor xenograft tissues were embedded in paraffin. Serial sections were
obtained and stained with hematoxylin and eosin (H&E) and immunohistochemistry. IHC
staining was performed with rabbit anti-cleaved caspase 3 antibody (Cell Signaling
Technology Inc., Danvers, MA) and rabbit anti-CD31 (Cell Signaling Technology Inc.,
Danvers, MA) following ABC-DAB methods. Antigen retrieval was performed with H3300 antigen unmasking solution (Vector Laboratories, Burlingame, CA). Slides were
scanned, and representative images were obtained at 100× magnification with Aperio
ImageScope (Lecia Biosystems Inc., Buffalo Grove, IL).
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Statistical Analysis and Calculations
Data was analyzed using Prism Software 5.0 (GraphPad Software, Inc., San
Diego, CA). Data was provided as mean ± SD unless otherwise indicated. Non-linear
regression of transformed data was used to calculate IC50 values for cytotoxicity assays.
Log P was calculated using Schrödinger Molecular Modeling Suite (Schrödinger LLC,
New York). The statistical significance (P < 0.05) was calculated by one-way ANOVA
followed by Dunnett’s multiple comparison test, comparing each treated group at the
final time point to the control group for the migration, colony, capillary-like formation in
vitro assays, and the tumor weight and final tumor volume in vivo studies.
Results and Discussion
Drug Design, Potency, and Metabolic Stability
We designated a four-ring system similar to 1f, and the starting scaffold (ring A in
red, ring B in purple, ring C in green, and ring D in pink) is shown at the top of Table
4-1. First, we designed and synthesized a series of seven heteropyrimidine derivatives
with a diverse A/B ring. These include pyridopyrimidines (4a and 4b), furopyrimidine
(6a), thiophenopyrimidine (6b), N-Methyl-pyrazolopyrimidine (8a), N-methyl-purine
(10), and 1H-pyrazolopyrimidine derivatives (14). The two pyridopyrimidines, 4a and
4b, showed exceptional IC50 values against melanoma cell lines (IC50 ~ 6 nM) and 4b
(IC50 ~ 4 nM) relative to the lead 1d (IC50 ~ 2 nM). These compounds also showed
increased water solubility (1d; logP = 4.5, 4a; logP = 3.7, 4b; logP = 4.0). The
furopyrimidine compound, 6a, also was highly active against the 3 tested cancer cell
lines, with an average IC50 of 3.9 nM.
Next, we synthesized three C ring modified derivatives, including a ketopyridopyrimidine (16), alcohol-pyridopyrimidine (17) and a morpholinopyridopyrimidine (19). While the alcohol-pyridopyrimidine showed moderate potency,
with an average IC50 of 45.5 nM, the other modifications were detrimental to activity
(Table 4-1).
Then, we investigated a series of modifications that involved opening the C ring,
and increasing the number of methoxy substituents on ring D, since many reported
tubulin inhibitors, including colchicine, contain trimethoxy groups. Dimethoxy (21a),
trimethoxy (21b) and dioxymethylene (23) and naphthyridin (25) analogs were
synthesized. The dimethoxy compound (21a) was found to possess moderate activity
with an IC50 value 42 nM, however, the more sterically hindered trimethoxy compound
(21b), the dioxymethylene compound (23) was and the naphthyridin compound (25) had
reduced or abolished activity against cancer cells (Table 4-1).
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Table 4-1.
Cytotoxic effects heterocyclic-fused pyrimidine analogs against
malignant melanoma cancer cell lines and log P values.
IC50 ± SEM (nM)
ID

a

Structure

Log
P

A375

M14

RPMI-7951

Average

4a

5.6 ± 1.6

5.5 ± 1.0

8.2 ± 1.5

6.4

3.7

4b

4.0 ± 0.2

4.2 ± 0.8

4.4 ± 0.6

4.2

4

6a

3.2 ± 0.5

3.3 ± 0.4

5.1 ± 0.9

3.9

3.9

6b

49.0 ± 3.3

52.6 ± 5.6

91.3 ± 9.8

64.3

4.8

8a

> 1000

> 1000

> 1000

> 1000

3.8

8b

16.1 ± 1.4

18.8 ± 1.0

17.6 ± 1.1

17.5

2.8

10

39.6 ± 2.9

41.2 ± 3.2

58.9 ± 3.1

46.6

3.4

14

> 1000

> 1000

> 1000

> 1000

2.9

16

> 1000

> 1000

> 1000

> 1000

2.5

17

36.1 ± 2.8

52.6 ± 5.6

41.9 ± 7.5

43.5

2.9

19

223.3 ± 22.2

268.9 ± 17.0

404.5 ± 49.9

298.9

3.2

21a

39.0 ± 4.3

39.5 ± 3.0

47.5 ± 4.4

42

3.4

21b

> 1000

> 1000

> 1000

> 1000

3.5

23

161.7 ± 14.0

164.1 ± 12.4

178.9 ± 21.4

168.2

2.8

25

> 1000

> 1000

> 1000

> 1000

4.5

colch

6.4 ± 0.3

6.5 ± 0.4

6.6 ± 0.5

6.5

3.5

A/B ring

C ring

C/D ring

a

Log P was calculated using Schrödinger Molecular Modeling Suite.
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Finally, we designed new pyridopyrimidine analogs with a dihydroquinoxalinone
head group, as compared to the tetrahydroquinoline head group in 4a analogs. We
hypothesize that switching to the dihydroquinoxalinone head group would make the
phenyl ring of the head group electron deficient, leading to a more inert and
metabolically stable methoxy group. Additionally, incrementing hydrogen bonds with the
tubulin binding site should render stronger binding and lead to improved anticancer
efficacy. We synthesized two different analogs, 5a and 5b, for this series and tested them
for their in vitro activity. In addition to melanoma cell lines tested for the previous
compounds, 5a and 5b were tested in additional melanoma cell lines including the P-gp
overexpressing M14/MDR1 cell line, as well as other cancer cell types including prostate,
lung, and breast cancers. (Table 4-2). We found that both compounds were highly potent,
particularly 5b, which demonstrated greater cytotoxic activity than colchicine against all
tested cell lines, with IC50s ranging from 1.2-10.3 nM. It is also notable that the P-gp
overexpressing M14/MDR1 cell line was significantly less sensitive to colchicine
treatment than the parental M14 cell line, whereas 5b was nearly equipotent against the
resistant cell line (RI=1.25). Similarly, PC-3/TxR cells were not resistant to treatment
with 5a or 5b but were about ~7-times more resistant to colchicine treatment.
Because we wanted to see if the modifications that improved the potency of the
analogs would also improve metabolic stability, we measured the half-life and clearance
of compounds 4a, 6a, 5a, and 5b in human, mouse, and rat liver microsomes (Table 4-3).
The modification of the A ring to a pyridopyrimidine or furopyrimidine (4a and 6a)
resulted in significant improvement in metabolic stability. In human liver microsomes, 4a
demonstrated a half-life of 84 mins, comparable to Azixa (79 mins), whereas 1d
previously reported a half-life of only 10 minutes (145). We also found that 5b had
improved metabolic stability, with a half-life in human liver microsomes 5.54 ± 0.32 hrs,
and 5a showed even greater improvement, with a half-life greater than 8 hours. Based on
these initial findings of our compounds on cell viability, metabolic stability, and water
solubility, the most promising compounds, 4a, 6a, 5a and 5b were selected to undergo
additional biological analysis (Structures shown in Figure 4-2A).
Mechanism of Action via the Colchicine Domain
To experimentally validate whether the newly designed analogs preserve their
mechanisms of action as tubulin polymerization inhibitors, we evaluated the lead
compounds (4a, 6a, 5a, and 5b) in a cell-free microtubule polymerization assay (Figure
4-2B). The greatest maximal velocity of tubulin polymerization was demonstrated by
paclitaxel, a potent enhancer to tubulin polymerization. The vehicle control treated group
also displayed robust polymerization. 4a, 6a, and 5b potently inhibited the tubulin
polymerization, while colchicine and 5a suppressed tubulin polymerization altogether. It
is interesting to note that while 5b had stronger efficacy against cancer cell lines, 5a
demonstrated greater inhibitory action on tubulin polymerization.
Next, we investigated the effect of drug treatment on microtubule networks in
vitro via confocal immunofluorescent microscopy. WM-164 melanoma cells were treated
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Table 4-2.
Cytotoxic effects of 5a and 5b against melanoma, prostate, lung, and
breast cancer cell lines.
Cancer Type

Melanoma

Prostate

Lung

Breast

IC50 ± SEM (nM)

Cell Line

5a

5b

Colchicine

A375

14.9 ± 1.3

4.1 ± 0.2

11.7 ± 0.2

RPMI-7951

20.6 ± 4.7

3.3 ± 0.5

16.8 ± 3.1

WM-164

50.3 ± 5.6

4.9 ± 0.2

14.4 ± 2.9

SK-MEL-1

44.0 ±12.4

2.6 ± 0.3

4.1 ± 0.6

M14

58.7 ± 4.8

8.2 ± 0.5

21.7 ± 1.3

M14/MDR1

258. ± 49.7

10.3 ±0.3

~800

PC-3

6.8 ± 0.6

4.4 ± 0.3

5.3 ± 1.5

PC-3/TxR

7.7 ± 0.4

4.3 ± 0.1

35.4 ± 4.2

DU-145

17.7 ± 1.8

6.2 ± 0.5

47.5 ±11.7

DU-145/TxR

65.8 ± 5.8

7.7 ± 0.3

846.1 ± 270.6

A549

182.6 ± 14.3

6.9 ± 0.5

75.8 ± 6.6

H460

169.8 ± 32.4

5.2 ± 0.7

27.6 ± 6.2

H1299

7.1 ± 0.8

2.5 ± 0.5

13.6 ± 2.5

MDA-MB-453

6.2 ±0.9

1.2 ± 0.4

3.9 ± 0.9

MDA-MB-231

7.7 ± 0.5

3.5 ± 0.7

11.1 ± 0.6

MDA-MB-468

8.8 ± 3.2

6.1 ± 2.1

6.2 ± 0.8
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Table 4-3.

Compound

In vitro metabolic stability of 4a, 6a, 5a and 5b in liver microsomes.
Metabolic Stability
(Human)
t1/2
Clint
(hr)
(mL/min/kg)

Metabolic Stability
(Mouse)
t1/2
Clint
(hr)
(mL/min/kg)

Metabolic Stability
(Rat)
t1/2
Clint
(hr)
(mL/min/kg)

Azixa

1.32 ± 0.10

15.80

0.06 ± 0.003

987.69

0.81 ± 0.07

57.53

4a

1.39 ± 0.08

15.0

0.15 ± 0.01

379.6

0.74 ±0.06

63.0

6a

0.32 ± 0.02

65.3

0.08 ± 0.003

748.2

0.09 ± 0.01

511.2

5a

36.00 ± 19.13

0.58

16.90 ± 2.79

3.38

ND

ND

5b

5.54 ± 0.32

3.75

1.02 ± 0.03

56.12

5.07 ± 0.20

9.23

Verapamil

1.40 ± 0.10

14.82

1.51 ± 0.12

37.74

3.39 ± 0.24

13.80

Data obtained by Lei Yang (St. Jude Children’s Research Hospital).
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Figure 4-2. New analogs potently inhibit tubulin polymerization.
A) Structures of lead compounds 4a, 6a, 5a, and 5b. B) Polymerization of purified
tubulin in a cell-free assay. Tubulin (3.33 mg/ml) was exposed to vehicle control or
compounds at the indicated concentrations (n=2). Absorbance at 340 nm was monitored
at 37°C every minute for 50 min.
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with 100 nM of compound 4a, 6a, 5a, 5b, docetaxel, or left untreated. The
immunofluorescent images obtained visually demonstrate how the microtubules are
affected by stabilizing or destabilizing agents (Figure 4-3A). The control cells display
fibrous microtubules extending throughout the cell, providing cellular shape and
structure. The newly synthesized lead compounds all induced extensive fragmentation of
the microtubules, decreased polymeric tubulin filaments, and increased cytoplasmic
soluble tubulin. Docetaxel treatment caused the opposite action on microtubules, and
dense tubulin accretion, representative of aggressive polymerization, can be observed.
These results clearly demonstrate that the Azixa analogs exhibit characteristics of tubulin
polymerization inhibitors and have a mechanism of action that is opposite of stabilizing
agents.
Unlike the paclitaxel or vinblastine binding sites, the colchicine binding site in
tubulin can accommodate diverse scaffolds of ligand structures which do not seem to
have apparent similarities (192). A seemingly minor change to a potent colchicine site
ligand could significantly compromise its binding and diminish antiproliferative potency
(144). The high flexibility of the loop α-T5 (Ala174-Val182 loop) in the α-tubulin
monomer and the loop β-T7 (Phe242-Asp249 loop) in the β-tubulin monomer are
partially responsible for the unique characteristics at the colchicine binding site.
However, this flexibility is also responsible for significant challenges in using molecular
modelling to predict correct binding poses of one ligand scaffold with existing crystal
structures of different ligand scaffolds. This proves an even greater obstacle for the Azixa
scaffold because of the structural similarity of the upper and lower part of the molecule
separated by the middle nitrogen atom.
Therefore, to unambiguously determine the real binding modes of these analogs to
tubulin and to correctly determine the detailed molecule interactions, we determined the
co-crystal structures of tubulin-RB3_SLD-TTL protein, in complex with two of the most
potent analogs, 4a, and, 6a (Figure 4-3B) In the un-liganded complex, the β-T7 loop has
a ‘closed’ conformation and it interacts with the α-T5 loop from α-tubulin (PDB ID:
4I55). These loops move apart as colchicine binds at the interface and occupies a pocket
in β-tubulin (Figure 4-3C). This loop opens to make a pocket in β-tubulin to
accommodate colchicine (PDB ID: 4O2B, violet color).
In case of our compounds, the α-T5 loop in α-tubulin remains in place as seen in
case of un-liganded complex, but β-T7 loop of β-tubulin opens as seen in case of
colchicine bound structure, although the two conformations of the loop are slightly
different. Both compounds bind at the site created as a result of loop opening, with ring A
and B occupying the pocket that contains the TMP moiety of colchicine, sandwiched
between the side chains of Cys239, Leu253 and Ala314 of β-tubulin. Ring C and D are
facing α-T5 loop of α-tubulin, sandwiched between side chains of Asn256 and Lys350 of
β-tubulin (Figure 4-3D and E). The chlorine attached to ring B interacts with the
hydrophobic side chain of Leu240 from β-tubulin. The D-ring with its methoxy group
also makes hydrophobic interactions with the side chain of Met257 from β-tubulin. There
is a water-mediated hydrogen bond between the 1-position N atom of ring B and main
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Figure 4-3. Compounds destabilize microtubules and target the colchicine binding site.
(A) Microtubules of WM-164 cells following 18 hr treatment with 100 nM of 5a, 5b, 4a, 6a, compared to docetaxel or untreated
control, visualized by α tubulin primary and AlexaFluor 647 secondary antibody via confocal microscopy. B) X-ray crystal structures
of the tubulin-RB3-SLD-TTL complex with the ligand. C) Superimposed un-liganded (grey), colchicine bound (violet) and 4a bound
(gold) tubulin-RB3-SLD-TTL complex showing the different loop conformations resulting from binding of ligands. D) High
resolution X-ray crystal structures of tubulin protein in complex with 4a (resolution 2.3 Հ), and E) 6a (resolution 2.7 Հ). The α-tubulin
monomer is shown in green and the β-tubulin monomer is shown in cyan. Crystallographic data obtained by Yuxi Wang (Sichuan
University, China) and interpreted by Dr. Stephen White and Dr. Gyanendra Kumar (St. Jude Children’s Research Hospital).
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chain -NH of Cys239. Additionally, the main chain C=O of Val236 is also within
hydrogen bonding distance of this water molecule. These crystal structures not only
provide a rationale for the affinity of these compounds, they also provide opportunities
for improving these compounds further. Surprisingly, the actual binding poses for these
Azixa derivatives determined by this X-ray crystallography study showed different
binding pose than previously published molecular modelling predictions of Azixa and its
derivatives, using available X-ray crystal structures containing colchicine (PDB ID:
4O2B) or its close analog DAMA-colchicine (PDB ID: 1SA0)(102, 145, 167, 250, 256).
In those molecular modelling predictions, the pyrimidine ring was oriented towards the αmonomer, and the 6-methoxyphenyl moiety overlapped the trimethoxyl moiety in
colchicine, which is oriented towards the β-monomer. In contrast, the high-resolution Xray crystal structures revealed that the 6-methoxyphenyl moiety is actually oriented
towards the α-monomer, instead of the β-monomer. These two dramatically different
binding poses would guide structural optimizations for the Axiza analogs in very
different directions. Thus, the current X-ray findings provide, for the first time, insight
into the true molecular interactions of Azixa analogs with the colchicine binding site of
tubulin and will help future X-ray crystallography-guided synthesis of more efficient
derivatives. It also underscores the complications associated with reliability of using
molecular modelling and the superiority of definitive X-ray crystallographic analysis.
Interference with Cellular Functions
To investigate the interference of cellular functions inflicted on cancer cells in
vitro by the selected compounds, we next tested their actions against anchoragedependent colony formation and proliferation. A375 cells were challenged with longterm exposure to 5a, 5b, and colchicine at concentrations ranging from 0.25 nM to 2 nM,
which are below their determined IC50s. 5b was able to reduce colony number
proportionally to the dug concentration (Figure 4-4A). 5a and colchicine showed a
nominal decrease in total colony number at the lower concentrations compared to the
control, and there was not a significant difference between the counted colony numbers
for the lower or higher concentrations within a treatment group. However, based on the
overall colony area coverage, there was a significant difference for all treated groups
compared to the control, as well as a trend within groups receiving different
concentrations of the same compound. This may indicate that 5a and colchicine can
inhibit proliferation at low concentrations but do not have as great of an effect on the
clonogenic potential, while 5b, the most potent compound, was able to inhibit the
clonogenicity and cellular propagation.
Since microtubule targeting agents can interfere with microtubule networks to
inhibit cell proliferation, migration, expansion and consequently cause morphological
changes to endothelial morphology, we wanted to determine if 5a and 5b would exhibit
similar actions against HUVECs in vitro (222). The capillary-like tubular network
collapse of HUVECs grown on Matrigel was measured as total tube length and number of
formed junctions (Figure 4-4B). 5a decreased total tube length by 31.9%, 54.0% and
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Figure 4-4. Compounds reduce formation of cancer cell colonies and HUVEC
tube cell networks.
A) Colony formation assay of A375 cells treated with 5a, 5b or colchicine at
concentrations from 0 to 2 nM (n=3). Colony assays were treated for 10 days in 6-well
plates and quantified as total number of colonies and colony surface area ± SD as
determined by VisionWorks software. B) Representative images of HUVEC capillary
formation on Matrigel taken after 4 hr incubation with indicated concentrations of 5a, 5b,
or colchicine. Quantification of total tube length and junction number was performed
with ImageJ analysis and expressed as mean ± SD (n=4). Statistical analysis for both
assays was performed using one-way ANOVA followed by Dunnett’s multiple
comparison test of treatment groups to the untreated control. (*p< 0.05, **p< 0.01, ***p<
0.001, ****p< 0.0001).
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47.4% at 25, 50, and 100 nM concentrations, respectively. Even at the highest
concentration, colchicine only reduced overall network length by 28.1%. 5b showed
reductions in total length between 49.5% and 52.8% at all concentrations. Junctions were
also quantified and provide more information on the extent of angiogenic inhibition. 5a
showed a linear trend, decreasing junction number by 58.2% at the lowest concentration
and up to 77.6% at the highest concentration. All tested 5b concentrations reduced the
total number of junctions formed by at least 74.4%. Colchicine, on the other hand, was
only able to decrease the junction number by 45.4% at the highest concentration of 100
nM. Statistical analysis was determined by comparing each treated group to the untreated
control group. Both 5a and 5b were more effective than colchicine by both measures
(network length and number of junctions). Because of the significant inhibition achieved
by 5b at the lowest concentration of 25 nM and the concentration-dependent effect
observed by 5a, these results show that the compounds impair formation and structure of
the capillary-like networks formed by HUVECs cultured on a Matrigel basement
membrane matrix. This offers further support that 5a and 5b may have additional actions
as VDAs/anti-angiogenic agents.
Drugs that target microtubules have also been reported to interfere with cell
migration and motility at low concentrations. We tested the ability of 4a to decrease cell
migration compared to colchicine and untreated control cells in a wound healing assay
(Figure 4-5A). The control A375 and RPMI-7951 cells that were not treated showed an
average wound closure of 60.7% ± 3.5% and 71.8% ± 1.8%, respectively. At 5 nM
concentrations, 4a caused less A375 and RPMI-7951 cells to migrate into the wound,
closing the gap by 36.4% ± 2.5% and 46.4% ± 2.0%. At higher concentrations of 25 nM,
even greater migration inhibition was observed by the cells, where cells migrated into
only 16.9% ± 1.7% and 25.5% ± 5.8% of the wound area for A375 and RPMI-7951,
respectively. A significant decrease in wound closure was observed by cells treated with
4a by both concentrations and against both cell lines compared to the control. Colchicine
showed less inhibition than 4a, where the A375 wound channel was closed by 46.0%
±1.4% and 20.7% ± 2.2% when treated with 5 nM and 25 nM of the drug, respectively.
The RPMI-7951 cells treated with 25 nM of colchicine migrated into 42.8% ± 5.8%, and
a significant decrease in migration was not observed when treated with 5 nM of
colchicine. 5b was also tested in scratch migration assay against A375 and M14
melanoma cells in a time-dependent and concentration-dependent manner (Figure 4-5B).
The wound density covered by the migrating cells was measured in real-time compared
to the starting wound area, and rate of change was calculated by the change in relative
wound density % per hour. For A375 cells, there was an obvious reduction in migration
for the 5b treated cells at concentrations as low as 2.5 nM compared to the control.
Treatments with 5b at 5 and 10 nM concentrations showed similar inhibitory effects but
to a greater degree. Colchicine did not show a concentration-dependent inhibition against
A375 cells from 2.5- 10 nM concentrations, though it still slowed cell migration more
than the untreated cells. The M14 cells demonstrate different results. Treatment with
colchicine was not effective at hindering cell migrations at concentrations up to 10 nM.
While little efficacy was apparent for 5b at 2.5 nM concentrations against this cell line, it
induced concentration-dependent action against cell migration at 5 and 10 nM
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Figure 4-5. Compounds inhibit melanoma cell migration.
A) Scratch migration assay of A375 (top) and RPMI-7951 (bottom) cell lines (n=4). Cells
were treated with 4a or colchicine at 5 or 25 nM for 24 hours and migration is presented
as mean percent of the area closed ± SD. ImageJ software was used to calculate scratch
area. Scale bar = 1000μm. Statistical significance was determined by one-way ANOVA
followed by Dunnett’s multiple comparison test, comparing each treatment group to the
control group. (**p< 0.01, ***p< 0.001, ****p< 0.0001). B) Wound density for A375
(left panels) and M14 (right panels) after treatment with 5b or colchicine at indicated
concentrations (n=4). Real-time analysis was performed with Incucyte live cell imagine
system every 2 hours for 24 hours. The top graph shows % relative wound density ± SD
and the bottom graphs show rate of change represented as change in relative wound
density per hour ± SD.
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concentrations. At the highest concentration, cell death became apparent beginning
around 18 hours, as evidenced by the decrease in wound density and increase in rate of
change during this time.
Compounds Induce G2/M Phase Cell Cycle Arrest and Apoptosis
A common feature of tubulin inhibitors targeting the colchicine binding site is that
they arrest cells in the G2/M phase of the cell cycle (100). To determine whether 5a and
5b would arrest cancer cells in a similar fashion, we carried out cell cycle analysis
utilizing flow cytometry to see if there was a dose-dependent effect. After syncing A375
the cells by serum-starvation, they were treated with a low or high concentration (10 or
50 nM) of 5a, 5b, or colchicine for 24 hrs (Figure. 4-6A). Compared to untreated control
cells, where 11.7% of the population were indicated to be in the G2/M phase of the cell
cycle after 24 hours after synchronization, 5a, 5b, and colchicine all increased cell
distribution at 50 nM concentrations, arresting 15.9%, 38.9% and 31.6% of the cells is
this phase, respectively. At lower concentrations of 10 nM, only 5b arrested cells in the
G2/M phase significantly more than the control cells, showing 35.4% of the population
arrested in this phase. Even though 5a and colchicine did not dramatically induce arrest at
10 nM, it is clear from the cell cycle distribution that the G2/M phase arrest is
concentration-dependent.
We also wanted to confirm that 5a and 5b treatment would lead to apoptotic cell
death. Therefore, we quantified the percentage cells that were undergoing early stage
apoptotic events (Annexin V positive stained cells) and late stage apoptotic events
(Annexin V and propidium iodide positive stained cells) compared to synchronized A375
cells (Figure 4-6B). Untreated cells only showed 4.6% of the population undergoing
apoptosis, while 50 nM of colchicine treatment led apoptosis for 33.7% of cells after 24
hrs. There was a modest increase in apoptotic events for 5a treated cells at 50 nM
concentrations, where 7.2% of cells were apoptotic. 10 nM treatment of 5b caused a
significant increase in the cells undergoing apoptosis, where 19.1% of the cell population
was apoptotic. At higher concentrations of 50 nM, there was not a proportional increase
in cell death initiation (20.7% apoptotic). However, these results correlate with the trend
we observed from the cell cycle analysis, where the higher concentration (50 nM) of 5b
yielded only a slight increase in the percentage of cells arrested in the G2/M compared to
cells treated at lower (10 nM) concentration. We concluded that 24 hr treatment of 5b
with these concentrations (10 and 50 nM) will demonstrate similar efficacy, and either
lower concentrations or time-dependent analysis would be needed to demonstrate a more
palpable trend. Targeted cleavage of the Poly(ADP-ribose) polymerase (PARP), a nuclear
protein, is another signature biomarker in the apoptotic process (257). We investigated
total vs cleaved PARP in A375 and M14 cells after treatment with our compounds to
determine if the results would correlate with our previous findings (Figure 4-6C). In both
cell lines, no cleaved PARP was evident from the control cell lysates, but 5a treatment
exhibited concentration-dependent PARP cleavage from 15-100 nM after 24 hrs. 5b
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Figure 4-6. Compounds induce G2/M phase arrest and apoptotic events.
A) Representative flow cytometry diagram of cell cycle distribution. Synchronized A375
cells were treated with 10 or 50 nM of 5a, 5b, or colchicine for 24 hours. B) Apoptosis
analysis under the same conditions and determined by Annexin V and PI staining, where
Q1 represents early state apoptosis and Q2 is late state apoptotic cells. C) Western blot
analysis for protein levels of A375 (top) and M14 (bottom) cell lines after 24 hr treatment
with 15, 40, or 100 nM concentrations of 5a, 5b, or colchicine. Apoptotic proteins (total
and cleaved PARP), cell survival proteins (total and phosphorylated Akt), and cell cycle
dependent protein phospho-histone3 are shown.
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treatment showed strong expression of the cleaved PARP protein at all concentrations in
the cell lystates, whereas colchicine-treated cells showed similar cleaved PARP levels to
5b at the highest concentration, but lower levels than 5b at 15 nM.
The phosphatidylinositol-3-kinase serine/protein kinase B (Akt) signaling
pathway plays an important role in regulating cell survival, and constitutive activation of
this pathway is commonly implicated in a variety of cancers, including melanomas (258,
259). The phosphorylation of Akt at Thr308 and Ser473 leads to its full activation, and
elevated expression levels of phospho-Akt (p-Akt) is correlated with melanoma
pathogenesis and progression, and it is inversely related to patient survival (260). We
found that treatment with 5a or 5b in melanoma A375 cells reduced p-Akt expression
levels. 5a caused the greatest reduction at 100 nM concentrations, and 5b was equally
effective at concentrations as low as 15 nM.
Finally, we looked at phospho-histone H3 levels, which distinguish cells between
the G2 and M phase of the cell cycle, and its expression is negligible or absent in other
stages (261). In M14 melanoma cells, 5a treatment caused only a slight increase in
phospho-histone H3 levels compared to the control cells. On the other hand, significant
protein expression was observed in the 5b and colchicine treated cells. This corroborates
the cell cycle analysis findings, which showed relatively weaker induction of cell cycle
arrest for the 5a treated cells compared to the profound effects observed from the 5b
treated cells. These in vitro studies verify that our compounds, particularly 5b, induce
apoptosis and arrest melanoma cells in the G2/M phase of the cell cycle in a similar
manner as colchicine.
In Vivo Antitumor Efficacy
We first determined the MTD in mice for compounds 4a and 6a (prior to full
xenograft studies) and found that i.p. administration of 50 mg/kg (4a) or 30 mg/kg (6a)
for 5 consecutive days was well-tolerated in mice and no apparent acute toxicities were
observed. This is in contrast with Azixa and its reported analogs, where 1~4 mg/kg doses
by i.v. injection were generally lethal for mice (145, 252, 254, 255, 262). We did consider
though, that plasma concentration following systemic administration by intravenous
injection does not necessarily proportionally reflect the drug levels achieved following
intraperitoneal intervention. Therefore, we also tested the MTD for Azixa formulated at
10 mg/kg via i.p. injection, and while we did not have an Azixa-treated comparison group
in our subsequent xenograft study, we did find that this was not a tolerable dose for the
mice. 4a and 6a have comparable in vitro potency to Azixa and demonstrated higher
MTDs, suggesting that our analogs may have an improved therapeutic index over Azixa
with this route of administration.
We next investigated the antitumor effects of these compounds in an A375
xenograft model in nude mice, following our previously reported protocols. Once tumors
developed, mice were randomized and treated by i.p. injection for two weeks with
compound 4a, 6a, paclitaxel, or a vehicle solution. Tumor growth inhibition (TGI) was
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calculated for the treatment groups compared to the vehicle control group (Figure 4-7A
and B). 4a treatment caused 57.1% and 72.3% TGIs for15 mg/kg and 30 mg/kg treatment
groups, respectively. 15 mg/kg doses of 6a was also able to inhibit tumor growth by
66.5%. The group receiving 15 mg/kg doses of paclitaxel was used as a positive control
and resulted in an overall TGI of 76.5%. Final tumor weights were also recorded prior to
IHC analysis and reiterated the effect of 4a and 6a treatment on tumor inhibition. We
found that 15mg/kg treatments with 4a and 6a reduced tumor weight by ~45%, and
higher doses of 30 mg/kg of 4a or paclitaxel treatment caused ~60% reduction compared
to the control group (Figure 4-7C). Abnormal deviations in animal body weight
indicative of acute toxicities were not observed (Figure 4-7D). One-way ANOVA
followed by Dunnett’s multiple comparison test demonstrated that each of the treatment
groups caused a significant reduction in tumor size compared to the control group,
yielding P values < 0.001.
After tumors were fixed, histological analysis was performed and IHC staining
revealed that there was an increase in the number of cells undergoing apoptosis for the
groups receiving treatment with 4a, 6a, or paclitaxel (Figure 4-7E). Furthermore, CD31
staining showed that tumors from the treated groups displayed less overall microvessel
density and exhibited morphological changes in the vessel structure. Although
comparable in vivo testing for 5a and 5b is still underway, the initial in vitro results
showing elevated apoptosis by flow cytometry, increased apoptotic activity indicated by
cleaved PARP, and endothelial network disturbance of HUVECs closely shadows the in
vivo results for 4a and 6a. Future testing in animal models with 5a and 5b is warranted to
confirm their efficacy in biologically relevant models and compare their anticancer
efficacy to their Azixa analog counterparts and other tubulin inhibitors.
Compound 4a Overcomes Taxane Resistance
To determine if 4a is capable of escaping resistance associated with taxanes, we
first tested the potency in parental prostate cancers PC-3 and DU-145, as well as
paclitaxel resistant PC-3/TxR and docetaxel resistant DU-145/TxR cell lines (Figure
4-8A). 4a was the most potent against PC-3/TxR cancer cells, with an IC50 of 8.7 ± 0.9
nM and a resistance index of 0.7. Colchicine treatment to PC-3/TxR cells revealed a
resistant index of 3.5, and PC-3/TxR cells were even less susceptible to paclitaxel and
docetaxel treatment (RI > 30). We then proceeded to determine the anticancer action of
4a in a PC-3/TxR xenograft model in nude mice. To prove the efficacy of paclitaxel
against non-resistant tumors, we conducted a study in parallel in a PC-3 xenograft model
and confirmed that the non-resistant tumors were highly prone to paclitaxel treatment
(Figure 4-8B). However, when paclitaxel was administrated to mice bearing paclitaxel
resistant tumors, there was no difference in tumor volumes compared to group that was
administered only the vehicle solution (Figure 4-8C and D). Additionally, mouse weight
began to drop moderately after 2 weeks of treatment, possibly as a result of toxicity
(Figure 4-8G). On the other hand, treatment with 30 mg/kg of 4a at the same frequency
resulted in a significant decrease in tumor volume (p < 0.01), with a calculated TGI of
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Figure 4-7.
Inhibition of tumor growth in vivo.
A) A375 xenograft model in nude mice for 4a, 6a, and paclitaxel treatment groups.
Graph represents mean tumor volume ± SEM (n=8). B) Individual tumor final volumes
represented as mean tumor volume for each group ± 95% confidence interval. C) Tumor
weights ± SEM. D) Mouse body weights represented as a % change of the initial weight
± SEM values. Statistical significance was determined by Dunnett’s multiple comparison
test for the treatment groups compared with the vehicle control group (****P <0.0001,
***P <0.001). E) Representative images of tumor samples for treatment groups by H&E
and IHC staining. Compared to the control, treatment groups displayed elevated cleaved
caspase-3 expression indicative of apoptosis (middle column), and decreased density of
CD31-stained microvessels (right column).
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Figure 4-8. 4a overcomes taxane resistance and demonstrates antitumor efficacy.
A) Cytotoxicity of 4a against parental and taxane-resistant prostate cancer cells lines.
Curve was fitted by nonlinear regression to determine IC50 values (n=4). B) Prostate
cancer xenograft models in nude mice for PC-3 tumors and C) paclitaxel-resistant PC3/TxR tumors represented as mean tumor volume ± SEM (n=7). D) Individual PC-3/TxR
tumor final volumes. Bar graph represents the mean tumor volume for each group ±
SEM. E) PC-3/TxR tumor weights ± SEM. F) Representative images of PC-3/TxR
tumors. G) Mouse body weights in the PC-3/TxR xenograft model represented as mean
body weight change as a percentage compared to initial weight ± SEM values. Statistical
significance was determined by ANOVA analysis followed by Dunnett’s multiple
comparison test for final tumor volumes and weights compared to the corresponding
control group (****P < 0.0001, **P < 0.01, *P < 0.05).
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55.6%. There was also a considerable difference in tumor weight for the 4a treated group
(p < 0.05) and observable differences in tumor size (Figure 4-7 and F). One-way
ANOVA showed statistical significance between groups based on final tumor volume (p
= 0.0007) and weight (p = 0.002).
In this paclitaxel-resistant PC-3/TxR prostate cancer cell line model, more than
200 genes are upregulated in addition to P-gp overexpression, representing a large
number of potentially clinically relevant taxane-resistant mechanisms (174, 175). The
efficacy of compound 4a in suppressing tumor growth in this highly aggressive, tumor
model suggests that these new analogs have the potential to overcome resistance
mechanisms employed by MDR tumors. This is also consistent with the general
properties of Azixa or its related analogs targeting the colchicine binding site in tubulin
(101, 242, 252).
Conclusions
In summary, we have reported the design and potency of new conformationally
restricted Azixa analogs with a heteropyrimidine scaffold as well as dihydroquinoxalinone pyridopyrimidine analogs. Biological assays indicated that two of the most
potent compounds of the series, 4a and 6a, had IC50 values in the low nanomolar range
against a panel of metastatic melanoma cell lines, similar to that of colchicine and
existing Azixa analogs. However, 4a and 6a showed significantly improved metabolic
stability in human liver microsomes than similar conformationally restricted Azixa
analogs (quinazoline analogs) reported by Xie et al. The 5a and 5b analogs showed even
greater improvement in metabolic stability and demonstrated strong anticancer potency in
a multitude of cancer types, including melanoma, prostate, lung, and breast cancer, as
well as including P-gp overexpressing M14/MDR1 cells and taxane resistant PC-3/TxR
and DU-145/TxR cell lines.
These new analogs inhibit tubulin polymerization, promote microtubule
destabilization, and directly target colchicine binding site, which was confirmed with
high-resolution crystal structures for representative compounds 4a, and 6a, in complex
with tubulin. Binding poses for these compounds revealed by the X-ray crystal structures
were dramatically different than binding conformations predicted from molecular
modeling, and this underscores the complexity and flexibility of the colchicine binding
site. The ability of the compounds to impede cellular activities was demonstrated though
a variety of mechanisms including migration, clonogenicity, endothelial cell network
formation. They also share trademark characteristics with other potent antimitotic agents
such as inducing G2/M phase cell cycle arrest and promoting apoptosis. In vivo, 4a and
6a significantly reduced tumor growth in a xenograft model in nude mice challenged with
A375 melanoma at the respective doses of 30 mg/ kg and 15 mg/kg after 2 weeks of
treatment. Subsequent immunohistochemistry analysis of the tumors also indicated that
treatment with 4a and 6a caused elevated apoptosis and extensive vascular disruption
within the tumors. Finally, compound 4a demonstrated the ability to overcome paclitaxel
resistance in vitro and in vivo (30 mg/kg), substantiating the efficacy of colchicine
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binding site inhibitors against resistant cancers. These studies demonstrate the potential
of 4a, 6a, 5a, and 5b as anticancer agents, provide proof-of-concept for their mechanisms
of action, and reveal the structural basis to support the continued development for these
lead compounds as tubulin inhibiting and vascular disrupting chemotherapeutic agents.

105

CHAPTER 5.

INTRODUCTION TO TARGETING THE INHIBITOR OF
APOPTOSIS PROTEINS4
Inhibitor of Apoptosis Proteins

Apoptosis is a critical component of cell regulation, homeostasis, and
programmed cell death. While cell death can proceed through several pathways such as
autophagy or necroptosis, apoptosis is perhaps the best-understood and primary pathway
through which programmed cell death is carried out. Dysregulation of apoptosis is
observed in many human diseases and is one of the hallmarks of cancers (263, 264). In
principle, evasion of programmed cell death is the result of failure to propagate apoptosis
and caspase activation pathways (265). Inhibitor of apoptosis proteins (IAPs) are upregulated in many types of cancer and contribute to tumor progression, treatment
resistance, and poor prognosis. They suppress apoptosis induced by an array of stimuli,
including death receptor activation, growth factor withdrawal, ionizing radiation, viral
infection, endoplasmic reticulum stress, and genotoxic damage (266, 267). IAPS also
promote cell survival through regulation of signaling pathways. While many traditional
treatment approaches such as radiation and chemotherapy seek to treat cancer by
inducing apoptosis, cancer cells often develop resistance to these treatment strategies,
particularly when IAP’s are upregulated. Targeting these apoptotic regulators and
suppressing their inhibitory function to promote cell death is an attractive anticancer
strategy (264, 268-270). Substantial progress has been made in the development small
molecules that are capable of penetrating the cell membrane and potent enough to restore
apoptotic function via IAP suppression. IAP inhibitors may induce cell death and tumor
regression as single agents by direct IAP interaction or synergize with additional
cytotoxic agents to sensitize cancer cells to apoptosis and overcome drug resistance.
Increased knowledge and greater insight of the biological mechanisms and structure of
IAPs has laid the groundwork for the targeting strategy of small-molecule IAP inhibitors
and has greatly contributed toward their translation and incorporation into clinical
practice.
Structure of IAP Proteins
IAP proteins are a family of endogenous anti-apoptotic proteins that hinder
apoptosis by interfering with caspase activation. In addition to their roles in apoptosis,
they can also influence non-apoptotic processes such as cell differentiation, invasion,
migration, and metastasis (271-273). The first IAP family member was identified during
a genetic screening of SF21 baculoviruses, where a 1.6kB gene encoding a 31kDa antiapoptotic protein with a zinc finger-like motif was discovered (274). To date, there are
eight mammalian Baculoviral IAP repeat-containing (BIRC) protein family members:
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neuronal IAP (NIAP, BIRC1), cellular IAP1 (cIAP1, BIRC2), cellular IAP2 (cIAP2,
BIRC3), X chromosome-linked IAP (XIAP, BIRC4), survivin (BIRC5), apollon
(BRUCE, BIRC6), melanoma IAP (ML-IAP, livin, BIRC7), and IAP-like protein 2 (ILP2, BIRC8) (275) (Fig. 1). Among these, XIAP, cIAP1, cIAP2, and ML-IAP are known to
participate in the inhibition of apoptosis through caspase inhibition and cell signaling
(276, 277).
Proteins in this family are characterized by at least one (but up to three)
baculoviral IAP repeat (BIR) domains in the N-terminal portion of the protein. The BIR
domains are highly conserved, comprised of ~80 amino acids, and contain histidine and
cysteine residues that coordinate a zinc ion. In the C-terminus they may also contain a
Really Interesting New Gene (RING) domain with E3-ligase activity, caspase activation
recruitment domain (CARD), a ubiquitin-conjugating (UBC) domain, or a ubiquitinassociated (UBA) domain (276)(Figure 5-1). Only X-linked IAP has been shown to
potently inhibit apoptosis through caspase interaction and suppression. The BIR domains
are largely responsible for binding to caspases, whereas RING domain-containing IAPs
can regulate apoptosis through their E3 ligase activity (278, 279). Dimerization of the
RING domain potentiates their E3 ubiquitin ligase activity, which induces IAP-mediated
ubiquitylation by recruiting E2 ubiquitin-conjugating enzymes and facilitating the
transfer of ubiquitin to target proteins and binding partners (280, 281). The function of
the CARD domain in cIAP1 and cIAP2 is largely unknown, though it has been indicated
to play regulatory role in auto-inhibition of E3 ligase activation by preventing RING
dimerization (282). The UBA domain enables IAP proteins to bind to mono-ubiquitin as
well as Lys 63- and Lys 48-linked poly-ubiquitin chains and is implicated in cell survival
and oncogenesis (283). Survivin is the smallest member of the IAP family, containing a
single BIR domain, but plays a versatile role in a multitude of cellular processes. While
its function is still somewhat controversial, it influences cell death by both anti-apoptotic
and pro-proliferation mechanisms. The direct interaction of survivin with caspases is
unclear, but it can interact with apoptotic proteins to induce caspase-independent cell
death (284, 285).
IAP Proteins Regulate Cell Death Pathways
All apoptotic signaling converges upon the activation of caspases, making their
activity a crucial determinant in programmed cell death (286). Caspases, or cysteinedependent aspartate specific proteases, are a family of cysteine proteases that cleave
target proteins after specific aspartic residues (287). They are synthesized as inactive
zymogens and remain latent until activated by cell death stimuli. Apoptotic caspases are
further classified as initiator or executioner caspases according to their mechanism of
action and manner of activation. Initiator caspase-8 and caspase-9 are activated by
dimerization and responsible for activating downstream executioner caspase-3, caspase-6
and caspase-7 by cleaving their catalytic domain (288, 289). Executioner caspases
catalyze a proteolytic cascade by cleaving cellular substrates that promote the ordered
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Figure 5-1. Domains of mammalian IAP proteins
The domain organization for the 8 identified mammalian IAP proteins is shown. The
defining characteristic is the presence of one or three baculoviral IAP repeat domains.
These domains are required for the majority of protein-protein interactions with caspases
or other apoptotic proteins. Several IAPs (XIAP, cIAP1, cIAP2, ML-IAP, and ILP-2)
contain an E3 ubiquitin ligase zinc-finger at the carboxy-terminus. Both cellular
inhibitors of apoptosis contain a caspase recruitment domain in the region between the
BIR and the RING domains. Ubiquitin-associated (UBA) domains of XIAP, cIAP1,
cIAP2, and ILP-2 are capable of binding to ubiquitin chains, and apollon contains a
ubiquitin-conjugating (UBC) E2 domain. IAPs with roles in mitosis (survivin and
apollon) have a slightly longer, type 2 BIR domain compared with the other IAPs.
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disassembly and destruction of the cell. Caspases propagate apoptosis through two major
pathways: the mitochondrial (intrinsic) pathway and the death receptor (extrinsic)
pathway (Figure 5-2).
Intrinsic and Extrinsic Pathways. The mitochondrial pathway is activated by a
vast array of non-receptor-mediated intracellular stress signals and pro-apoptotic stimuli
such as cellular injury by toxins, viral infections, radiation, free-radicals, hypoxia or
DNA damage. These stimuli cause permeability changes in the mitochondrial outer
membrane, a process which is tightly regulated by several BCL-2 family proteins, and
results in the loss of transmembrane potential (290, 291). Upon activation, BCL-2 family
proteins BAK and BAX form pores in the outer mitochondrial membrane and direct the
release of cytochrome c from the intermembrane space to the cytosol. Cystolic
cytochrome c then binds to apoptotic protease-activating factor 1 (Apaf-1) to form a
complex called the apoptosome (292, 293). The apoptosome recruits and processes
procaspase-9 into active caspase-9, forming a holoenzyme complex (294). Caspase-9
then cleaves and activates executioner caspase-3, which in turn targets downstream
substrates to induce the final stages of apoptosis and cell death (295). Concurrent with
cytochrome c efflux from the mitochondria, SMAC is also introduced into the cytosol
and neutralizes the inhibitory effects IAP proteins (296). SMAC and its functions will be
covered in greater a detail.
The extrinsic apoptosis pathway is initiated by the binding of death ligands such
as FasL/CD95 ligand, TNF-related apoptosis-inducing ligand (TRAIL), or tumor necrosis
factor α (TNFα), to their respective cell death receptors, Fas/CD95, DR4 or DR5, and
TNFR1. Binding of death receptors ligands such as TRAIL or FasL stimulates receptor
oligomerization and leads to the recruitment of the adaptor protein Fas-associated death
domain (FADD/Mort-1) and procaspase-8. This forms the death-inducing signaling
complex (DISC), which processes and activates caspase-8. Alternatively, the binding of
TNFα with TNFR1 stimulates the formation of two complexes (297-299). Firstly,
complex I is assembled at the membrane in conjunction with TNFR1 and consists of TNF
receptor-associated death domain (TRADD), TNF receptor-associated factor 2 (TRAF2)
and receptor-interacting protein 1 (RIP1). Complex I can translocate into the cytosol and
recruit FADD and procaspase-8 form complex II assembly. Complex I internalization can
be inhibited by cIAP1/2-mediated ubiquitylation of RIP1, which consequently suppresses
apoptotic signaling (300, 301). As with DISC, complex II generates active caspase-8,
which can then cleave and activate caspases-3 and caspase-7. Additionally, caspase-8 can
advance apoptosis by cleaving and activating Bid, a pro-apoptotic BCL-2 family protein
that is critical in pathway convergence (302, 303). The activated form of Bid, truncated
Bid (tBid), migrates to the mitochondria and leads to activation of BAX and BAK,
mitochondria membrane permeabilization, cytochrome c release, and induction of the
intrinsic pathway (304-306). Executioner caspases-3 and caspase-7 elicit downstream
apoptotic protein activation, including the nuclear enzyme poly ADP ribose polymerase
(PARP), ultimately resulting in DNA fragmentation, degradation of nuclear and
cytoskeletal proteins, formation of apoptotic bodies, expression of ligands for phagocytic
uptake and cell death (307, 308).
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Figure 5-2. Cell death pathways.
The extrinsic (death receptor) pathway is activated by the binding of cell death ligands to
their respective receptors, which trigger the formation of signaling complexes that
activate caspase-8. Caspase-8 can either process Bid to truncated Bid (tBid), which
stimulates the activation of the mitochondrial pathway, or it can directly interact with and
activate downstream caspases. The mitochondrial pathway is stimulated by a variety of
death stimuli and results in the release of SMAC and cytochrome c from the
mitochondria through mediator proteins BAK and BAX. Cytochrome c release leads to
the activation of initiator caspase-9 and then subsequent executioner caspases, whereas
SMAC promotes apoptosis by inhibiting XIAP. cIAP proteins can block the formation of
complex II by ubiquitylation of RIP1.
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A third minor pathway involves granzyme B, a granule-associated serine protease
found in cytotoxic T-cells and natural killer cells. It can initiate cell death by caspase-3
activation, Bid cleavage, and digestion of regulatory proteins (309, 310).
Mechanisms of Action of Different IAP Proteins. XIAP is probably the bestcategorized IAP in terms of its role in apoptotic regulation and can potently suppress
apoptosis through direct binding of caspase-3, caspase-7, and caspase-9 (311). The linker
region between the BIR1 and BIR2 domain of XIAP is essential for caspase-3 and
caspase-7 inhibition and competitively binds at the active site. Inhibition of caspase-3
requires only the linker region, whereas caspase-7 requires binding of both the linker
region and the subsequent binding of the XIAP BIR2 domain (312-314). The BIR3
domain of XIAP inhibits caspase-9 by binding to its monomeric, inactive form. This is
achieved by forming a heterodimer with procaspase-9, which prevents its dimerization
and activation (315, 316). Another mechanism by which XIAP regulates apoptotic
function involves the E3 ubiquitin-ligase activity of the RING domain. Studies have
shown that removal of the RING domain resulted in an increase in caspase-3 activation,
accelerated rate of apoptosis, and enhanced organism survival in a Eμ-Myc mouse
lymphoma model (317). This underscores the importance of the ubiquitin-ligase function
of XIAP for the inhibition of caspases and tumorigenicity. In addition to caspase
inhibition, XIAP proteins participate in cell signaling and NF-κB activation. One surface
of the BIR1 domain of XIAP binds with the N-terminal domain of the TGF-β activated
kinase 1 (TAK1) binding protein, TAB1, while the opposite surface is responsible for
BIR1 dimerization. This interaction and dimerization propagates XIAP-induced TAK1
activation and stimulates NF-κB signaling (316, 318, 319). Altogether, inhibiting
caspases through direct interaction is the primary mechanism by which XIAP suppresses
apoptosis, but it can also influence cell survival through cell signaling pathways.
IAPs do not all obstruct apoptosis in the same manner. Weak inhibitors of
caspases, such as ML-IAP, influence cell survival by binding and sequestering SMAC, an
endogenous inhibitor of IAP proteins. In the absence of SMAC, XIAP is uninhibited and
may more freely promote cell survival (320, 321). On the other hand, while cIAPs can
participate in caspase binding, they mainly regulate apoptosis via the E3 ubiquitin ligase
activity of their RING domain (322, 323). They are capable of inducing both crossubiquitylation of a multitude of substrates as well as auto-ubiquitylation and subsequent
degradation (281, 324, 325). For example, cIAP1 can promote ubiquitylation of caspase3 and caspase-7 and can also mediate ubiquitylation of other IAP proteins including
cIAP2 and XIAP (326). In the death receptor pathway, cIAPs impede apoptosis by
maintaining constitutive ubiquitylation of RIP1, preventing its association with FADD
activation of caspase-8 (327). Unlike XIAP, the BIR1 domains of cIAP1 and cIAP2
interact with TRAF2 and regulate intracellular signal transduction of TNF receptors (328,
329). cIAPs are also implicated in MAPK signaling and regulate TNFα-mediated NF-κB
activation (330, 331).
The mechanism of action of survivin regarding the inhibition of apoptosis is not
as clearly defined and further complicated by its involvement in other cellular processes,
particularly cell division. There is support for a variety of mechanisms by which survivin
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regulates apoptosis, including direct binding to effector caspases (332), interacting with
SMAC and releasing bound IAPs (333, 334), reducing DNA fragmentation by decreasing
levels of mitochondrial apoptosis-inducing factor (AIF) in the nucleus (335), and forming
a complex with cofactor hepatitis B X-interacting protein (HBXIP), which binds to
procaspase-9 and obstructs subsequent processing (336). Survivin also cooperates with
XIAP to inhibit caspase activity by forming an XIAP-survivin complex that increases
XIAP stability and protects it against ubiquitylation and proteasomal degradation (337).
Survivin is prognostically important because of its minimal expression in normal
differentiated adult cells compared to its elevated levels of expression in a wide range of
cancers (338). It has been suggested that this could serve as diagnostic tool and
biomarker for detection of malignancy (339).
IAP Proteins Regulate Cell Signaling Pathways
Nuclear factor-κB (NF-κB) signaling mediates many facets of biological activity
including inflammation, proliferation, and survival. Its activation stimulates the
expression of many proteins that promote cell cycle progression, resist apoptosis, and
facilitate cell adhesion, angiogenesis, and metastasis. It is not surprising that NF-κB is
strongly correlated with carcinogenesis and enables malignant transformation and tumor
progression (340). As mentioned previously, IAPs, especially cIAP1 and cIAP2, play a
critical role in apoptotic suppression by ubiquitylation of NF-κB protein substrates and
mediating cell signaling. cIAPs positively regulate the canonical NF-κB pathway and
negatively regulate non-canonical NF-κB signaling (341) (Figure 5-3).
The canonical pathway is initiated by the binding of TNFα to TNFR1, followed
by the recruitment of TRADD and RIP1. TRADD then engages TRAF2 and
cIAP1/cIAP2, which are bound to TRAF2 through their BIR1 domain. cIAPs induce E3
ligase-mediated poly-ubiquitylation of RIP1 (300, 327) to generate a binding platform for
the induction and activation of the inhibitor of κB kinase (IKK) complex, composed of
IKKα, IKKβ, and NF-κB essential modulator (NEMO). Additionally, the TAK1-TAB1
complex and the linear ubiquitin chain assembly complex (LUBAC) are recruited to the
binding platform. The activated IKK complex phosphorylates and degrades the inhibitor
of NF-κB (IκB), causing the release of its p50 and RelA dimers (342). p50 and the
transcription factor RelA then translocate into the nucleus to activate transcription of
targeted genes and NF-κB signaling (343). Therefore, the presence of cIAP1/cIAP2
promotes cell survival through activation of the NF-κB pathway by ubiquitylation of
RIP1 (344).
In the non-canonical pathway (also referred to as the alternative pathway),
constitutive degradation of NF-κB inducting kinase (NIK) by cIAP1/2 in a complex with
TRAF3/TRAF2 represses the activation of NF-κB signaling (324). In the absence of
activation signals, TRAF3 recruits TRAF2-bound-cIAP proteins to NIK in the cytoplasm.
cIAP-mediated ubiquitylation of NIK causes its subsequent destabilization and
degradation, which prevents activation of IKKα proteins downstream. When the TNFrelated weak inducer of apoptosis (TWEAK) ligand binds to the FN14 receptor, it
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Figure 5-3. NF-κB signaling pathways.
cIAP proteins are positive regulators in the canonical pathway and negative regulators in
the non-canonical signaling. In the canonical pathway, ubiquitination of RIP1 forms a
binding platform for the IKK complex (composed of NEMO, IKKα, and IKKβ), the
TAB1-TAK1 complex, and the linear ubiquitin chain assembly complex (LUBAC).
Activated IKKβ leads to proteasomal degradation of inhibitor of NF-κB (IκB) and
subsequent translocation of p50/RelA into the nucleus to activate of target genes. In the
non-canonical pathway, constitutive degradation of NIK by cIAP proteins represses NFκB signaling. Degradation of cIAP proteins (either initiated by binding of ligands such as
TWEAK to FN14 or by IAP antagonists), allows NIK to stabilize and accumulate. This
leads to phosphorylation of IKKα, processing of p100 to p52, and the translocation of the
p52/RelB dimer into the nucleus to activate NF-κB signaling.
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engages the TRAF proteins and induces lysosomal degradation of cIAP1-TRAF2 (345).
Alternatively, IAP antagonists may induce rapid proteasomal degradation of cIAPs. The
absence of cIAP proteins allows for stabilization and accumulation of NIK, which can
then phosphorylate IKKα (346). Activated IKKα causes a chain of events resulting in the
dissociation of p100 from p52, its dimerization with RelB, and transcription of NF-κB
target genes (347). Thus, the E3 ubiquitin ligase function of cIAPs and their ability to
bind to TRAF2 are essential elements in the regulation of NF-κB pathways and
promotion of cell survival.
IAPs also play a role in the other signaling pathways such as Jun N-terminal
kinase (JNK), p38 mitogen-activated protein kinase (MAPK), TGF-β, Myc, and
PI3K/Akt (348). In the Myc pathway, cIAP1 catalyzes ubiquitylation and degradation of
a cellular antagonist of Myc and promotes cellular proliferation (349). cIAPs also
orchestrate NOD-induced signaling by poly-ubiquitylation of RIP2, which leads to the
activation of TAK1 and MAPK signaling (350). In addition to its role in TAK1-mediated
NF-κB signaling, XIAP can serve as a cofactor to several TGF-β proteins and potentiate
TGF-β signaling (351). Also, XIAP, NAIP, and ML-IAP can activate the JNK1 pathway
through their interactions TAK1 (352). This data further demonstrates the anti-apoptotic
functions of IAPs by activation and regulation of pro-survival pathways.
IAP Proteins in Cancer
IAPs are aberrantly expressed in a multitude of human cancer, and the elevated
levels have been linked with tumor progression and aggressiveness, treatment resistance,
and poor prognosis. For example, high nuclear XIAP expression in breast carcinoma
patients significantly increases risk of relapse (353) and shortened overall survival (354).
XIAP expression is also indicative of poor prognosis in colorectal cancer (355), bladder
cancer (356, 357), chronic lymphocytic leukemia (358), and numerous other cancers
(359). XIAP expression also increased with advanced tumor stage and was correlated
with tumor aggression in clear-cell renal carcinomas (360, 361) and metastatic
melanomas (362).While XIAP expression levels in gastric adenocarcinomas were not
significant independently, disturbances in the balance of XIAP to XIAP-associated factor
1 (XAF1), particularly increased ratios of XIAP:XAF1, were substantial determining
factors in metastasis and patient survival (363, 364). Similarly, its overexpression has
been linked to chemoresistance in ovarian carcinoma cells after cisplatin treatment (365)
and XAF1 expression was drastically lower than XIAP in malignant versus nonmalignant tumors (366). In hepatocellular carcinoma, elevated XIAP expression
increased the risk of relapse after total liver resection and orthotopic liver transplantation,
promoted metastasis, increased CDK4/Cyclin D1 expression, and corresponded with poor
overall prognosis (97, 367, 368).
IAP expression is not necessarily an indicator of unfavorable outcome in every
case. Studies have indicated there is no correlation between XIAP, cIAP1, or cIAP2
expression and predictive response to chemotherapy in non-small cell lung cancer
(NSCLC) patients (369, 370) nor is XIAP expression pertinent to disease stage and
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patient survival in cervical carcinoma (371). The relevance of XIAP expression in acute
myeloid leukemia is somewhat ambiguous, as contradicting results have been reported
(372). Some studies indicated no prognostic relevance of XIAP or survivin levels (373),
though numerous other studies demonstrated lower XIAP expression was in accordance
with longer survival and remission duration (374-376).While elevated expression of
several IAP proteins is evident in prostate cancer, XIAP expression has been reported to
actually correlate with lower incidences of reoccurrence (377, 378). Nevertheless,
targeting specific IAPs in relevant subgroups of cancer patients still warrants
investigation, and additional studies are needed to define these parameters and identify
prognostic biomarkers.
Genetic aberrations contribute to overexpression of IAPs and resistance to
apoptosis. Amplification of 11q21-11q23, which contains the genes encoding cIAP1 and
cIAP2, occurs frequently in a multitude of cancers including cervical carcinomas (379),
esophageal carcinomas (380), liver cancer (381), glioblastomas (382), lung carcinomas
(383), and renal cell carcinomas (270). The amplification of 11q22, specifically cIAP1,
increased the risk of radiotherapy resistance in cervical cancer patients (379) and related
to carcinogenesis in esophageal cancer patients (380). Additional proof demonstrating
that cIAPs are oncogenic drivers is evidenced by the amplification of chromosome 9A1,
the syntenic region the human chromosome 11q22, in murine osteosarcoma and
hepatocellular cancer models (381, 384).
Another genetic error affiliated with cIAP expression and its oncogenic potential
involves translocation events in mucosa-associated lymphoid tissue (MALT) lymphomas.
The t(1;14)(p22;q32) and t(14;18)(q32;q21) affect the regulation of Bcl10 and Malt1
genes and promote NF-κB signaling (385). The t(11;18)(q21;q21) is the most frequently
genetic abnormality associated with MALT lymphoma and is found in about half of all
low-grade MALT lymphomas (386). This translocation fuses the protein 1 (MALT1)
gene on chromosome 18 with the cIAP2 gene on chromosome 11 (341, 387, 388). The
anti-apoptotic cIAP2-MALT1 fusion protein, containing the N-terminal BIR domains of
cIAP2 (but not the RING domain) and the caspase-like domain in C terminal of MALT1,
forces constitutive activation of both pathways of NF-κB signaling and promotes
tumorigenesis (389-392). Several mechanisms have been proposed for activation of
canonical signaling, including IKK stimulation by cleavage of A20, a negative regulator
of NF-κB, binding to TRAF2 and/or TRAF6, and enhancement by Bcl10 interaction with
the fusion protein (393). Whereas potent activation has been attributed to the
functionality of both domains in the fusion protein for canonical signaling, the loss of E3
ubiquitin ligase function in the RING-deficient cIAP2-MALT1 fusion protein is
sufficient to induce non-canonical signaling through NIK stabilization (394). In addition
to their oncogenic properties, cIAPs also play a tumor-suppressing role because of their
ability to both positively and negatively regulate NF-κB signaling. For instance, in
multiple myeloma, genetic deletion of cIAP1/2 results in aberrant non-canonical pathway
stimulation (395-397). Though cIAPs can act as tumor suppressors or oncogenes,
dysregulation of cIAP expression in human malignancies always results in elevated NFκB signaling, leads to cell survival, and enhances tumorigenesis (270).
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Survivin expression is elevated in most hematologic malignancies, and is
associated with chemotherapy resistance, relapse, and lower patient survival. In most
tumor types, it is a significant independent prognostic indicator of unfavorable outcome,
some exceptions being gastric cancer, non–small-cell lung cancer and osteosarcoma
(398). Discrepancies in prognostic value may occur due to differing functions of splice
variants, detection methods, or subcellular localization (nuclear or cytoplasmic). Survivin
regulates multiple pro-survival processes, especially in the mitotic stage, such as
cytoprotection, cell cycle regulation, and evasion of cell death. Because of its ubiquitous
expression in cancers and undetectable levels in most transformed cells, it is an attractive
therapeutic target. However, there is recent evidence that it is also expressed in primitive
hematopoietic cells, progenitor cells, T lymphocytes, polymorphonuclear neutrophils, and
vascular endothelial cells, and is necessary for their proliferation and normal cell function
(398). The pathways through which survivin regulates proliferation of tumor cells and
normal cells and the overlap between the two needs to be further defined, though it seems
that mitochondrial survivin is exclusive to tumor transformation (399). Clarification of its
differential expression, propagation, and function in malignant and housekeeping
regulation, especially in hematopoietic and immune systems, is needed to maximize
therapeutic benefit and minimize toxicity in anticancer strategies targeting survivin.
Similar to survivin, ML-IAP is not expressed in differentiated adult tissue but is
preferentially and highly expressed in cancers such as melanoma and renal cell carcinoma
(400, 401). High ML-IAP expression is indicative of poor prognosis in neuroblastoma
patients (402) and correlated with tumor stages and pathogenesis of esophageal
carcinoma (403). Nuclear expression in patients high-grade central osteosarcoma patients
dramatically patient shortened life-span compared to those with only cytoplasmic
expression (404) but was a favorable independent predictor of cancer-specific survival
and progression-free survival in RCC patients (405). Its expression in childhood acute
lymphoblastic leukemia (ALL) was associated with sensitivity to chemotherapy and
positive prognosis (406), but found to be a negatively correlated with survival in adult
ALL (407). Another study showed that ML-IAP expression was not detectable in
malignant mesothelioma, even when other IAPs were found (408). The inconsistency
with the correlation between ML-IAP expression and prognosis can probably be
attributed to its dual functionality. It has been redefined as a regulator of apoptosis rather
than anti-apoptotic protein due to the discovery that its different isoforms promote
opposite effects on cell survival. Not only do its alpha and beta isoforms contribute
differently to tumorigenicity, its anti-apoptotic role is reversed by cleavage to its
truncated (tLivin) form by a strong apoptotic stimulus (409, 410). Cleavage of Livin-β
potently suppresses tumor proliferation, and the balance between the full-length and
cleaved protein, subsequent processing of tLivin, and its subcellular localization all
influence its regulation of apoptosis (411).
SMAC: The Endogenous Inhibitor of IAP Proteins
SMAC, also referred to as DIABLO (direct IAP-binding protein with low pI), is
an endogenous antagonist of IAP proteins. It promotes caspase activation in the
mitochondrial pathway by binding to IAPs, particularly XIAP (412, 413). preSMAC is
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translated in the cytosol and then transported into the mitochondrial intermembrane space
to undergo processing, where it remains until activated by apoptotic stimuli (414). The
mature form of SMAC is generated from the monomeric SMAC precursor molecule by
proteolytic cleavage of the 55 amino acid residue sequence in the N-terminus and
undergoes subsequent homodimerization formed through extensive hydrophobic
interactions (296, 414). SMAC efflux into the cytosol is also mediated by BCL-2 family
proteins but is a caspase-catalyzed event that occurs downstream of cytochrome c release,
whereas cytochrome c release is largely independent of caspase activity (415).
The mature form of SMAC has only four amino acid residues (Ala-Val-Pro-Ile)
located in the amino terminal that make up the IAP binding motif responsible for the
interaction with IAPs (296, 416-418). This AVPI tetra-peptide is able to bind to the BIR2
and BIR3 domains of XIAP, but not BIR1 (296, 419). SMAC suppresses XIAP-mediated
inhibition of apoptosis by binding to the BIR3 domain of XIAP and disrupting its
interaction with the ATPF tetra-peptide binding motif in the linker region of caspase-9
(420). SMAC simultaneously binds to the BIR2 domain of XIAP, reduces exposure of
the linker region in XIAP through steric hindrance, and relives executioner caspase
inhibition (421-423). The presence of both BIR2 and BIR3 domains of XIAP is required
for effective and efficient antagonism by the SMAC dimer. Also, while not directly
interacting with XIAP BIR1, SMAC antagonizes the XIAP-TAB1 interaction via steric
exclusion when it concurrently binds to the BIR2 and BIR3 domain of XIAP and
therefore prevents XIAP-induced NF-κB activation (319).
Another important method by which SMAC antagonizes IAPs is by promoting
proteasomal degradation of cIAP proteins. The AVPI binding motif of SMAC interacts
with the BIR domains of cIAP1 and cIAP2 and induces RING domain-mediated autoubiquitylation (324, 424). Overall, SMAC is an effective antagonist against several
critical IAP proteins and capable of promoting apoptosis, thereby supporting the rationale
for designing small-molecule drugs mimicking SMAC for anticancer therapy.
Targeting IAP Proteins for Cancer Therapy
In the past decade, great strides have been taken in implementing inhibitors of
IAPs to restore apoptotic function in laboratory and clinical settings. Some strategies to
inhibit IAPs target mRNA and down-regulate protein levels with antisense
oligonucleotides, ribozymes, or small-interfering RNAs (425-427). Another approach
utilizes antigen-based vaccinations to target IAPs and promote immune-mediated tumor
destruction (428-431). One of the most appealing strategies for targeting IAPs has been
with the use of small-molecule IAP antagonists, and several of these compounds have
reached clinical trials (341, 432, 433). Two classes of small-molecule IAP inhibitors are
SMAC mimetics and survivin-specific antagonists. There have been other small-molecule
XIAP antagonizing compounds identified, such as embelin, a naturally occurring
compound that comes from a Japanese Ardisia herb (434). However, its poor solubility
has prevented further preclinical development (435). Other screening strategies have led
to the discovery of polyphenylurea-based antagonists 1396-12 and 1396-34 (436) and
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aryl sulfonamide analogs including TWX006 and TWX024 (437), which can block (or
reverse) XIAP-mediated caspase-3 inhibition. But again, these compounds also have not
undergone additional clinical development. Therefore, the scope of this review will be
limited to the design, development, and therapeutic potential small-molecule SMAC
mimetics and survivin inhibitors, focusing on a selection of compounds that are
undergoing clinical advancement.
SMAC Mimetics: Design and Mechanism of Action
The design of SMAC mimetics was initially based on the crystal structure (416)
and NMR (418) of SMAC in complex with the BIR3 domain of XIAP. These structural
studies revealed that the AVPI binding region of SMAC recognizes and binds to a surface
groove on BIR3 domain of XIAP. The exact mode of binding at each peptide and
structural basis for the design of SMAC mimetics was previously described by Sun et al.
(438). To summarize, the methyl group on the first alanine fits into a hydrophobic pocket
in the surface grove of the XIAP BIR3 domain and the free amino group forms hydrogen
bonds with Glu314 and Gln319 in BIR3. The carbonyl backbone can participate in
hydrogen bonding to Trp323 in BIR3. In the second position, valine’s amino and
carbonyl groups can form optimal hydrogen bonds with Thr308. In the third position,
proline participates in van der Waals interactions with Trp323 and Tyr324. In the final
position of the AVPI tetra-peptide, the amino group of isoleucine forms a hydrogen bond
with Gly306. The side chain of isoleucine fits into a hydrophobic pocket formed by the
side chains of Leu292 and Val298, as well as the hydrophobic portion of Lys297 and
Lys299 (438) (Figure 5-4). Based on these monumental structural findings revealing the
binding interactions between XIAP and SMAC, both peptidic and non-peptidic SMAC
mimetics have been developed.
Through biochemical analysis of peptide variations and modifications, the
minimum sequence requirements to still achieve potent binding were determined, as well
as favorable and undesirable substitutions of SMAC-based peptides (439, 440). In the
first position, the alanine residue cannot tolerate replacement with another amino acid
without significantly reducing its binding affinity but demonstrated comparable binding
affinity when it was replaced by 2-aminobutyric acid, indicating that a methyl or ethyl
side chain is ideal in the first position for activity. The second position is flexible to
replacement by an array of amino acids or residues, however replacement with proline,
aspartic acid, or valine is not favorable. The replacement of the cyclic proline with a 4 or
6-member ring decreases binding affinity, but activity can be enhanced if a hydrophobic
group is attached to the proline ring. A hydrophobic substitution in the fourth position is
desirable, with phenylalanine showing the greatest affinity, whereas polar molecules
obliterate activity (438). While SMAC-based peptides could attain potent binding
affinities to XIAP, they were not cell-permeable without a carrier to facilitate delivery
into the cell. Extensive chemical modifications had to be made for generation of the first
SMAC-based peptidomimetic that demonstrated cell-permeability and XIAP antagonism
(441). It was also established that demethylation at position 1 reduced activity, an L-
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Figure 5-4. Crystal structure of the SMAC in complex with XIAP.
Detailed interactions of the AVPI binding motif of SMAC in complex with the BIR3
domain of XIAP (Protein Data Bank access code: IG73). Hydrogen bonds for Ala1, Val2,
and Ile4 are shown in yellow. Van der Waals interactions are between Pro3 and the side
chains of Trp323 and Tyr324. A hydrophobic pocket is formed by the Leu292 and
Val298 side chains and the hydrophobic portion of Lys297 and Lys299 side chains.
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configuration was required for position 2, adding hydrophobic groups to position 3
increases affinity, and the position 4 favors hydrophobic entities, particularly
phenylalanine and phenylglycine (418, 438, 441). These compounds provided the first
proof-of concept for small-molecule SMAC peptidomimetics as potential anticancer
agents and served as prototypes for small-molecule SMAC mimetics. Another significant
improvement to the design of these compounds was incorporation of a conformationally
constrained scaffold, which improved affinity and permeability (442-444).
To date, there are two types of SMAC mimetics: monovalent compounds
designed to mimic a single IAP binding site of SMAC and bivalent compounds
containing two SMAC mimetics tethered together by a chemical linker. Because mature
SMAC can form an elongated homodimer that interacts with both BIR2 and BIR3
domains, it was reasoned that bivalent, non-peptidic SMAC mimetics resembling the
SMAC dimer should be more potent and effective in promoting apoptosis by
concurrently interacting with both domains to restore caspase activity. The first bivalent
molecules that were discovered demonstrated that bivalent compounds did achieve
greater affinity than their monomeric analogs, leading to this new category of IAP
inhibitors (268). In addition to increased affinity, bivalent SMAC mimetics are
remarkably more potent in inducing apoptosis in tumor cells, with some studies
suggesting by a factor pf 100-1000 fold (438). The significant increase in potency is
partially due to their ability to promote cIAP dimerization, auto-ubiquitylation, and
proteasomal degradation, thereby inducing the autocrine/paracrine TNFα signaling loop
and NF-κB signaling (324, 445). However, it has been suggested that the more profound
effect on potency is due to the ability of bivalent compounds to engage in binding
multiple domains of XIAP, resulting in activation of executioner caspase-3 and caspase-7
in addition to caspase-9 (341, 446).
Though SMAC mimetics were designed around the SMAC-BIR3 interaction of
XIAP, they can also interact with the BIR domains of cIAP1, cIAP2 and ML-IAP. The
inactivated cIAP1 is conformationally constructed such that its RING domain is
sequestered within its monomeric structure and unable to dimerize. IAP antagonists
preferentially bind to the BIR3 domain and cause conformational changes that induce
dimerization of the RING domain and generate the E3 ligase function (447). The BIR3,
UBA, and CARD domains of cIAP1 are inhibitory elements to RING dimerization but
can be overcome by SMAC mimetics (448). Upon binding, cIAP1 undergoes rapidly
auto-ubiquitylation and depletion, whereas the cIAP2 dimer has a higher intrinsic E3
ligase activity, is more stable, and less influenced by SMAC mimetics. Elevated E3 ligase
activity causes cIAP-mediated ubiquitylation and activation of RIP1 and promotes
canonical NF-κB signaling pathway. This activation is merely transient, however, since
cIAPs are subsequently degraded. Since cIAPs negatively regulate the non-canonical
pathway by consistent ubiquitylation of NIK, cIAP inhibitors activate this pathway by
inducing cIAP degradation. Additionally, the combination of TNFα production and the
loss of cIAPs lead to RIP1/FADD association, triggering caspase-8 activation and
extrinsic apoptosis (300, 324, 445). Therefore, inhibitors of IAP proteins are capable of
reversing the pro-survival action of cIAP proteins by triggering E3 ligase mediated-cIAP
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degradation, inducing non-canonical TNFα production, and stimulating extrinsic TNFR1mediated apoptosis.
IAP inhibitors were initially designed to be non-specific and able to bind to
different families of IAP proteins. However, to understand the divergent apoptotic
mechanisms of different IAPs, cIAP-specific inhibitors were developed. Selective
targeting of cIAP by antagonists demonstrated that inhibition of cIAP alone can induce
cell death in tumor cells and did not require binding to the XIAP BIR3 domain (449).
Nevertheless, molecules that simultaneously target both cIAP and XIAP proteins are
more potent and can more efficiently induce cell death than by cIAP-only antagonism
(450). Site-specific SMAC mimetics that bind to a single BIR domain have also been
developed. BIR2-selective SMAC mimetics have demonstrated the ability to sensitize
TRAIL-resistant breast cancer cells (451) and TRAIL-resistant prostate cancer cells (452)
to apoptosis in vitro but were not toxic as a single agents. Discovery of BIR2-specific
benzazepinones has provided useful insights to the apoptotic events that differ
mechanistically from pan-IAP inhibitors, but initially had shortcomings that limited their
clinical utility (453). Optimization of these compounds provided further proof-of-concept
of their ability to promote apoptosis in xenograft models by caspase-3 and caspase-7
activation without inducing TNFα release (454). Still, it is suggested that BIR2 and BIR3
should instantaneously be targeted for optimal activation and potency (341, 359). Several
SMAC mimetics showing strong IAP inhibition and favorable toxicity profiles have
moved into clinical trials and are being evaluated as single agents and in combination
therapy. The chemical structure, clinical stage, and developer for the following selection
of compounds can be found in Figure 5-5A.
Clinical Development of SMAC Mimetics
GDC-0152 and GDC-0917/CUDC-427. The first SMAC mimetic to enter
clinical trials was designed by Genentech and was one of a series of monovalent
compounds developed to mimic the AVPI binding motif. Initial studies have shown
GDC-0152 to be a potent antagonist of cIAP1/2, ML-IAP, and XIAP (455). Using a
peptidomimetic approach, each position was assessed for its overall contribution to
binding affinity and evaluated to see if substitutions could be made to improve its
binding. For example, it was learned that while the P1 alanine was buried within a
hydrophobic pocket of the BIR domain, positions 2-4 were more amenable to
substitution. GDC-0152 demonstrated a Ki binding affinity of <50nM, and induced autoubiquitylation and proteasomal degradation of cIAP1 in melanoma cells. GDC-0152
promoted cell death in MDA-MB-231 breast cancer cells without affecting human
mammary epithelial cells in cell viability assays. Additionally, GDC-0152 inhibited
tumor growth in MDA-MB-231 xenograft models. A phase 1a first-in-human standard
dose-escalation study revealed linear pharmacokinetics with moderate clearance and
volume of distribution (455). Another study showed that GDC-0152 was able to induce
apoptosis through the down-regulation of IAPs and inhibit growth of K562 and HL60
leukemia cells in a dose-and time-dependent manner (456). Its toxicity and efficacy are
driven by TNFα levels as a result of increased NF-κB transcriptional activity (457).
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Figure 5-5. Preclinical and clinical development of small-molecule SMAC
mimetics and survivin inhibitors
A) SMAC mimetics in the preclinical stage include SM-164 (University of Michigan)
and BV6 (Genentech). Phase I SMAC mimetics include SM-406/AT-406/Debio 1143
(University of Michigan/Ascenta Therapeutics/Debiopharm), GDC-0152 (Genentech),
GDC-0917/CUDC427 (Genentech/Curis), and AEG40826/HGS1029 (Aegera
Therapeutic) (not shown). Compounds advancing to Phase II clinical trials include
LCL161 (Novartis), and Birinapant/TL32711 (TetraLogic Pharmaceuticals). B) Survivin
inhibitors in preclinical stages include FL118 (Canget BioTekpharma) and Shepherdin
(University of Massachusetts). Phase II inhibitors include YM155 (Astellas) and AICAR
(PeriCor Therapeutics).

122

Also developed by Genentech, GDC-0917 (CUDC-427) is an orally bioavailable,
second-generation IAP antagonists. While much of the assessment of this drug was built
on its predecessor, GDC-0152, a combination of mathematical modeling, simulation
techniques, and in-vivo pharmacokinetic studies demonstrate its potential as an anticancer
agent. GDC-0917 binds with affinities similar to that of GDC-0152 and has a more robust
effect MDA-MB-231 breast cancer cells while still exhibiting little toxicity to normal
human mammary epithelial cells. Favorable pharmacokinetic properties in terms of
hepatic clearance, volume, and half-life have been reported (458). One of its main
advantages is that it can be administered orally unlike its predecessor, which was given
by IV every 2 weeks. Human simulations to determine ED50 and ED90 are expected to be
72mg and 660mg assuming a 5 mg starting dose. These expectations were based on
MDA-MB-231 xenograft models and were predicted to be reached in a time frame of
about 1-2 years (458). Curis licensed GDC-0917 from Genentech, and it has since been
renamed CUDC-427. Phase 1 trials in patients with advanced or refractory solid tumors
or lymphoma are ongoing.
LCL161. Novartis is responsible for the development of the monovalent, orally
bioavailable SMAC mimetic LCL161. It targets cIAP1 to induce apoptotic activity
through E3 ubiquitylation ligases, thereby promoting TNFα secretion and NF-κB
pathway activation (459). Cleavage of caspase-3 was confirmed in mouse xenograft
models. Further evaluation in TNFα mRNA indicated a strong correlation between TNFα
expression and LCL161 dose, where the greatest inhibitory growth response was
presented by tumors with the highest basal TNFα levels. LCL161 has been investigated
as both a single agent and in combination and has produced mixed results. Studies done
by Pediatric Preclinical Testing Program did not show significant LCL161 activity as a
single agent in SCID mice xenograft models and pediatric cell lines, which they
concluded was due to LCL161 being ineffective in a majority of cell lines (460). This
remains somewhat controversial, as previous reports had indicated efficacy in multiple
tumor models and cell lines (461). Another study concluded that paclitaxel sensitized
hepatocellular carcinoma cells to LCL161, but there was significant inhibition of offtarget proteins such as pERK and pJNK, suggesting apoptosis resulted from toxicity as
opposed to direct action of LCL161-mediated IAP inhibition (462). Additionally, the
anticancer mechanism was mainly by anti-proliferative effects instead of apoptotic
stimulation. In a phase 1 first-in-human study of LCL161 as a single agent, it was
determined that a dose of 1800 mg was above what would be required to achieve target
inhibition. However, because of the lack of efficacy, sensitivity to LCL161 as single
agent was not conclusive. Adverse effects included cytokine release syndrome consistent
with robust NF-κB activity (461). Finding an appropriate level of inflammatory cytokine
production may ultimately be the key to success if the primary function of the drug
involves NF-κB pathway activation and TNFα production (463). In a phase 1b study,
increasing doses of LCL161 were combined with paclitaxel in patients with advanced
tumors and was well tolerated with manageable toxicities, predominantly neutropenia,
fatigue, and neuropathy (464). Altogether, these results suggest that LCL161 is a
promising anticancer agent, particularly in combination therapy, and warrants further
investigation to optimize its therapeutic value.

123

SM-406/At-406/Debio 1143. SM-406, renamed AT-406 for Ascenta
Therapeutics, is a small-molecule, non-peptidic SMAC mimetic capable of binding
XIAP, cIAP1 and cIAP2 (465). As it was previously discovered that designing SMAC
mimetics that are conformationally constrained improved their binding affinity, the
design of these molecule incorporated a rigid scaffold (442, 443, 446). Preclinical trials
show good antagonists activity of XIAP at the BIR3 domain and restored caspase-9
activity, induced rapid cIAP degradation, and increased cell death in a time-and-dose
dependent manner in MDA-MB-231 cells (465). SM-406 effectively inhibited tumor
growth in MDA-MB-231 xenograft models with minimal toxicity and achieved complete
tumor inhibition at 100 mg/kg oral dosing. AT-406 was further evaluated as a single
agent and in combination therapy with carboplatin, a first line platinum therapy (466). As
a single agent, AT-406 induced apoptosis in 3 out of 5 carboplatin resistant cancer cell
lines. The primary function of AT-406 is down-regulating XIAP protein levels, which
have greater expression in chemoresistant ovarian cancer cells compared to normal ovary
cells. These provide additional evidence that reduction of cIAP1 alone is not sufficient to
induce apoptosis. AT-406 also showed the ability to sensitize resistant cells to carboplatin
in vitro and in vivo, as indicated by prolonged mouse survival (466). Phase 1 trials have
been completed for Debio 1143 (AT-406) for patients with advanced solid tumors and
lymphomas and phase II studies are ongoing.
SM-122 and SM-164. SM-122 is a monovalent, non-peptidic mimetic of SMAC
and SM-164 is a bivalent analog created from two SM-122 analogs tethered together by a
chemical linker (467). The bivalent properties of SM-164 allow for binding to BIR2 and
BIR3 domains of XIAP simultaneously. SM-122 and SM-164 both bind to cIAP1 and the
BIR3 domain of cIAP2 and exhibit Ki values ranging between .31 and 2.7 nmol/L, where
SM-122 showed a slightly greater affinity. SM-164 was 300 times more potent than SM122 in binding to XIAP and 1000 times more potent in inducing apoptosis. These results
clearly demonstrate the impact of XIAP antagonism on apoptosis (467). It was then
shown to effectively promote cell death in MDA-MB-231 tumor tissues of mouse models
at a 5mg/kg dose. Within an hour, there was a significant decrease in cIAP1 levels, and
by 3 hours, activation of caspase-8, caspase-9 and caspase-3 and PARP cleavage was
observed. Damage was limited to the tumor tissue and normal, even highly proliferative
tissues were unaffected. More impressively, tumor growth was reduced by 65% without
causing toxicity or weight loss by day 36. In order to achieve stronger apoptotic
activation, SM-164 has also been tested in combination with TRAIL (468). While TRAIL
demonstrates low cytotoxicity and is well tolerated, its applications have previously been
limited (469, 470). SM-164 was highly synergistic with TRAIL in 12 out of 19 TRAILresistant and TRAIL-sensitive cancer cell lines of breast, prostate, and colon tumor types.
While these two compounds failed to achieve appreciable antitumor activity as single
agents, they reduced tumor volume by an average of 80% after two weeks of combination
treatment in a 2LMP xenograft model. The synergy between TRAIL and SMAC
mimetics relies on the interaction of procaspase-8 with RIP1 and enhanced by the
ablation of cIAP1 and XIAP (468). In a separate combination study with doxorubicin,
SM-164 sensitized hepatocellular carcinoma cells to TNFα-related apoptosis and
suppressed activation of Akt in vitro (471). These preclinical data provide support for the
potential of combination therapy with SM-164 for a variety of cancers.
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Birinapant. Birinapant (TL32711), by Tetralogic Pharmaceuticals, is a bisindolebased bivalent SMAC mimetic that binds with high affinity to the BIR3 domains of
XIAP, cIAP1, cIAP2, and the single binding domain of ML-IAP (472, 473). Though its
first-generation analog had a greater biding potency to the BIR3 domains of XIAP and
cIAP2, birinapant exhibited greater tolerability in an MDA-MB-231 xenograft model and
demonstrated dose-dependent tumor regression. The improvements are attributed to
decreased potency against cIAP2, lower affinity for XIAP BIR3 and activation of
caspase-dependent apoptosis while avoiding inhibition of XIAP-dependent NF-κB
signaling (473). Potent activation of apoptosis was evidenced by cleavage of PARP, a
substrate of caspase-3, in MDA-MB-231 cells 72 hours post treatment. Subsequent
corresponding studies showed that birinapant induced rapid degradation of TRAF-bound
cIAP1 and cIAP2 to inhibit TNFα-mediated NF-κB activation and promoted cell death as
a single agent (472). Birinapant also promoted activation of caspase-8 via DISC complex
formation in birinapant-sensitive cells following TNF stimulation and was active in
approximately 60% of a panel of 111 cell lines tested as a single agent or in combination
with TNFα and TRAIL. In vivo studies revealed observable antitumor activity after 5
treatments of 30mg/kg in approximately one third of the 50 patient-derived
xenotransplant models tested and potentiated the cytotoxicity of certain chemotherapeutic
agents including SN-38 (the active metabolite of irinotecan), gemcitabine, and 5azacytidine. Consistent with these findings, an aggressive, inflammatory breast cancer
model increased apoptotic activity in TRAIL-insensitive ErbB2-overexpressing cells and
significantly increased potency of TRAIL-induced cell death in aggressive TRAILsensitive tumors (474). In combination with TNFα, it inhibited proliferation in melanoma
cells with acquired resistance to BRAF (475). A Phase I first-in-man study of adult
patients with advanced solid tumors and lymphoma showed that it was well tolerated
when administered intravenously with no dose-limiting toxicities (476). Birinapant has
been evaluated in combination with multiple chemotherapies including liposomal,
doxorubicin, gemcitabine, docetaxel, irinotecan, and paclitaxel at standard dosing and
demonstrated excellent tolerability (477). Phase 2 studies of birinapant in combination
with irinotecan in colorectal patients showed an overall clinical benefit rate of 57%,
supporting the hypothesis of synergy between birinapant and irinotecan as a TNFαinducing agent (478). Clinical investigations of birinapant in patients with solid tumors
and hematological malignancies are ongoing.
BV6. BV6, another of compound by Genentech, is a bivalent SMAC mimetic that
is able to engage in binding of both cIAP and XIAP to produce apoptotic activation. Like
other SMAC mimetics, BV6 effectually diminishes the pro-survival effects cIAP1 and
cIAP2 through induced auto-ubiquitylation and degradation and it inhibits XIAP through
antagonism of caspase binding (324). This study made profound contributions to the
understanding of IAP antagonist-induced cell death dependent on NF-κB signaling. BV6
is capable of sensitizing several cell lines to radiation-induced apoptosis of non-small cell
lung carcinoma in vitro, including the SMAC mimetic resistant cell line, H460 (479).
Another study investigated whether BV6 could sensitize tumor cells to non-specific
cytokine-induced killer cells (480). While it was shown that BV6 did sensitize
hematologic and solid malignancies to CIK cells, it also promoted apoptosis in the CIK
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cells themselves as well as other peripheral mononuclear cells (PMNCs). Despite its
effect on CIK cells, the fact that it still sensitized non-malignant cells such as PMNCs
toward CIK cell-mediated killing limits its potential in combination with CIK immunebased therapies. On the other hand, BV6 has been shown to interact synergistically with
glucocorticoids such as dexamethasone to enhance glucocorticoid-triggered cell death in
pediatric acute lymphoblastic leukemia (481). Additional trials with BV6 in combination
therapy are warranted.
AEG40826/HSG1029. AEG40826, renamed HSG1029, is a bivalent SMAC
mimetic developed by Aegera Therapeutics and licensed by Human Genome Sciences for
clinical development. The results of phase 1 HGS1029 trials indicate a favorable safety
profile with IV administration and good tolerability in patients with advanced solid
malignancies. However, dose limiting toxicities such as dose-dependent short-lived
lymphocytopenia and possibly a transient neutrophilia in some patients were observed
(482). As expected, HGS1029 stimulated decrease in cIAP1 and up-regulation of
monocyte chemoattractant protein 1 levels. No structural data has been published.
Small-Molecule Survivin Inhibitors
Though survivin is reported to inhibit apoptosis, the exact mechanism by which it
does so remains elusive. This is further complicated by the myriad of cell cycle processes
in which it is involved, including cellular homoeostasis, cell division, intracellular
signaling and apoptosis (338). Several strategies that selectively target survivin are under
development, but there are only a handful that do so by targeting the protein with small
molecules. Even so, these small molecules do not seek to inhibit survivin by forcing
suppression by direct binding but rather target promoter regions or disrupt protein-protein
interactions in survivin complexes (270, 339, 427). The chemical structure, clinical stage,
and developer for the following selection of compounds can be found in Figure 5-5B.
Clinical Development of Survivin Inhibitors
YM155. YM155, or sepantronium bromide, is a small imidazolium-based
molecule that was identified by high-throughput screening (HTS) of chemical libraries of
compounds that diminished survivin expression in a survivin promoter-luciferase assay.
YM155, unlike SMAC mimetics, suppresses survivin expression by interfering with the
promoter transcription region (483). The molecular mechanism by which YM155
inhibits survivin is at least in part by dissociation and subcellular relocalization of
transcription factors such as Sp1 from its DNA binding sites and acts in cell cycleindependent manner without G1 cell arrests (484). Preclinical studies of YM155
demonstrated inhibition of cell growth in a broad spectrum of cancer cell lines including
non-Hodgkin’s lymphoma, hormone-refractory prostate cancer, ovarian cancer, sarcoma,
non-small-cell lung cancer, breast cancer, leukemia and melanoma (485). Additionally,
YM155 was able to produce antitumor activity in p53-defective human tumor xenograft
models. Because abnormal p-53 expression is associated with increased survivin
expression, this could provide an advantage over current therapies. In phase 1 trials, it
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was shown to be well tolerated in patients with advanced solid tumors or hematologic
malignancies (485). Phase 2 studies have been less encouraging though: while severe side
effects were uncommon, it only achieved modest efficacy at best as a single agent or in
combination therapy (372, 486, 487). YM155 is a substrate for p-glycoprotein-mediated
transport, making it susceptible to multidrug resistance and therefore limiting its
therapeutic applications (488).
FL118. FL118 is a small-molecule identified through HTS of compound libraries.
It not only inhibits survivin promoter activity, but also inhibits anti-apoptotic Mcl-1,
XIAP and cIAP2 expression without disrupting control genes (489). FL118 had superior
antitumor activity in mouse xenograft models when compared with YM155 and acts in a
p53-independent manner. It was even able to completely eradicate colon and head-andneck tumors in a mouse model. Furthermore, it is suggested that FL118 is not a substrate
for the ABCG2 pump and could potential bypass multiple treatment-resistant mechanisms (490). Its clinical potential has been further realized by improvements on its
formulation and route of administration (491). Based on these findings, it is a favorable
candidate for clinical trials.
Shepherdin and AICAR. Shepherdin is a small-molecule peptidomimetic that
was designed to interfere with the interaction between survivin and Heat-shock protein90
(Hsp90) (492, 493). Hsp90 is a molecular chaperone protein that binds to and stabilizes
survivin. Disruption of the Hsp90-survivin complex leads to survivin degradation and
mitochondrial-dependent apoptosis (494). Within the BIR1 domain, residues Lys79 –
Leu87 are essential for the association of survivin with Hsp90. Shepherdin exploits that
interaction and binds extensively to the ATP pocket of Hsp90 to destabilizes survivin and
induce tumor cell death by both apoptotic and non-apoptotic mechanisms (492). Not only
does it disrupt the Hsp90-survivin interface, is acts as a global inhibitor of Hsp90
function by competition with ATP. Systemic administration of shepherdin in vivo was
found to be well-tolerated and inhibited human tumor growth in mice without significant
toxicity. It also achieved anticancer activity in vivo in an acute myeloid leukemia
xenograft model as determined by loss of expression of survivin and Akt without causing
toxicity to normal tissue (495). Clinical evaluation of shepherdin in patients has not yet
been reported. Other small molecules targeting of Hsp90 include nonpeptidic 5aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR). Other studies yielded
similar results, indicating that destabilization of Hsp90 led to apoptosis in multiple tumor
cell lines while not affecting proliferation of normal human fibroblasts (493). However,
because AICAR is a potent agonist of AMP-activated protein kinase (AMPK),
deleterious side effects such as significant drop in plasma potassium levels have been
reported (496). Further studies are needed to address concerns associated with survivin
antagonism.
Challenges for Clinical Development
Though IAP antagonists have demonstrated antitumor efficacy in a variety of
cancer types, there are still challenges that need to be addressed in order to incorporate
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them into practical anticancer regimens. One potential issue observed is due to the potent
activation of cIAP-dependent NF-κB signaling. While up-regulation of this pathway and
its targeted genes such as TNFα are responsible for the TNFα-mediated apoptosis, they
can also pose the threat of provoking toxic side effects associated with stimulation of
inflammatory cytokine production (463). Some IAP antagonists may therefore cause
adverse side effects such as Cytokine Release Syndrome, exemplified by LCL161 in a
phase 1 dose escalation study (461). Because it is the same pathway that both drives
apoptosis and causes unintended side effects associated with inflammatory cytokines,
additional studies are warranted to optimize a therapeutic window to effectively inhibit
antitumor activity and decreases risk of cytotoxicity. Other issues correlated with
elevated NF-κB signaling include increased osteoclastogenesis and osteoporosis
development as a result of NIK stabilization (497).
Another challenge encountered is determining suitable biomarkers in patient
population to assess susceptibility to IAP antagonist treatment. Preclinical and clinical
studies have identified several biomarkers for potential response, including serum
cytokines and cIAP levels (498). However, SMAC mimetics may induce cIAP
degradation at non-toxic concentrations, in non-tumor tissues, and in non-response
malignancies, so cIAP loss would not be indicative of therapeutic relevance (341).
Baseline TNFα levels may serve as more suit able biomarkers and additionally may
induce non-apoptotic forms of cell death, such as by necroptosis (499, 500). However, it
is still unknown if there are other cytokines or apoptotic markers that may have serve as a
more reliable source for predicting therapeutic efficacy (463). Furthermore, IAP
expression is not always directly correlated with adverse prognosis. For example, XIAP
is elevated in prostate cancer, but recent studies indicate that elevated levels decrease the
risk of tumor reoccurrence compared to subjects with lower levels (378). Studies on
patients with advanced non-small cell lung cancer indicate no relation between XIAP
expression and clinical outcome (501). Additional studies are required to determine
indicators of potential efficacy to IAP antagonist treatment. Caution should be exercised
with therapies targeting XIAP concomitantly with death receptors. The corresponding
increased rate of apoptosis can become deleterious for type II cells, such as hepatocytes
pancreatic beta cells, and lead to liver toxicity (502).
Small-molecule survivin antagonists may also produce deleterious effects.
Because it is a chromosomal passenger protein complex that participates in multiple
facets of cell division, survivin antagonism can cause generation of polyploidy cells and
are more susceptible to mutations, genetic variation and instability. This may result in
increased tumor aggression and resistance to treatment (270, 503). Moreover, although
survivin is not expressed in adult differentiated cells, it is still expressed in proliferating
cells, such as in the immune system. Loss of survivin can affect T-cell maturation and
proliferation (504). Also, because of the dynamic role of survivin in numerous biological
processes including mitosis, apoptosis, cell cycle regulation, and autophagy as well as its
interaction with numerous endogenous molecules, it is difficult to evaluate the efficacy
and target specificity of its clinical candidates by any high throughput assay. These
complexities also obscure the therapeutic significance of small-molecule survivin
antagonists (338, 505).
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Another crucial question lies in the synergism between IAP inhibitors in
combination with other agents to achieve cell death. As single agents, SMAC mimetics
trigger apoptosis in only a small subset of cancer cell lines. In combinations with death
receptor ligands such as TNFα, TRAIL, and CD95, IAP antagonists have a greater
capacity to elicit potent activation of apoptosis in a variety of cell lines (506). The answer
may lie in determining which combination regimen produces the most robust effect on
tumor regression without toxicity to healthy tissues. Additionally, IAPs can prime cancer
cells toward apoptosis by lowering the apoptotic threshold and rendering them vulnerable
to a variety of cytotoxic factors including chemotherapeutic agents (507). The
combination of IAP antagonists with chemotherapeutics, radiation therapy, and kinase
inhibitors is being explored but is still largely unknown.
Summary
In summary, IAPs inhibit cell death pathways, promote pro-survival signaling,
and are up-regulated in many types of cancer, making them desirable molecular targets
for anticancer therapy. Significant progress has been made in developing IAP inhibitors,
particularly with small molecules, and these drugs represent a promising strategy for
inducing cell death in human diseases and malignancies. SMAC mimetics have shown
the ability to interact with XIAP and suppress their inhibitory action on caspases as well
as the ability to bind cIAPs and produce apoptotic effects by regulating NF-κB signaling
and extrinsic cell death pathways. Other small-molecule inhibitors also aim to suppress
the anti-apoptotic effects of survivin but must overcome additional complexities due to its
multifaceted role in many cellular processes. While a handful of small molecules have
progressed into clinical trials, there are still many challenges that need to be addressed
such as off-target toxicities associated with increased NF-κB signaling, identifying
appropriate biomarkers that correlate with elicited response, and developing synergistic
combination therapies, especially to avoid development of multiple drug resistance.
Overall, small-molecule IAP antagonists have great potential as anticancer drugs as
single agents or in combination with existing therapies.
Hypothesis for Novel Survivin Inhibitors
In Chapter 6, we investigate a series of new survivin inhibitors modified from the
UC-112 scaffold, which was previously identified through virtual screening. UC-112
demonstrated favorable properties over the most widely studied survivin inhibitor
YM155 in that it was shown to be highly effective against drug efflux pump mediated
resistance (508). SAR analysis of a predecessor drug, MX-106, revealed pertinent
structural information for optimizing the UC-112 scaffold and suggested that a
hydrophobic substituent on the benzene is amenable to activity. We therefore
hypothesized that further modification to the benzyloxy moiety in MX-106 would yield
potent analogs and that these analogs would maintain activity against P-gp
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overexpressing cell lines, selectively inhibit survivin over other IAP family members, and
demonstrate strong tumor growth inhibition against xenograft tumors in mice.
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CHAPTER 6.

INDOLE-BASED UC-112 ANALOGS AS POTENT AND
SELECTIVE SURVIVIN INHIBITORS5
Introduction

Survivin is the smallest member in the IAP protein. Its expression is very low in
healthy tissues and is highly expressed in tumors (509). The overexpression of survivin in
tumor cells has been positively correlated with their development of multidrug resistance
and radiation resistance (510, 511). For example, it is well established that cancer cells
with high expression of survivin (e.g., prostate, ovarian and colorectal cancer cells)
develop resistance to cisplatin and vincristine much easier than tumors cells with low
expression of survivin (512). Survivin is therefore considered as a cancer specific
biomarker and an attractive therapeutic target for the development of anticancer therapy
(339) (513).
Several reported strategies have been applied to block the anti-apoptotic ability of
survivin. These strategies include but are not limited to introducing recombinant cellpermeable dominant-negative survivin protein (514, 515), obstructing protein translation
using antisense oligonucleotides (516), and developing small-molecule based survivin
antagonists (517, 518). The crystal structure of human survivin was obtained in the early
of this century, revealing its unusual bow tie-shape dimer structure (519). However,
targeting survivin using small-molecule survivin inhibitors has been proven to be
challenging because no experimentally validated binding pocket in survivin has been
identified yet. The difficulty in developing a survivin specific small-molecule inhibitor
also lies in the fact that survivin interacts with many other proteins to mediate apoptosis
and mitosis, such as p53, STAT3, caspases and elements in the notch signaling pathway
(520-523). A number of scaffolds have been reported in the literature to significantly
suppress the expression of survivin and some have entered clinical trials for cancer
treatment (483, 489, 505, 508, 524-529). However, none of these molecules have gained
FDA approval. The most widely studied survivin inhibitor is YM155 which was initially
discovered by Astellas Pharma in 2007. YM155 has an IC50 in the sub-nanomolar range
against several types of cancer cell lines (484). It inhibits survivin expression by
inhibiting survivin promotor activity instead of directly degrading survivin protein. In
clinical trials, YM155 was evaluated as monotherapy or combinational forms for patient
with different cancer types, including blood cancer and solid tumors (530).
Unfortunately, YM155 was withdrawn in phase II clinical trials due to its low ability to
degrade survivin and high systemic toxicity.
We have recently discovered UC-112 through virtual screening followed by
biological validation (Figure 6-1)(508). UC-112 is a potent survivin inhibitor that

5

Modified with permission from Elsevier. Qinghui Wang*, Kinsie Arnst*, Yi Xue*, Zi-Ning Lei, ZheSheng Chen, Duane D. Miller, Wei Li. Synthesis and biological evaluation of indole-based UC-112 analogs
as potent and selective survivin inhibitors. European Journal of Medicinal Chemistry. 2018; 149:211-224.
*
Equally contributing authors.
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Figure 6-1.

Structure of UC-112 and MX-106.
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selectively degrades survivin protein via the proteasome pathway, activating caspases 3/7
and 9, and thus leads to cancer cell apoptosis. Unlike YM155 which is highly susceptible
to P-gp mediated drug efflux pump mediated drug resistance, UC-112 was shown to be
effective against P-gp overexpressing multidrug-resistant cancer cell lines. Subsequent
structural modifications of UC-112 results in MX-106 (Figure 6-1), which showed
improvements in suppressing survivin expression both in vitro and in vivo (531).
According to the SAR analyses, the 8-hydroxyquinoline and the pyrrolidine in UC-112
are essential for maximum activity; hydrophobic substituent on the benzene is beneficial
to activity. With this observation, we created analogs with modifications to the benzyloxy
moiety in UC-112 as well as conformational restricted analogs formed by reducing the
flexibility of the benzyloxy moiety in this scaffold to improve the activity. In this chapter,
we reveal our results from modifying the benzyloxy moiety in the UC-112 scaffold and
the biological investigation that followed. Thirty-three UC-112 analogs were synthesized
and evaluated for their initial potency activities and lead compounds were further
evaluated for their selective survivin inhibition and in vivo efficacy.
Materials and Methods
Cell Culture and Reagents
Human melanoma A375, M14, WM-164, RPMI-7951, and M14/MDR1 cell lines
were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA),
and cultured in DMEM media (Mediatech, Inc., Manassas, VA) at 37 qC in a humidified
atmosphere containing 5% CO2. The culture media were supplemented with 10% fetal
bovine serum (Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic-antimycotic
mixture (Sigma-Aldrich, St. Louis, MO). Compounds were dissolved in dimethylsulfoxide (DMSO; Sigma-Aldrich) to make a stock solution of 10 mM. Compound
solutions were freshly prepared by diluting stocks with cell culture medium before use
(final solution contained less than 0.5% DMSO). 5000 cells in logarithm growing phase
were seeded overnight into each well of a 96-well plate. Then the cells were continuously
incubated for 48 h with sequential diluted compound solution (100 μM to 3 nM, 100 μL
per well) in cell culture medium. The cell viability was determined in MTS assay and
IC50 was calculated (n = 4), following similar procedures as described previously (100,
143, 508, 531). Dulbecco’s modified Eagle’s Medium (DMEM), fetal bovine serum
(FBS), penicillin/streptomycin and trypsin 0.25% were purchased from Hyclone (GE
Healthcare Life Science, Pittsburgh, PA). Phosphate buffered saline (PBS) was purchased
from Invitrogen GIBCO (Grand Island, NY). Dimethyl sulfoxide (DMSO) and 3-(4,5dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide (MTT) were purchased from
Sigma Chemical Co (St. Louis, MO). The P-glycoprotein (P-gp) overexpressing KB-C2
cell line was established from a parental human epidermoid carcinoma cell line KB-3-1,
by a step-wise selection of KB-3-1 in increasing concentrations of colchicine up to 2
μg/mL (532). SW620/Ad300, which is also a P-gp overexpressing drug resistant cell line,
was established by stepwise exposure of the parental human colon cancer cell line
SW620 to increasing concentrations of doxorubicin up to 300 ng/mL(533). The KB-3-1
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and KB-C2 cell lines were generously provided by Dr. Shin-Ichi Akiyama (Kagoshima
University, Japan), and the SW620 and SW620/Ad300 cell lines were kindly provided by
Dr. Susan E. Bates (Columbia University, NY, USA) and Dr. Robert W. Robey (NIH,
MD, USA). All the cell lines were grown in DMEM supplemented with 10% FBS and
100 unit/mL penicillin/streptomycin in a humidified incubator containing 5% CO2 at 37
°C.
Cytotoxicity Assays
A375, M14, WM-164, RPMI-7951, and M14/MDR1 were seeded in 96-well
plates at a concentration of 1,000–5,000 cells per well, depending on growth rate of the
cell line. After overnight incubation, the media was replaced, and cells were treated with
the test compounds at 10 concentrations ranging from 0.03 nM to 1 μM plus a vehicle
control for 72 h in four replicates. Following treatment, the MTS reagent (Promega,
Madison, WI) was added to the cells and incubated in dark at 37°C for at least 1 h.
Absorbance at 490 nm was measured using a plate reader (DYNEX Technologies,
Chantilly VA). Percentages of cell survival versus drug concentrations were plotted, and
the IC50 (concentration that inhibited cell growth by 50% of untreated control) values
were obtained by nonlinear regression analysis using GraphPad Prism (GraphPad
Software, San Diego, CA).
Cytotoxicity against P-gp overexpressing cell lines by the MTT assay was
obtained by Zi-Ning Lei (St. John’s University). Cells were seeded in 96-well plates at
5000 cells/well (KB-3-1 or KB-C2 cells) or at 7,000 cells/well (SW620 or SW620/Ad300
cells) in 180 μL completed medium and cultured overnight. Then various concentrations
of the compounds (20 μL) were added to the designated wells. After 72 hr continuous
drug incubation, 20 μL of MTT reagent (4 mg/mL) was added to each well and the plates
were incubated at 37 °C for 4 hr. Subsequently, the medium was removed and 100 μL of
DMSO were added to dissolve the formazan crystals in each well. The absorbance was
determined at 570 nm by the accuSkan™ GO UV/Vis Microplate Spectrophotometer
(Fisher Sci., Fair Lawn, NJ). The IC50 values of each compound on each cell line were
calculated from the survival curves to represent the cytotoxicity of the compounds. The
fold of drug resistance was calculated by dividing the IC50 of the P-gp overexpressing
cells by that of the parental cells. Two known P-gp substrates, YM155 and paclitaxel,
were used as positive controls for P-gp overexpressing cell lines. On the other hand,
cisplatin, which is not a substrate of P-gp, was used as negative control.
Liver Microsomes Stability Assay
Liver microsome assays were performed by Dr. Lei Yang (St. Jude Children’s
Research Hospital). NADPH regenerating agent solutions A (catalog#: 451220) and B
(catalog#: 451200) and mouse liver microsomes (CD-1, mixture of male,
catalog#:452701, and female, catalog#: 452702) were obtained from BD Gentest
(Woburn, MA). Liver microsomes stability assay was conducted following literature
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reports (238, 239). For each test compound, the mouse liver microsomal solution was
prepared by adding 0.058 mL of concentrated mouse liver microsomes (20 mg/mL
protein concentration) to 1.756 mL of 0.1 M potassium phosphate buffer (pH 7.4)
containing 5 μL of 0.5 M EDTA to make a 0.6381 mg/mL (protein) microsomal solution.
Each test compound (2.2 μL of 10 mM DMSO solution) was added directly to 1.79 mL
of mouse liver microsomal solution and 90 μL was transferred to wells in 96-well plates
(0, 0.25, 0.5, 1, 2, and 4 h time points each in triplicate). The NADPH regenerating agent
was prepared by mixing 0.113 mL of NADPH regenerating agent Solutions A, 0.023 mL
of solution B and 0.315 mL of 0.1 M potassium phosphate buffer (pH 7.4) for each tested
compound. To each well of the 96-well plate, 22.5 μL of the NADPH regenerating agent
was added to initiate the reaction, and the plate was incubated at 37 °C for each time
point (0, 0.25, 0.5, 1, 2, and 4 h time points each in triplicate). The reaction was quenched
by adding 225 μL of cold acetonitrile containing warfarin (4 mg/mL) as internal control
to each well. All of the plates were centrifuged at 4,000 rpm for 20 min and the
supernatants (100 μL) were transferred to another 96-well plates for analysis on UPLC–
MS (Waters Acquity UPLC linked to Waters Acquity Photodiode Array Detector and
Waters Acquity Single Quadrupole Mass Detector) on Acquity UPLC BEH C18 1.7 mm
(2.1x50 mm) column by running 90–5% gradient for water (+0.1% formic acid) and
acetonitrile (+0.1% formic acid) in 2 min. The area under the single ion recording (SIR)
channel for the test compound divided by the area under the SIR for internal control at 0
time concentration was considered as 100% to calculate remaining concentration at each
time point. The terminal phase rate constant (ke) was estimated by linear regression of
logarithmic transformed concentration versus the data, where ke = slope × (−ln 10). The
half-life t1/2 was calculated as ln 2/ke. The intrinsic clearance (CLint,app)= (0.693/in vitro
t1/2) x (1 mL incubation volume/0.5 mg of microsomal protein) × (45 mg microsomal
protein/gram of liver) x (55 g of liver/kg body weight) .
Western Blot
To determine the change of protein levels of survivin and closely related IAPs,
lysates of A375 or M14 melanoma cells treated by the compound solution for 24 h were
used for western blotting analysis and determined by Dr. Yi Xue (UTHSC). Primary
rabbit antibodies against IAP proteins including survivin (#2808), XIAP (#2045), cIAP1
(#7065), Livin (#5471), Cleaved PARP (#9185) and the loading control protein GAPDH
(HRP Conjugate) (#3683) were purchased from Cell Signaling Technology, Inc.
(Danvers, MA) and used according to manufacture instructions as reported previously.
Molecular Modeling
Molecular modeling data was provided by Dr. Wei Li (UTHSC). The molecular
docking studies were conducted in Schrodinger Molecular Modeling Suite 2014
(Schrodinger Inc., Portland, OR) following previously described procedures (508, 531).
Ligand was prepared to generate various conformation before being docked into the
SMAC AVPI binding site of a human survivin crystal structure (Protein Data Bank entry:
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3UIH). Prior to molecular dynamic calculation, the docking to minimize the energy of
potential ligand binding poses was performed. Results were visualized using the Maestro
interface of the Schrodinger software.
In Vivo Xenograft Model
All animal experiments were performed in accordance with the NIH animal use
guidelines and protocol approved by the Institutional Animal Care and Use Committee at
the University of Tennessee Health Science Center. Nude mice, 6–8 weeks old, were
purchased from Envigo (Indianapolis, IN).
Logarithmic growth phase A375 cells (5 × 107 cells per mL) were prepared in
phenyl red-free, FBS-free media and mixed with Matrigel immediately before injecting
into mice. Tumors were established by injecting 100 μL of this mixture subcutaneously in
the dorsal flank of each mouse (2.5 × 106 cells). After tumor volumes reached
approximately 150 mm3 mice were randomized into control or treatment groups (n=7~8).
10f or paclitaxel was dissolved in a 1:1 ratio of PEG300: PBS solution to produce desired
concentrations. The vehicle control solution was formulated with equal parts PEG300 and
PBS only. 100 μl of the drug treatment or vehicle control was administered via i.p.
injection every other day two weeks.
Tumor volume was measured three times a week with a caliper and calculated by
using the formula a×b2×0.5, where a and b represented the larger and smaller diameters,
respectively. Tumor growth inhibition (TGI) at the conclusion of the experiments was
calculated as 100 – 100 ×((T − T0)/(C − C0)), where T, T0, C and C0 are the mean tumor
volume for the specific group on the last day of treatment, mean tumor volume of the
same group on the first day of treatment, mean tumor volume for the vehicle control
group on the last day of treatment and mean tumor volume for the vehicle control group
on the first day of treatment, respectively. Animal activity and body weights were
monitored during the entire experiment period to assess potential acute toxicity. At the
end of the experiment, mice were sacrificed and the tumors were weighed. Tumors and
tissues were dissected out and preserved in 10% buffered formalin phosphate solution.
Results and Discussion
UC-112 Analogs with Modification of the Benzyloxy Moiety
Our preliminary SAR investigation of UC-112 emphasized the replacement of the
benzyloxy with other substructures and has led to the syntheses of analogs 2a-2d, 6a-6f,
8 and 10a (Table 6-1). Compared to the reference compound MX-106, 2a (5fluoroindazole analog), 2b (benzotriazole analog) and 2c (4-chloropurine analog)
exhibited 3~5-fold reduced activities. Replacement of the benzyloxy with the other
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Table 6-1.
In vitro cytotoxic effects of UC-112 analogs with modification to the
benzyloxy moiety.
IC50 ± SEM (μM)
a

RI

A375

WM-164

RPMI7951

2a

3.6 ± 0.2

8.6 ± 1.1

11.1 ± 0.7

5.4 ± 0.3

7.0 ± 0.1

1.3

2b

1.9 ± 0.1

>30.0

6.5 ± 0.2

2.3 ± 0.1

3.1 ± 0.1

1.3

2c

3.9 ± 0.1

56.4 ± 1.1

17.4 ± 1.2

4.1 ± 0.2

7.9 ± 0.1

1.9

2d

14.1 ± 0.7

33.9 ± 1.1

21.0 ± 0.4

11.5 ± 0.4

14.3 ± 0.2

1.2

6a

>30.0

13.0 ± 0.5

>30.0

>30.0

>30.0

6b

4.7 ± 0.2

3.7 ± 0.3

26.2 ± 6.2

5.1 ± 0.1

10.7 ± 1.2

2.1

6c

3.5 ± 0.3

2.8 ± 0.2

18.4 ± 0.3

8.6 ± 0.2

7.4 ± 1.2

0.9

6d

1.5 ± 0.1

1.6 ± 0.1

12.9 ± 0.2

>30.0

12.2 ± 0.2

ND

6e

6.0 ±1.3

24.9 ±1.0

25.3 ± 2.4

6.7 ± 0.3

12.2 ± 0.5

1.8

6f

2.9 ± 0.15

ND

6.8 ± 0.6

2.4 ± 0.1

3.3 ± 0.2

1.4

8

>30.0

20.18 ± 0.49

17.3 ± 0.3

>30.0

8.7 ± 0.2

ND

10a

0.8 ± 0.1

0.9 ± 0.1

4.4 ± 0.3

0.8 ± 0.1

2.1 ± 0.1

2.6

UC-112

1.9 ± 0.6

ND

ND

2.1 ± 0.4

3.2 ± 0.5

1.5

MX-106

0.9 ± 0.1

1.1 ± 0.2

ND

0.8 ± 0.2

1.8 ± 0.4

2.3

a

M14

M14/MDR1

b

ND

RI: Resistance index is calculated by dividing the IC50 values on multidrug-resistant cell
line by IC50 by the matching parental cell line.
b
ND: Not Determined.
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moiety as shown in compounds 2d resulted in significant reduction of inhibitory effects
(> 3-fold). Replacing the benzyloxy with phenyl acetamides (analogs 6a-6d) was
detrimental to the antiproliferative activities. Shortening the linkage by one methylene in
6b and 6d resulted in analogs 6e-6f and was revealed to not affect the activities. The
introduction of a benzylurea (analog 8) dramatically attenuated the antiproliferative
activity. Among all analogs in this series, non-substituted indole analog 10a, exhibited
the most potent activity and was comparable to that of MX-106, having an average IC50
of 0.9 μM.
UC-112 Analogs with Substitutions on the Indole Moiety
Because the indole analog 10a had an equipotency to that of MX-106, we
subsequently focused our effort to investigate the substitutional effect on the indole ring.
Analogs 10b-10p with mono-substituent and analogs 10q-10v with di-substituents were
then synthesized (Table 6-2). For the 2-position substituted analogs, 10b with a methyl
group and 10c with an ethyl group showed slightly reduced activities compared to 10a.
Introducing substituents to the 4-position on the indole diminished the antiproliferative
activity, which was demonstrated by analogs 10d and 10e. For analogs that had
substituents on the 5-position of indole, comparable activities to that of 10a were
observed, for example, compounds 10f, 10g and 10h had IC50 values ranging from 0.7 to
1.1 μM; analog 10i that had bulky ester functional group showed ~2-fold reduced activity
in comparison with MX-106. In the series of analogs with substituents on the 6-position
of the indole (10j-10n), they were generally equipotent to MX-106 and 10a, having IC50
values as low as 0.7 μM. Analogs having substituents on the 7-position of indole were
slightly less potent than corresponding 5- or 6-position substituted counterparts. All the
six di-substituted analogs did not show any improvement of activity compared to their
mono-substituted counterparts. 10s-10v were designed based on the most potent monosubstituted analogs 10f, 10k, and 10n. Incorporation of a secondary substituent to 5fluoroindole, 6-chloro, or 6-methoxyindole generally was not beneficial to activity; for
example, 10s and 10u showed reduced cytotoxicities compared to 10f and had IC50 values
of >1.5 μM; the 3-cyano-6-methoxy indole analog 10t was less potent than the monosubstituted counterpart 10n; 5,6-dichloroindole analog 10v showed cytotoxicity
comparable to that of 5-chloroindole analog 10k.
Potency Against P-gp Overexpressing Cell Lines
P-gp belongs to the family of ABC transporters and is encoded by the ABCB1
gene. P-gp is responsible for the decline of concentrations of extensive anticancer drugs
in multidrug resistant cells. Therefore, the ability to overcome P-gp mediated drugresistance is a favorable property for drug candidates. In addition to the M14 melanoma
cell line, its P-gp overexpressed daughter line M14/MDR1 was also tested to evaluate the
abilities of new analogs to overcome P-gp mediated drug-resistance (Table 6-2).
According to assay result, more than twelve of the twenty-two indole analogs exhibited
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Table 6-2.
In vitro cytotoxic effects of UC-112 analogs with mono- and disubstituents on the indole moiety.
IC50 ± SEM (μM)
Structure

Monosubstituent

ID

A375

WM-164

RPMI7951

M14

M14/MD
R1

a

RI

10a

H

0.8 ± 0.1

0.9 ± 0.1

4.4 ± 0.3

0.8 ± 0.1

2.1 ± 0.1

2.6

10b

2-Me

2.2 ± 0.2

7.5 ± 1.2

2.2 ± 0.2

1.4 ± 0.2

0.7 ± 0.1

0.5

10c

2-Et

2.0 ± 0.1

8.9 ± 1.4

3.2 ± 0.4

1.5 ± 0.2

1.1 ± 0.1

0.7

10d

4-F

1.6 ± 0.3

6.5 ± 0.6

2.2 ± 0.2

1.2 ± 0.2

0.8 ± 0.1

0.7

10e

4-NO2

1.8 ± 0.1

7.0 ± 0.3

0.6 ± 0.1

2.1 ± 0.1

0.6 ± 0.1

0.3

10f

5-F

0.7 ± 0.2

0.7 ± 0.2

b

ND

1.9 ± 0.4

ND

ND

10g

5-CN

1.0 ± 0.1

1.1 ± 0.1

ND

5.1 ± 0.3

ND

ND

10h

5-NO2

0.7 ± 0.1

0.8 ± 0.1

3.7 ± 0.3

ND

2.2 ± 0.1

ND

10i

5-COOEt

1.9 ± 0.2

4.7 ± 0.6

1.5 ± 0.1

2.4 ± 0.2

0.8 ± 0.1

0.3

10j

6-F

0.9 ± 0.1

0.7 ± 0.1

2.7 ± 0.5

1.3 ± 0.1

1.3 ± 0.1

1.0

10k

6-Cl

0.9 ± 0.4

0.9 ± 0.4

7.7 ± 0.5

0.8 ± 0.4

3.8 ± 0.1

4.8

10l

6-Br

0.9 ± 0.1

1.4 ± 0.2

5.3 ± 0.6

3.5 ± 0.3

0.7 ± 0.1

0.2

10m

6-NO2

0.9 ± 0.1

0.7 ± 0.1

4.3 ± 0.7

2.8 ± 0.2

2.8 ± 0.2

1.0

10n

6-OMe

0.8 ± 0.2

0.7 ± 0.1

6.2 ± 0.4

0.9 ± 0.4

2.8 ± 0.1

3.1

10o

7-F

1.7 ± 0.2

1.9 ± 0.2

ND

2.6 ± 0.4

ND

ND

10p

7-Me

2.0 ± 0.2

11.5 ± 0.8

2.6 ± 0.2

1.4 ± 0.1

0.9 ± 0.1

0.6

10q

2,3-(Me)2

1.9 ± 0.2

7.1 ± 0.8

8.2 ± 0.6

1.5 ± 0.2

1.0 ± 0.1

0.7

1.9 ± 0.2

4.6 ± 0.1

2.1 ± 0.1

2.0 ± 0.1

1.0 ± 0.1

0.5

2.0 ± 0.2

8.5 ± 0.8

3.6 ± 0.4

1.3 ± 0.1

1.0 ± 0.1

0.7

1.7 ± 0.1

16.7 ± 0.5

3.7 ± 0.1

1.6 ± 0.1

1.9 ± 0.1

1.2

10r
10s
10t
Disubstituent

R

2-Me-5OMe
2-COOEt5-F
3-CN-6OMe

10u

5-F-6-Cl

2.0 ± 0.2

4.5 ± 0.2

1.7 ± 0.1

2.0 ± 0.2

1.0 ± 0.1

0.5

10v

5,6-(Cl)2

0.7 ± 0.1

0.9 ± 0.1

9.3 ± 1.1

8.5 ± 0.2

2.2 ± 0.1

0.3

a

RI: Resistance index is calculated by dividing IC50 values on multidrug-resistant cell line
M14/MDR1 by IC50 values on the matching sensitive parental cell line M14.
b
ND: Not Determined.
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more potent inhibitory effects against P-gp overexpressing M14/MDR1 cell line than the
parental drug sensitive M14 cell line and had resistance indexes pf less than 1, indicating
that new indole analogs had significant ability to circumvent drug-resistance mediated by
P-gp overexpression. It is worth noting that five out of the six di-substituted indole
analogs have RIs less than 1, suggesting that a secondary substituent on the indole is
beneficial for overcoming drug-resistance.
In addition to melanoma cell lines, cervical and colorectal carcinoma cell lines
were also tested to confirm the capabilities of the new analogs to circumvent P-gp
mediated drug resistance (Table 6-3). The small-molecular survivin inhibitor YM-155
showed remarkable cytotoxicity against KB-3-1 and SW620 cell lines with IC50 values of
4.9 nM and 3.9 nM, respectively. YM155, however, displayed significantly reduced
activities against the corresponding P-gp overexpressing cell lines (KB-C2 and
SW620/Ad300) and had IC50 values of more than 20 μM. Similarly, paclitaxel, a known
substrate of P-gp, was not effective against P-gp overexpressing cell lines. In contrast,
our indole analogs 10f, 10h, 10k, 10n and the previously reported MX-106 showed
stronger inhibitory effects against P-gp overexpressing cell lines (KB-C2 and
SW620/Ad300) than their corresponding parent cell lines (KB-3-1 and SW620). While
the IC50 values range from 1.28 to 1.71 μM in the non-resistant KB-3-1 cell line for 10f,
10h, 10k and 10n, their potency against the P-gp overexpressing KB-C2 cell line
significantly increased (IC50 values range from 0.17 to 0.44 μM). Similarly, 10f, 10h, 10k
and 10n had IC50 values ranging from 0.16 to 0.31 μM against non-resistant SW620 cell
line while their activities in KB-C2 cell line were 3-6 folds more potent with IC50 values
ranging from 0.027 to 0.1 μM. Collectively, these new indole analogs of UC-112 can
show potential to reverse drug-resistance mediated by P-gp overexpression.
In Vitro Metabolic Stability Study
Prior to in vivo study, the in vitro metabolic stabilities of analogs 10f, 10h, 10k
and 10n were examined by measuring their half-life upon incubation with mouse, rat, and
human liver microsomes in the presence of an NADPH regeneration system (Table 6-4).
All compounds possessed acceptable stability profile in three microsome species. They
were more stable in human microsome than in mouse and rat microsomes. Among the
four analogs, 10f with a 5-fluoro was the most stable against mouse and human
microsomes.
UC-112 Analogs Maintain Selective Inhibition for Survivin among IAPs
To determine whether our new UC-112 analogs maintains their selective
inhibition of survivin as the prototype UC-112 does, we measured protein levels of
several IAPs including cIAP1, XIAP, Livin, and survivin after treatment with 10f, 10h,
10k and 10n in A375 cells (Figure 6-2). All four compounds strongly inhibited survivin
expression in A375 cell line in a concentration-dependent manner, while the other IAP
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Table 6-3.
In vitro cytotoxic effects UC-112 analogs against P-gp overexpressing
cervical cancer and colorectal cell lines.
IC50 ± SD (μM)

IC50 ± SD (μM)
a

Compound

RI

RI

SW620

SW620/
Ad300

0.13

0.16 ± 0.04

0.027± 0.006

0.17

0.18 ± 0.05

0.13

0.19 ± 0.09

0.06 ± 0.02

0.32

1.71 ± 0.22

0.25 ± 0.05

0.15

0.24 ± 0.09

0.05 ± 0.03

0.21

10n

1.28 ± 0.25

0.44 ± 0.28

0.34

0.31 ± 0.05

0.10 ± 0.04

0.32

MX-106

1.25 ± 0.10

0.33 ± 0.12

0.26

0.15 ± 0.01

0.03± 0.01

0.20

YM155

0.0049 ± 0.0005

37.30± 3.97

7612.24

0.0039 ± 0.0056

23.37 ± 2.37

5992.3

Paclitaxel

0.0005 ± 0.0001

0.25 ± 0.01

500.00

0.030 ± 0.001

1.97 ± 0.36

65.67

Doxorubicin

0.37 ± 0.07

1.69 ± 0.44

4.57

0.21 ± 0.03

15.24 ± 2.89

72.57

Cisplatin

1.15 ± 0.13

1.73 ± 0.11

1.50

1.79 ± 0.06

5.12 ± 0.65

2.86

KB-3-1

KB-C2

10f

1.36 ± 0.19

0.17 ± 0.09

10h

1.39 ± 0.41

10k

Data obtained by Zi-Ning Lei (St. John’s University).
a
RI: Resistance index is calculated by dividing IC50 values for multidrug-resistant cell
lines by IC50 values for the matching sensitive parental cell lines.

141

Table 6-4.

Compound

In vitro metabolic stability of UC-112 analogs in liver microsomes.
Metabolic Stability
(Human)
t1/2
Clint
(hr)
(mL/min/kg)

Metabolic Stability
(Mouse)
t1/2
Clint
(hr)
(mL/min/kg)

Metabolic Stability
(Rat)
t1/2
Clint
(hr)
(mL/min/kg)

10f

4.59 ± 0.39

4.5

1.36 ± 0.06

42.1

1.29 ± 0.03

4.5

10h

2.16 ± 0.19

9.6

1.17 ± 0.06

48.7

1.20 ± 0.05

39.0

10k

3.50 ± 0.36

5.9

1.20 ± 0.07

47.8

1.62 ± 0.10

29.0

10n

2.80 ± 0.18

7.4

0.88 ± 0.06

65.1

1.26 ± 0.06

37.0

Data obtained by Lei Yang (St. Jude Children’s Research Hospital).

142

Figure 6-2. UC-112 analogs selectively downregulate survivin.
Western blot analysis A375 cells treated with 1, 3, or 10 μM of 10f, 10h, 10k and 10n for
24 h. Protein levels of various IAP proteins show that UC-112 analogs selectively target
survivin over other IAPs (cIAP1, XIAP, and Livin) and increase apoptotic protein
cleaved-PARP. Western blot was performed by Dr. Yi Xue (UTHSC).
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family proteins were not affected. This evidence indicates high selectivity of survivin
inhibition among the IAP proteins. Consistent with survivin inhibition, all four analogs
effectively induced cancer cell apoptosis, as indicated by the elevated level of cleaved
PARP.
Molecular Modeling of Lead Compound
To explain the observed strong potency of 10f, a molecular modeling study was
developed using the complex of human survivin-SMAC AVPI (PDB entry: 3UIH)
(Figure 6-3A and B). 10f formed appealing hydrogen bonding and π-π stacking
interactions with the survivin protein BIR domain: (1) two hydrogen bonding interactions
between the 8-hydroxyquinoline of 10f and residues Glu76 and Lys79; (2) two hydrogen
bonding interactions between the pyrrolidine of 10f and residue Asp71; (3) π-π stacking
interaction between the 8-hydroxyquinoline of 10f and residue His80; (4) π-π stacking
interaction between the 5-F indole of 10f and residue His80; (5) π-cation interaction
between the pyrrolidine of 10f and residue Trp67 (red line in Figure 6-3B). The
molecular modeling result suggested that substitute on the 7-position of the indole ring
will introduce the repulse between the 8-hydroxyquinoline and indole ring and further
lead to attenuated π- π stacking interactions mentioned above, for example, 10p and 10q
exhibited significantly decreased potency in comparison with 10a.
In Vivo Antitumor Efficacy Assessment
As one of the most potent indole analog, 10f not only exhibited the most
favorable stability against mouse and human liver microsomes but also significantly
inhibited the survivin expression at a low concentration; therefore, 10f was selected for
further evaluating antitumor efficacy in vivo. An A375 melanoma xenograft model in
nude mice was used. Tumors were implanted by inoculating mice with A375 human
melanoma cancer cells subcutaneously in their hindflank. After the development of viable
tumors, mice were treated every other day for two weeks by i.p. injection with 20 mg/kg
10f, 15 mg/kg paclitaxel, or vehicle solution only. After 15 days of treatment, the groups
receiving 20 mg/kg 10f had significantly smaller tumor volumes than the vehicle control
group with a calculated TGI of 68.6% (Figure 6-4A). This was very similar to the
paclitaxel treated group which averaged a TGI of 70.6% compared to the vehicle control
group. One-way ANOVA followed by Dunnett’s multiple comparison test also revealed
that there was a significant reduction in final tumor volume (P < 0.0001) for all treatment
groups compared to the vehicle control group. These results are in accord with the tumor
final weights, where the average tumor weight for the control group was 2.08 ± 0.32
grams, and 10f and paclitaxel groups averaged 0.85 ± 0.26 grams and 0.78 ± 0.12 grams,
respectively (Figure 6-4B). Statistically analysis was performed the same and yielded an
overall P value of 0.0012, and a significant difference (P < 0.01) for each treated group
compared to the control group. Mouse body weight was measured, and animal activity
was monitored throughout the experiment, and no significant deviations in animal weight
or behavior were observed (Figure 6-4C).
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Figure 6-3. Potential binding mode of 10f to survivin.
A) The best docking pose of 10f binding in survivin (survivin PDB: 3UIH), shown with
electron potential color-coded survivin surface (red: electron negative potential; blue:
electron positive potential). Interactions between 10f and nearby residues in survivin are
shown. B) Types of interactions are shown with color-coded lines between 10f with
residues in survivin protein in this 2D interaction map. Molecular modeling generated by
Dr. Wei Li (UTHSC).
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Figure 6-4. 10f inhibits tumor growth in vivo.
A) Average tumor volumes ± SEM in an A375 xenograft model in nude mice (n=7-8). B)
Individual tumor weights. Long line represents mean and error bars represent SEM.
Statistical significance was determined by one-way ANOVA (P= 0.0012) analysis
followed by Dunnett’s multiple comparison test for each treatment group compared to the
control group (** P < 0.01). C) Average mouse body weights ± SEM. Graph represents
percent change in body weight compared to the starting weight.
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Conclusions
In this report, thirty-three new analogs of UC-112 were synthesized and their
SAR was investigated. The results showed that most indole analogs exhibited potencies
stronger than or comparable to UC-112 and MX-106. The most potent activities were
observed in 10f, 10h, 10k and 10n. Compared to YM155, a widely studied survivin
promoter inhibitor, our new indole analogs of UC-112 showed stronger activities against
P-gp overexpressing cancer cell lines and parental cancer cell lines. Mechanistic studies
revealed that new indole analogs of UC-112 selectively suppressed the expression of the
survivin protein in a dose-dependent manner without affecting other members of the IAP
family. In an in vivo xenograft model in nude mice, 10f exhibited significant tumor
growth inhibition without signs of toxicity. These results support conducting detailed
SAR investigation of novel scaffolds to develop optimized analogs and ultimately led to
the discovery of 10f, a potent and selective survivin inhibitor with strong anticancer
action.
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CHAPTER 7.

SUMMARY AND FUTURE DIRECTIONS FOR TUBULIN
INHIBITORS AND SURVIVIN INHIBITORS

In the tubulin project, we investigated several scaffolds of small molecules that
specifically target the colchicine binding site on tubulin. Colchicine binding site agents,
unlike vinca alkaloids or taxanes, have been reported to circumvent several mechanisms
of multidrug resistance, particularly resistance mediated by the overexpression of P-gp
and other drug efflux pumps. Therefore, we had the overall goal to develop compounds
that would show broad anticancer effects, demonstrate improved IC50s, and disrupt
microtubule networks and mitotic spindle formation. We also aimed to generate analogs
that would optimally target the colchicine binding site and would thus maintain a low
resistance index against ABC transporter overexpressing cell lines and show significant
efficacy against taxane-resistant tumors in animal models.
In Chapter 2, we hypothesized that our lead indolyl-imidazopyridines, DJ95 and
DJ101, would show strong potency to a variety of cell lines including those exhibiting
MDR. This was confirmed by their cytotoxicity against our expanded melanoma cell
panel and against the NCI-60 cell lines. DJ101 showed the greatest activity against
melanomas, with IC50s below 10 nM. Both DJ101 and DJ95 showed low resistance
factors to taxane-resistant prostate cancer cell lines, especially when compared to other
tubulin inhibitors including colchicine, paclitaxel, and docetaxel. DJ95 was also
evaluated against gene-transfected cell lines overexpressing ABCB1, ABCC1, and
ABCG2, and additionally against drug-selected MDR cell lines. MDR cell lines were
more receptive to DJ95 treatment than to colchicine, vincristine, and paclitaxel. To test
our hypothesis regarding their effects on microtubule networks, we demonstrated their
strong destabilizing action and disruption to mitotic spindles via confocal microscopy,
followed by X-ray crystallographic analysis detailing their verified interaction at the
colchicine domain. Finally, we hypothesized that the compounds would show potent
anticancer activity in animal models. Both DJ95 and DJ101 demonstrated tumor growth
inhibition in melanoma xenografts. DJ101 presented superior activity, where 30 mg/kg
doses inhibited tumor growth by 92.8%. In a subsequent metastatic melanoma xenograft
model, treatment with DJ101 using the same dosing regimen drastically reduced
pulmonary metastatic nodules by 83.8% compared to the control group. Finally, DJ101
treatments potently inhibited the growth of taxane-resistant prostate cancer tumors,
confirming its activity in vivo and against MDR-presenting cancers. Therefore, we
confirmed the hypothesis for this series of agents, with DJ101 showing the greatest
anticancer activity.
In Chapter 3, we set out to test the assumption that the indole moiety and 3,4,5trimethoxyphenyl moiety of VERU-111 could be optimized to generate analogs with
lower IC50s, greater activity against tubulin polymerization, and in vivo efficacy in mouse
models. We identified the best candidate from each series of modifications: indole
substitution (10ab), indolyl rotation (10bb) and TMP modification (13f). We then
demonstrated their high efficacy against taxane-resistant cell lines and validated their
mechanism of action through their ability to potently prohibit polymerization of purified
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tubulin protein. Their destabilization action was further established with confocal
microscopy, and their activity against microtubules resulted in fragmentation and
decreased polymeric tubulin. Even with its unique allosteric replacement of the critical
TMP moiety, 13f still showed direct interactions with the colchicine binding site by Xray crystallography. Finally, based on their potency and metabolic stabilities in liver
microsomes, we tested 10bb and 13f in melanoma xenograft models, and 30 mg/kg
treatments suppressed tumor growth by 73.9% and 90.6%, respectively. 10bb also
effectively inhibited metastasis and taxane-resistant tumor proliferation in two additional
animal models without showing signs of toxicity. The pharmacological profile of 10bb
did not indicate significant interactions with physiologically important off-targets based
on the Safety Screen panel, nor did the toxicological analysis of major organs (heart,
liver, kidney, lungs, and spleen) from the drug-treated xenograft model groups exhibit
apparent drug-related injury to the tissues. Therefore, we identified improved analogs of
VERU-111, and the most promising compound, 10bb, showed significant in vivo activity
against MDR tumors, inhibited the development of metastases, and improved the
therapeutic window.
In Chapter 4, we hypothesized we could design Azixa analogs that had improved
metabolic stabilities, could induce vascular disrupting effects, interfere with cellular
processes through tubulin inhibition, promote G2/M phase mitotic arrest, and finally,
demonstrate potent antitumor effects. First, we selected 4a, 6a, 5a, and 5b from a series
of heteropyrimidines based on their exceptional potencies in initial cell viability assays.
5a and 5b were tested in additional cancer types, including malignant melanomas,
prostate, lung, and breast cancer cell lines as well as several drug-resistant sublines. 5b
outperformed colchicine in every instance and revealed that it was a poor substrate of Pgp. Compared to Azixa, 4a, 5a, and 5b all showed better metabolic stabilities in human
liver microsomes and were substantially better than other reported Azixa analogs. All
four compounds showed robust destabilizing activity based on tubulin polymerization
and microtubule morphology, and two compounds (4a and 6a) had confirmed binding to
the colchicine site at the interface of the of the α and β tubulin subunit, all supporting
their action as colchicine binding site inhibitors. 5a and 5b hindered cell migration,
inhibited colony proliferation, induced G2/M phase cell cycle arrest and apoptosis in a
concertation-dependent manner, and disturbed HUVEC capillary-like formation in vitro.
4a and 6a were assessed in vivo and inhibited melanoma tumor growth by 72.3% and
76.5%, respectively, following 30 mg/kg treatments, and 4a treatment also reduced
taxane-resistant prostate cancer tumor volume by 55.6%. Tumor sections from the treated
groups showed greatly diminished overall microvessel formation and morphologically
distortion vasculature, and additionally revealed elevated levels of apoptosis compared to
the control group. These in vivo results of 4a and 6a correlate with the in vitro data
demonstrated by 5a and 5b, ultimately confirming our hypothesis and supporting their
action as both tubulin inhibitors and as vascular disrupting agents capable of inducing
strong anticancer action against clinically significant drug-resistant models.
In conclusion, from our overall evaluation of tubulin inhibitors, we optimized
several scaffolds of colchicine binding site agents and generated lead analogs with
improved potency, metabolic stability, and antitumor efficacy. After confirming their
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cytotoxic effects against a variety of cell lines, lead compounds underwent additional
biological analysis to confirm their mechanisms of action. We determined that they
shared common characteristics with other colchicine binding site agents including;
inhibiting tubulin polymerization, destabilizing microtubules and mitotic spindles,
directly interacting with the colchicine binding site, inducing G2/M phase cell cycle
arrest, and hindering migration. Furthermore, several of the compounds were evaluated in
ABC transporter overexpressing cell lines, drug-selected resistant cell lines, and taxaneresistant xenograft models, and showed improved efficacy. Two of the compounds were
able to potently suppress the establishment of pulmonary metastases of melanoma in
vivo, supporting their use for metastatic intervention. We also investigated the vascular
disrupting potential of some of the compounds and presented their capacity to inhibit
endothelial cell network formation and diminish intra-tumor vasculature.
Pharmacological profile screenings revealed that the compounds minimally interact with
off-target receptors, transporters, ion channels, kinases, and enzymes, which may reduce
the attrition risk at later stages in the drug development process. Overall, we identified
promising candidates, including indolyl-imidazopyridines (DJ95 and DJ101), VERU-111
analogs (10ab, 10bb, and 13f), and heterocyclic pyrimidines (4a, 6a, 5a, and 5b),
confirmed the mechanism of action as colchicine binding site agents, and demonstrated
their anticancer potential, particularly against MDR cell lines and tumor models.
To effectively escape the shortcomings of current anticancer drugs, newer
generations of tubulin inhibitors should exploit the colchicine binding site to decrease the
susceptibility of transporter-mediated efflux and resistance to the βIII tubulin isoform.
Additionally, drugs targeting this site often are effective as vascular disrupting agents and
can accommodate a large range of structurally diverse scaffolds. Innovative strategies for
microtubule targeting agents should capitalize on combination therapies to reduce the
emergence of multidrug resistance. Other issues limiting the clinical potential of
microtubule targeting agents are poor solubility, low metabolic stability, and doselimiting neural and cardiotoxicities. Several techniques have been employed to improve
drug properties and limit toxicity such as delivery via nanoparticle formulations and
antibody-drug conjugation. Finally, the emergence of dual kinase tubulin inhibitors
provides several benefits for this class of drug, as these dual inhibitors may improve the
therapeutic window and reduce the risk of drug resistance development by targeting
multiple pathways. While the scaffolds of the tubulin compounds we investigated were
quite diverse in structure, their common feature was that they all target the colchicine
binding site and were highly effective against multiple mechanisms of resistance. We
believe that of the investigated compounds, DJ101 is one of the strongest candidates to
avidly push forward with characterization. Additional models could be used to test its
efficacy, such as patient derived xenograft models, and further characterization of the
biological events that ensue for it to maintain efficacy against MDR phenotypes will
reveal the compound’s clinical potential. Ultimately, our studies collectively support the
continued development of the investigated scaffolds as anticancer therapeutics, especially
as an alternative treatment to taxane-resistant cancers.
In the survivin project, we explored analogs of UC-112, an IAP inhibitor selective
to survivin. We hypothesized that by modifying the benzyloxy moiety, we could generate
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analogs with improved potency against P-gp overexpressing cell lines, specifically target
survivin with high selectivity, and show in vivo anticancer efficacy. After attempts to
modify the benzyloxy with numerous other substructures, we determined that the nonsubstituted indole analog had the most comparable potency to the parent compound.
From there, we shifted our focus to determining the best substitution on the indole ring
and identified 10f (containing a fluorine at the 5-position of indole). 10f, the most
promising candidate, demonstrated exceptional potency against parental and resistant
cancer cell lines and selectively suppressed the expression of the survivin protein in a
dose-dependent manner without affecting other members of the IAP family. Finally, 10f
treatment of 20 mg/kg significantly inhibited tumor volume in a xenograft model by
68.6%, which was equally as effective as paclitaxel treatment (TGI of 70.6%), without
causing toxicity to the animals. Therefore, our hypothesis regarding UC-112
modification, survivin selectivity, and anticancer action was confirmed.
Identifying appropriate biomarkers that correlate with elicited response and
developing synergistic combination therapies, especially to avoid development of
multiple drug resistance, could prove to be invaluable strategies to maximize clinical
efficacy for IAP inhibiting agents in general and particularly for survivin inhibitors.
Because dynamicity of survivin and its implicated in many critical biological processes
including mitosis, apoptosis, cell cycle regulation, and autophagy, it is important to
evaluate the anticancer efficacy of survivin antagonism against the potential dysfunction
of other cell regulating mechanisms that may provoke deleterious side effects. Overall,
our results validated the in-depth investigation for this novel survivin inhibitor scaffold,
and additional biochemical and mechanistic characterization is warranted in the future.
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APPENDIX. DOSE RESPONSE CURVES FROM NCI-60 CELL LINES

Figure A-1. Dose-response curves of DJ101 against the NCI-60 cell line panel.
Percent growth of NCI-60 cell lines treated with DJ101 in 5- dose assay as determined by
the National Cancer Institute Developmental Therapeutics Program (NCI-DTP).
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Figure A-2. Dose-response curves of DJ95 against the NCI-60 cell line panel.
Percent growth of NCI-60 cell lines treated with DJ95 in one-dose (top) and 5-dose
(bottom) assays as determined by the NCI-DTP.
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